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Abstract 
The following thesis contains three parts, where the common overall goal 
was to develop useful applications for synthesis and modification of pyrrole 
heterocycles. 
A range of desmethyl, cis-hydroxy analogues of the biologically active natural 
product (–)-codonopsine were prepared, using the controlled oxidation of N-
methylpyrrole with both hypervalent iodine reagents and photooxidation as a 
key step. Dihydroxylation, Friedel–Crafts alkylation using aromatic 
nucleophiles, and reduction with LiAlH4 were used to transform these γ-
lactam intermediates to the desired analogues in mostly good overall yields. 
The relative stereocontrol observed in these processes was expanded to 
develop two approaches to asymmetric syntheses of these analogues. The 
use of chiral bicyclic scaffolds gave complete stereoselectivty, but the 
intermediates were too stable for further modification. The use of an amino 
acid methyl ester chiral auxiliary gave separable diastereomers, but further 
functionalization led to scrambling of stereocenters.  
Chiral dihydroxylated bicyclic γ-lactam intermediates were applied to the 
synthesis of chiral fluorinated GABA analogues, due to their selective binding 
to particular GABA receptors. Direct fluorination of bicyclic diols using 
Deoxofluor and DAST led to separable mixtures of mono- and difluorinated 
products. These proved more amenable to ring-opening of the bicyclic 
lactams through trapping of iminium ions than the corresponding diol-
substituted bicyclic lactams, due to hyperconjugation effects of the fluorine 
substituents. A proof of concept preparation of a fluorohydrin analogue of 
GABA was successfully completed. 
An approach was developed for the selective preparation of stable pyrroles 
and pyrrolidines from the readily available 1,4-dialdehyde natural product 
polygodial. A modified Paal-Knorr approach under reducing conditions made 
it possible to selectively produce stable pyrroles or pyrrolidines in good to 
excellent yields. One of the pyrroles was taken and subjected to controlled 
pyrrole oxidation and Friedel–Crafts alkylation to give novel analogues of the 
antifungal natural product (+)-Crispin A. These compounds were also 
Abstract 
vi 
investigated as scaffolds for the preparation of chiral amines with potential 
applications as organocatalysts.
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Chapter 1 Introduction 
1 
Chapter 1: Towards the Synthesis of (–)-Codonopsine 
Analogues From Pyrroles 
1.1 Introduction to (–)-Codonopsine and Related Alkaloids 
Two polyhydroxylated pyrrolidine alkaloids, (–)-codonopsine and (–)-
codonopsinine (1 and 2, Figure 1.1), have received a significant amount of 
attention for their biological properties. Both were originally isolated from the 
plant Codonopsis clematidea by Matkhalikova and colleagues in 1969, using 
samples of the plant collected in Kashka-Dar’ya Oblast in the former Uzbek 
Soviet Socialist Republic (modern day Qashqadaryo province in the Republic 
of Uzbekistan).1,2 A structurally similar compound, named codonopsinol (3), 
was isolated from the same species in 2008 by Ishida and colleagues, from 
specimens of the plant collected in the same province.3 
Figure 1.1: (–)-Codonopsine, (–)-Codonopsinine and Codonopsinol 
Matkhalikova and colleagues proposed structures for (–)-codonopsine and (–
)-codonopsinine based on their analysis of vicinal coupling constants in 1H 
NMR spectra of these compounds.4-6 However, their stereochemical 
assignments were later found to be incorrect. The actual structures of the two 
were determined by Kibayashi and colleagues in 1985, through a more 
definitive total synthesis and x-ray crystallographic analysis.7-9 Additionally 
Tashkhodzhaev and co-workers, apparently unaware of Kibayashi’s work, 
also established the correct structure through crystallographic analysis, in 
2004.10 
One study, by Matkhalikova and colleagues, proposed that codonopsine and 
codonopsinine have antibiotic and hypotensive effects without adversely 
affecting the central nervous system.11 It has also reportedly been used in 
conjunction with a number of other plants in Uzbek traditional medicines.3 
However, more important to their study today is their observed effectiveness 
N
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2 
as sugar mimics – aza-sugars that closely resemble natural sugars such that 
they can be used to inhibit sugar-processing enzymes. In particular, they 
have been reported to exhibit effectiveness in inhibiting α-L-fucosidase, an 
enzyme found at increased concentrations in tumour and cancer cells, which 
has led to their structure being used as the basis for developing new 
potential cancer treatments.12,13 
Aside from Kibayashi’s structure determination work, many syntheses of 
codonopsine and codonopsinine have been developed over the years. 
Importantly, many of these have also involved the synthesis of a range of 
analogues of the two, allowing for compound library development and 
working toward the establishment of structure activity relationships (SARs). 
Their role as sugar mimics has informed a number of the syntheses 
developed, such that analogues have been prepared from similarly 
substituted sugars (and sugar derivatives) such as D-ribose,13 L-xylose12,14 
and D-mannitol (Scheme 1.1).15 Other approaches have been wide-ranging, 
although a common feature is that the pyrrolidine is most often formed 
through a ring-closing event of an acyclic starting material.16-21 None of these 
syntheses to date have taken advantage of the aromatic nitrogen heterocycle 
pyrrole (6) as a starting point.  
Scheme 1.1: Representative approach to preparing (–)-codonopsinine from sugars 
via acyclic intermediates 
1.2 Introduction to Dearomatisation and Controlled Oxidation 
of Pyrroles  
Dearomatisation of aromatic systems can be a useful tool in organic 
synthesis, and this strategy has been employed for both carbo- and 
heterocyclic systems using a variety of methods.22-24 Pyrrole provides a good 
example of an aromatic heterocyclic moiety that can undergo substitution 
reactions prior to dearomatisation.25 Pyrrole dearomatisation has been 
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3 
dominated by reductive methods, mainly partial reduction and 
hydrogenation.26 The Birch reduction, a dissolving-metal partial reduction 
apporoach, is a key example of these reductive methods. It has been used 
widely in the dearomatisation of pyrroles towards the synthesis of pyrrolidine 
natural product targets. This includes work by Donohoe and colleagues to 
prepare natural products such as 1-epiaustraline (7, Figure 1.2) and 
hyacinthacine A1 (8),22,27,28 and also in Smith’s synthesis of anisomycin (9),29 
amongst others.  
Figure 1.2: Pyrrole, and pyrrolidines prepared through reductive methods 
An alternative to reductive dearomatisation of pyrroles would be an oxidative 
process. At least conceptually this could be an even more synthetically useful 
route. While reduction gives a pyrroline or pyrrolidine from a pyrrole, this 
decreases the amount of functionality available for transformation to an 
alkene at the most, necessitating that any other transformations be carried 
out on the pyrrole beforehand (Scheme 1.2). Oxidative processes, on the 
other hand, give highly substituted products with multiple functional handles 
free for further modification, such a an alkene, a hemiaminal and an 
amide/α,β-unsaturated carbonyl. Such an approach could prove particularly 
fruitful if polyhdroxylated pyrrolidines, such as the aforementioned (–)-
codonopsine and (–)-codonopsinine, were targets of interest. 
Historically and through to the present day using pyrrole oxidation in total or 
practical synthesis has been dismissed as not being viable, thanks largely to 
the perception that under acidic and oxidising conditions pyrrole polymerises 
uncontrollably to give pyrrole black. There is evidence to support this belief.30 
However, considerable work undertaken over the last hundred years 
investigating the viability of controlled pyrrole oxidation to provide pyrroline 
and pyrrolidine products, has led to the development of an array of methods 
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(Scheme 1.2). The results of these studies have been far from negative, as 
shown in a recent of review of the work published by our group.31  
Scheme 1.2: General scheme comparing reduction and oxidation of pyrroles 
The earliest work on controlled pyrrole oxidation was undertaken using 
hydrogen peroxide in the 1920s, with major observed products being 
identified as 5-hydroxy-3-pyrrolin-2-one species (such as 13), generally in 
low yields.32,33 Since that time, this approach has been refined by a few 
groups, such as Bocchi’s,34,35 and Pichon-Santander’s36 and continues to be 
used in research working toward pyrrolidine products, with higher yields and 
more selective oxidations.37,38 Cases where benzoyl peroxide is used as the 
oxidant have also been reported, which instead of oxidising to the pyrrolinone 
gave mixtures of 2,3 and 4-benzoyloxy-substituted pyrroles as products. For 
example, for a range of N-substituted pyrroles Aiura and colleagues reported 
a mixture of 2-benzoyloxy and 2,5-dibenzoyloxy products (Scheme 1.3).39,40 
Scheme 1.3: Use of benzoyl peroxide to reach benzoyloxypyrroles 
Other approaches to reach pyrrolinones 13 include the use of organic 
oxidants such as o-chloranil,41 DDQ42,43 and m-CPBA;44,45 electrochemical 
oxidation;46-49 inorganic oxidants such as lead tetraacetate;50-55 Kao and co-
workers examples with nickel peroxide and also oxone,56,57 Reynolds and 
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5 
colleagues use of TPAP/NMO,58 and aryl iodide-catalysed peracetic acid 
oxidation-cyclisations.59 
Another class of oxidant used, which is of particular interest in this work, is 
that of the hypervalent iodine reagents.  Reports in this area have been more 
limited than the more traditional peroxides or even photooxidation, but a few 
key papers have appeared in recent years that point toward their utility in 
controlled oxidation of pyrroles. Alp and co-workers reported the controlled 
oxidation of the electron-deficient N-tosylpyrrole 16 using the reagent 
phenyliodinebis(trifluoroacetate) (PIFA, Scheme 1.4).60 They observed 
quantitative conversion of N-tosylpyrrole into two γ-lactam species, 17 and 
18, the latter with a 5-hydroxy substituent, on treatment with 1.1 molar 
equivalents of the hypervalent iodine reagent. When 2.2 equivalents were 
used, complete conversion to 18 was achieved.  
Scheme 1.4: Alp and colleague’s oxidation of pyrroles with PIFA 
The Suna group reported similar results through their work investigating the 
oxidisation of pyrroles by introducing acetoxy groups in the 2-position.61 
Using phenyliodine (III) diacetate (PIDA), they first isolated pyrrole iodonium 
species (such as 20, Scheme 1.5), which were then treated with Pd(OAc)2 to 
rearrange into the acetoxypyrroles (Such as 21). This process could also be 
carried out with comparable results in one pot. When this procedure was 
carried out at elevated temperatures, it was observed that some pyrrole 
substrates converted into pyrrolinones (22), much like those seen in Alp’s 
work, or maleimides (23), rather than the intended acetoxypyrroles.  
 
 
N
Ts
N
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O N
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OHO
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CH2Cl2
N
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OHO
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6 
Scheme 1.5:  Examples from Suna and co-author’s work using PIDA 
Work in our own group investigated this link between the use of hypervalent 
iodine reagents and pyrrolinone formation in more detail, and showed that 
Dess–Martin periodinane (DMP, 24) was a desirable reagent for achieving 
this purpose on a variety of pyrrole substrates, giving pyrroline-2-ones 25  
incorporating the oxidant as a 5-iodoaroyloxy substituent (Scheme 1.6).62 
This approach was found to be widely applicable and high yielding, and 
furthermore was selective for oxidising pyrroles over alcohols, which 
historically has been DMP’s main synthetic use.62-64 The exact reaction 
mechanism for these oxidations are unknown. It is theorised to proceed 
either through an iodonium intermediate, as in Suna’s work, followed by 
rearrangement to give the benzoate species; or alternatively through some 
kind of direct attack by the pyrrole on the oxygen of DMP, which is without 
precedent but would explain why none (or very little) of the 5-acetoxy product 
is observed under these conditions.  
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Scheme 1.6: Controlled oxidation of pyrroles using Dess–Martin periodinane 
It has also been found that 2-iodoxybenzoic acid (IBX, 26), a precursor of 
Dess–Martin periodinane, can be used in its place to provide the 2-acetoxy 
lactams, when the reaction is carried out in neat acetic acid (Scheme 1.7). 
This was investigated both because it would be a more atom-economical 
reagent, and one that is simply prepared from the inexpensive starting 
materials Oxone® and iodobenzoic acid.65 Also, mechanistic studies suggest 
that the active species reacting in Dess–Martin periodinane oxidations is in 
fact a hydrolysed form of the reagent 27 arising from trace quantities of water 
present in the reaction.63 It was theorised that IBX could form the same 
active species in the presence of acetic acid, which was borne out by NMR 
studies of IBX with acetic acid leading to resonances consistent with those of 
27 as reported by Schreiber.63,66   
Scheme 1.7: Use of IBX as an alternative oxidant 
The amount of acetic acid used for the pyrrole oxidation reaction could be 
reduced by carrying out the reaction in a mixture of dichloromethane and 
acetic acid. However, it should be noted that as the proportion of acetic acid 
is reduced the yield decreases and a mixture of 5-iodoaroyloxy and 5-
acetoxy substituted products 25 and 29 are obtained. It remained a necessity 
to have a significant amount of acetic acid present, due both to IBX’s 
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8 
insolubility in dichloromethane and the fact that high concentrations of the 
acid were required to effect conversion to the active oxidant 27.66 
Another approach that has received significant attention is the use of singlet 
oxygen to oxidise pyrroles and other heterocycles.31,67 Singlet oxygen is 
generated either through decomposition of a chemical reagent, or more 
commonly through excitation of a photoactive dye (a dye-sensitised process). 
Dye-sensitised reactions have become quite common in organic synthesis in 
general,68,69 but the methods have been found to be less effective in 
oxidising pyrroles, giving low yields and generally a range of pyrrolidine (13) 
and maleimide (30) products, with other by-products such as ring-opening 
products occasionally observed (Scheme 1.8).70-72  
Scheme 1.8: General scheme for singlet oxygen oxidation of pyrroles to lactams 
and maleimides 
An exception to this was demonstrated by Boger and Baldino, who prepared 
a single pyrrolidinone product regioselectively by starting with pyrrole-2-
carboxylic acid 31 (Scheme 1.9). In this case, the oxidation occurs with a 
concomitant decarboxylation.73,74  
Scheme 1.9:  Boger and Baldino’s regioselective decarboxylation-photooxidation 
Other research has been carried out by Demir and colleagues, who explored 
oxidations to give bicyclic γ-lactams 34, by trapping an N-acyliminium 
intermediate (Scheme 1.10).75  
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Scheme 1.10: Demir and colleagues’ photooxidation of 2-methylpyrroles to give 
bicyclic pyrroline-2-ones 
Recent work in our group explored ways to make this process more efficient 
and effective, and considered the intrinsic reactivity of pyrroles in light to do 
so. It was proposed that the decomposition of pyrroles commonly observed 
was due to exposure of the pyrrole to a strong flux of UV light and heat, 
which most conventional lamps used for photoreactors emit in addition to the 
visible light needed for the oxidation to occur.76,77 By using LEDs with a 
narrow band of visible light emission tuned to the sensitiser used (i.e. using 
green LEDs to excite the dye Rose bengal, in an alcoholic solvent),71,78,79 
undesired wavelengths of light (such as UV) were eliminated, and a range of 
pyrroles were oxidised in good yields on multi-gram scale (Scheme 1.11).80 
There was some precedence for this LED approach to photochemical 
reactions in the micro-batch work of Hulce and colleagues.81 The reactions 
are also carried out in custom photoreactors constructed using cheap LED 
strips and lab glassware to make the process simple and low cost, thus 
affording a practical method for the formation of 5-hydroxypyrrolidinones as 
intermediates for synthesis.  
Scheme 1.11: Photochemical Approach to Controlled Pyrrole Oxidation 
N
R
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1.3 Proposed Approaches for Racemic Codonopsine 
Analogue Synthesis 
1.3.1 Preliminary Results of Racemic (–)-Codonopsine Analogue 
Synthesis 
Previous work focussed on developing a synthetic route to racemic 
analogues of (–)-codonopsine and (–)-codonopsinine using the Dess–Martin 
periodinane and/or IBX oxidation of N-methylpyrrole 28 as the starting 
point.82 In this work, the γ-lactam derived from N-methylpyrrole either using 
DMP as the oxidant (37) or IBX (29) were subjected to a range of 
transformations to assess their suitability to the synthesis of (–)-codonopsine 
analogues (Scheme 1.12).  
Dihydoxylation under Upjohn conditions83 of the alkene at C3-C4 of lactam 
29/37 was chosen as the method for simply introducing the diol moiety into 
the analogues, as the [3+2]-suprafacial nature of these additions gives 
predictable formation of a cis diol.84 This gave analogues that contrasted with 
(–)-codonopsine and (–)-codonopsinine, which have trans-3,4-diols. These 
reactions proceeded smoothly, but difficulties in purification by flash column 
chromatography (believed to be due to hydrolysis at C5 on silica to give a 
strongly polar triol species) necessitated the protection of the crude diol as 
the acetoxy derivative 40, achieved by simply stirring the crude reaction 
mixture from the dihydroxylation in a mixture of Ac2O and pyridine. For Dess–
Martin oxidation-derived lactam 37, this protection procedure also led to an 
exchange of the iodoaroyloxy group at C5 with an acetoxy group, such that 
the 3,4-diacetoxy lactam 38 and 3,4,5-triacetoxy species 39 were the 
products in a combined 78% yield.    
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Scheme 1.12: Scope of preliminary work investigating codonopsine analogues 
Following the dihydroxylation/protection procedure, a small range of aryl 
substituents were introduced at the C5 position through Friedel–Crafts 
alkylation, where the Lewis acid BF3.OEt2 was used to generate an iminium 
ion at that position before addition of the nucleophile. Lactams 38 and 39 
were used as a mixture, as both would convert to the same N-acyliminium 
intermediate when treated with a Lewis acid. It was proposed that these 
systems would be particularly amenable to these types of reaction due to the 
reported higher reactivity of N-acyliminium ions where the acyl functionality is 
endocyclic.85 These reactions gave conversion to the desired aryl subsitiuted 
lactams 40 in mostly good overall yields. The 1H NMR spectra showed no 
coupling between the protons at C4 and C5, giving only singlet and doublet 
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resonances for each of these respectively. This indicated that these two 
hydrogen atoms were in a trans relationship to each other. Consideration of 
the Karplus equation supported our prediction that relative stereocontrol 
would be maintained for this transformation by the acetoxy groups in C3 and 
C4.86 A number methoxy-substituted benzene derivatives were trialled, with 
benzene itself proving unreactive, presumably to its being less electron-rich 
and hence less nucleophilic than the other electron-rich methoxyaryl 
substrates.  
Finally, two of these substrates (those derived from 1,2-dimethoxybenzene 
and 1,4-dimethoxybenzene) were treated with LiAlH4 to reduce the amide at 
C2 to an amine and to simultaneously remove the two acetoxy protecting 
groups from the alcohols at C3 and C4 to yield the cis-diol, giving moderate 
to good yields of the desired products 43 and 44. The 1,2-dimethoxybenzene 
derivative was also treated with MeOH/K2CO3 to remove the acetoxy 
protecting groups, giving the dihydroxy lactam 45 in good yield. Further 
substrates were not explored due to time constraints on the project, but what 
was achieved indicated that this was a relatively efficient, quite mild and 
convenient route to racemic, cis-diol, desmethyl analogues of (–)-
codonopsine and related compounds.  
1.3.2 Plans for Expansion of Racemic Work 
Given the success of these methods in reaching cis-dihydroxy analogues of 
codonopsine-type alkaloids, it was decided that a range of additional 
analogues could be synthesised to give a good representative body of work 
to explore their biological activity, and so develop structure activity 
relationships for these compounds (Figure 1.3). To this end, a range of other 
aryl and heterocyclic substrates were selected to be subjected to the same 
reaction procedure; that is, dihydroxylation/diacetoxylation, Friedel–Crafts 
alkylation, and then either reduction with LiAlH4 to give one class of amine 
desmethyl analogues, or deprotection of the acetoxy groups to give a 
selection of dihydroxy lactam analogues. The chosen list of substrates to be 
tested included other methoxy-substituted benzenes, most importantly 
methoxybenzene which can give analogues most similar to codonopsinine. 
Also considered were some pyrrolidines featuring aromatic heterocycles at 
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their α-positions, which could have interesting biological activities compared 
with the other aryls, and N-methylpyrrole, N-tosylpyrrole, furan and imidazole 
were chosen for this purpose.  
Figure 1.3: Proposed targets for full racemic investigation 
 It was also decided that one or more analogues could be pursued using 
purine derivatives, such as 6-methoxypurine (65, Figure 1.4) as the 
nucleophile for the Friedel–Crafts reaction. This would give structures that 
were very similar to aza-analogues of known biologically active nucleosides 
such as clofarabine (68).87 Methods for the installation of purine derivatives 
into these systems have been previously reported and generally employ 
Lewis acids stronger than BF3.OEt2, such as TiCl4.88 Other similar 
approaches have been reported, such as Alibés and colleagues’ use of tin 
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(SnCl4) with added N,O-bis(trimethylsilyl)acetamide,89 and Martínez-Montero 
and co-workers use of TMSOTf.87  
Figure 1.4: An example of purine targets, and a purine-containing nucleoside 
In addition to reaching the desmethyl derivatives, it was also planned to 
utilise the lactam to introduce an alkyl group in the 2-position. Applied to the 
para-methoxybenzene derivative this would allow the synthesis of the 
analogue 3-epi-codonopsinine (64, Scheme 1.14).  
It was envisioned that this could be achieved by an additional step to the 
route taken for the desmethyl analogues, carrying out an alkyl addition at the 
amide carbonyl, followed by reduction (Scheme 1.13). Such addition-
reduction procedures have been reported in the literature, and usually 
involve the use of either Grignard or alkyllithium reagents, with a reducing 
agent such as diisobutylaluminium hydride (DIBAL-H) or lithium aluminium 
hydride employed either to reduce the amide to an carbinolamine or to 
reduce the alcohol resulting from attack by the Grignard/alkyllithium on the 
amide carbonyl.90,91 A more recent approach has been developed by Huang 
and colleagues, that utilises the same principal of using a Grignard reagent 
with LiAlH4, but includes 2,6-ditertbutylpyridine as an additive to assist the 
reaction.92,93  
Scheme 1.13: Huang and colleague’s approach to alkylation-reduction 
It seemed likely that the acetoxy-protecting groups used to access the other 
analogues would not be compatible with these reaction conditions, as 
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undesired side-reactions could occur. Instead, TBDMS-protected 
intermediate 71 would be more suitable (Scheme 1.14). This could be taken 
and presumably subjected to alkylation under Huang’s or other conditions to 
give the methyl derivative 72. Finally, the TBS protecting groups could be 
cleaved using TBAF to give the diol 73.  
Scheme 1.14: Planned route to methylated analogue  
Previous work by Gourlay found an interesting result when synthesising (–)-
codonopsinine via a different route.94 In that research the final step in the 
synthesis was the acidic ring-opening of the epoxide of a diastereomeric 
mixture of 74a and 74b, to reach the natural trans diol of the natural product 
(Scheme 1.15). However, NMR data was found to be inconsistent with that 
reported by Kibayashi,9 and instead seemed to support formation of cis-diol 
products 75a and 75b. This would be a highly unusual result, as ring-
openings of epoxides in this fashion are normally expected to yield only 
trans-diol products.  Thus, the full synthesis of cis-dihydroxy (–)-
codonopsinine analogue 73 would also be invaluable in providing 
unambiguous NMR spectral evidence to support Gourlay’s structural 
assignments for diols 75a and 75b.  
Scheme 1.15: Gourlay’s epoxide ring-opening 
As such, it was planned to deliberately synthesise a cis analogue of (–)-
codonopsinine via a pyrrole oxidation pathway, which would allow for 
comparison with the reported NMR data for Gourlay’s product and (–)-
codonopsinine to give conclusive evidence about the products formed in 
Gourlay’s work.  
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With the full range of desmethyl analogues and the epi-codonopsinine 
analogue successfully prepared, a good range of substrates would have 
been accessed. This would provide evidence for controlled pyrrole oxidation 
being a useful technique for efficiently accessing biologicaly active natural 
product analogue libraries, and provide the basis for biological activity 
studies on these compounds.  
1.4 Results of Racemic Work 
1.4.1 Preparation of Racemic (–)-Codonopsine Analogues 
Previous work pursued the synthesis of racemic (–)-codonopsine analogues 
by first oxidising N-methylpyrrole with Dess–Martin periodinane or IBX. This 
expanded study began by following the procedure using IBX, to give the 
acetoxylactam 29 in an excellent 94% yield (Scheme 1.16). This was then 
subjected to dihydroxylation and acetate protection to give triacetate 39 as a 
single product in a 66% yield over two steps.  
Scheme 1.16: Accessing diacetoxy intermediates through IBX oxidation of N-
methylpyrrole 
As the low-cost and atom-economical photooxidation method and reactors 
became available, the production of these intermediates was switched over 
to this approach (Scheme 1.17). In this case, N-methylpyrrole was oxidised 
to give a mixture of 5-hydroxylactam 76 and 5-ethoxylactam 77 in a 
combined yield of 44%. These two products were then taken as a mixture 
and subjected to dihydroxylation and diacetoxylation to give what was 
identified as triacetoxy derivative 39 and diacetoxy ethoxy derivative 78 in a 
2:1 ratio, in identical yield to the IBX procedure. While these products were 
not separated, triacetoxy compound 39 was identified through its 1H NMR 
spectrum matching that obtained through the oxidation/diacetoxylation of N-
N
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17 
methylpyrrole with IBX. The second product was identified as the diacetoxy 
product with a 5-ethoxy substituent through the diagnostic ethyl triplet and 
quartet resonances at 1.23 and 4.09 ppm, respectively. The C5 methine 
proton of 78 was also upfield of that observed in triacetoxy derivative 39, at 
4.60 ppm rather than 6.01 ppm.  
 Scheme 1.17: Accessing diacetoxy intermediates through photooxidation of N-
methylpyrrole  
The major advantage of the photooxidation method over the IBX approach 
was that no stoichiometric organic oxidant was required, and the short 
reaction times meant that gram-quantities could be prepared simply by 
carrying out multiple 0.5 g scale reactions in parallel and combining crude 
products together for purification. By comparison, the DMP and IBX methods 
suffer from needing very large quantities of oxidant to be added, increasing 
the expense of the reactions and making the workup procedures more 
laborious. From a combined 8 runs of photooxidations, using a total of 4 g of 
N-methylpyrrole, a modest yield of 32% was obtained. While the yields would 
have been higher for a hypervalent iodine procedure, 34.5 g of IBX or 52.3 g 
of DMP would be required to oxidise the same amount of N-methylpyrrole. 
The following step in the synthesis of racemic (–)-codonopsinine analogues 
was to generate an N-acyliminium ion at C5 using a Lewis acid, followed by 
alkylation of aryl substrates. As such, both the single compound 39 and the 
mixture of 39 and 78 were appropriate, as the same N-acyliminium 
intermediate could be generated from both compounds. 
A suite of Friedel–Crafts alkylation reactions were then performed using 
BF3.OEt2 as the Lewis acid and the desired aromatic substituents. For the 
most part, these transformations were successful, giving single products in 
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moderate to excellent yields. (Scheme 1.18)  Repeats of previously prepared 
compounds using veratrole (79) and 1,4-dimethoxybenzene (80) gave single 
regioisomers, as did furan (82), the less electron-rich N-tosylpyrrole (83) and 
indole (84). Success of the reactions was supported by the appearance of 
key aromatic 1H and 13C NMR spectral resonances, and a general up field 
(relative to triacetoxy 39) shift of the C5 methine proton resonances to 
between 4.46–5.05 ppm. HRMS analysis of each of the compounds also 
supported their identities.  
Scheme 1.18: Preparation of single product aryl derivatives from diacetoxy 
intermediates 
The relative stereochemistry of the diol and the newly introducded aryl 
substituents was determined through analysis of the 1H NMR spectra of 
these compounds. The coupling constant for the methine proton in the 5-
position with the hydrogen atom geminal to an alcohol in the 4-posiiton was 
found to be close to or exactly 0 Hz. Thus the C5 proton resonance appeared 
as a singlet. The mutually coupled diol proton resonances, by contrast, 
appeared as doublets. For example, in the case of 1,2-dimethoxybenzene-
substituted analogue 79, the vicinal C3 and C4 methine proton resonances at 
NAr O
CH3
AcO OAc
CH2Cl2, 0 oC – rt, 16 h
79–84
BF3.OEt2 (1.5 eq.)
Aryl (1.2 eq.)
N
CH3
ORO
AcO OAc
39 R = Ac
78 R = Et
N O
H3CO CH3
AcO OAc
79 (32%)
H3CO N
CH3
AcO OAcOH3C
H3CO
80 (60%)
O
N O
CH3
AcO OAcOH3C
OH3C
H3CO
81 (68%)
N
CH3
AcO OAc
O
O
82 (54%)
N
CH3
AcO OAc
NTs
83 (65%)
O N
CH3
O
AcO OAc
HN
84 (69%)
Chapter 1  Results and Discussion 
 
 
19 
5.16 and 5.45 ppm shared a coupling of 5.6 Hz, while the methine proton 
resonance for C5 at 4.46 ppm showed no evidence of coupling. 
Issues were encountered in the realm of regioselectivity for three of the other 
substrates. The 1,3-dimethoxybenzene and anisole derivatives both yielded 
two regioisomers for the Friedel–Crafts reaction (Scheme 1.19). Where 
anisole was used the reaction gave a 1:1 ratio of ortho-substituted product 85 
and para-substituted product 86, which proved to be chromatographically 
inseparable. Similarly, 1,3-dimethoxybenzene gave a 5:1 ratio of the 1,2,4- 
and 1,2,3-substituted products (87 and 88). These two compounds were also 
inseparable.  
Scheme 1.19: Regioselectivtiy in Friedel–Crafts alkylations 
The identities of these inseparable compounds were established through 
analysis of the 1H NMR spectrum of the mixture, and use of 2D NMR spectra 
to assign each resonance to a particular product. For example, a doublet 
associated with the isomer 85 at 7.06 ppm, with a coupling constant of 8.6 
Hz and integrating for two hydrogen atoms was consistent with a resonance 
expected for a 1,4-substituted benzene. By contrast 86 featured a more 
complicated aromatic resonance at 7.29 ppm (a doublet of doublets of 
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doublets) indicative of a 1,2-substituted benzene with more couplings 
observed between aromatic hydrogen atoms. 
While the mixtures of these products could be purified by chromatography 
and identified by NMR analysis, it was not possible to isolate the individual 
products at this stage. For the 1,3-dimethoxy adduct, it was decided to end 
the synthesis at this step given the wide range of other compounds to 
prepare. However, the anisole adduct was considered important to pursue 
due to its similarity to the natural product and the need to reach its methyl 
analogue for comparison with Gourlay’s work.  
The use of N-methylpyrrole also led to the formation of two products. These 
were identified as products where alkylation had occurred at the C2 and C3-
positions of the pyrrole, lactams 89 and 90, in a ratio of nearly 1:1. This was 
surprising as N-methylpyrrole typically only yields 2-substituted pyrroles. The 
lack of selectivity for this reaction compared with the N-tosyl derivative can 
be explained by this pyrrole being more electron-rich, and thus both C2 and 
C3 positions are viable sites for alkylation to take place.  Fortunately it was 
possible to separate the N-methyl adducts by flash column chromatography, 
and establish which was which through analysis of the 1H NMR spectra. For 
2-substituted derivative 89, a triplet signal at 6.07 ppm provides evidence 
that the proton at C4 of the pyrrole is adjacent to two other protons, 
supporting the proposed substitution pattern. For the 3-substituted 90, this 
level of coupling of aromatic region protons is not observed. 
Finally for these Friedel–Crafts alkylation investigations, it was attempted to 
introduce a purine derivative, 6-methoxypurine, by a similar approach 
(Scheme 1.20). Initial tests were carried out under roughly the same 
conditions as the previous experiments, starting with the triacetoxy-lactam 
and treating it with a small excess of 6-methoxypurine and an excess of 
BF3.OEt2 at room temperature. The reaction was monitored by TLC analysis 
and, when no reaction was observed after 2 hours, the mixture was heated at 
reflux and monitored by TLC for a further two hours before quenching. 1H 
NMR analysis of the crude products indicated that the only identifiable 
compounds were unreacted starting material, 6-methoxypurine, a compound 
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that appeared to be amide 91 (where the C5-acetoxy group had evidently 
been cleaved/reduced), and decomposition.  
Scheme 1.20: Attempts at using purine and imidazole 
After this first attempt more forcing conditions were trialled, with the stronger 
Lewis acid TiCl4, in modest excess at room temperature or at reflux over 20 
h. Unfortunately, only unreacted starting material and decomposition 
products were observed.  
To probe whether similar substrates other than the 6-methoxypurine might be 
more successful, imidazole was also trialled as the aryl under a similar range 
of conditions (Scheme 1.18). Using TiCl4 or BF3.OEt2 as the Lewis acid at 
room temperature or at reflux overnight in all cases led to mixtures of what 
appeared to be the reduced product 91, starting material and mostly 
decomposition, with no incorporation of the imidazole. In case the desired 
products were forming and then decomposing, TiCl4 was used at reflux but 
with the reaction carefully monitored and stopped as soon as TLC analysis 
showed consumption of the starting materials. In this case more distinct 
products were observed in the 1H NMR spectrum of the crude reaction 
mixture, but there was again no evidence of imidazole being incorporated 
onto the pyrrolidine, and approximately 90% of the starting mass was lost 
due to decomposition. 
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The successfully prepared single acetoxy-protected diols 79–84 and 89–90 
were all taken and subjected to deprotection, to yield the diol lactams 
(Scheme 1.21). Previously, this reaction was allowed to stir for several hours 
before removing the solvent under reduced pressure, which in a number of 
cases resulted in product decomposition. To overcome this problem, the 
amount of base and reaction times were both reduced and the reaction 
mixture immediately filtered through a silica plug without evaporation. This 
gave clean products in a much more efficient and convenient manner than 
the previous approach. 
Scheme 1.21: Acetoxy cleavage to give (–)-codonopsine analogues 
The success of these reactions was supported by the disappearance of the 
two acetoxy CH3 resonances in the 1H NMR spectrum and the appearance of 
only a single carbonyl signal for each in the 13C NMR spectrum. IR spectra 
showing only a single carbonyl stretch at about 1690 cm-1 and a broad OH 
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stretch at approximately 3300 cm-1, and HRMS analysis provided further 
evidence.  
Likewise, the diacetoxy substrates were taken and subjected to reduction 
with LiAlH4 (Scheme 1.22). Yields were mostly reasonable and in many 
cases the products were obtained pure without need for any purification. The 
products were identified by the disappearance of any carbonyl resonances in 
the 13C NMR spectrum and IR spectra, and by the appearance of two new 
CH resonances in the 1H NMR spectra.  These were accompanied by a 
noticeable up field shift of the 1H NMR resonances associated with the 
protons on the pyrrolidine ring. The lack of any carbonyl stretches between 
1600–1700 cm-1 and appearance of a broad OH stretch in the IR spectra 
provided further evidence.  
Scheme 1.22: LiAlH4 reduction to give (–)-codonopsine analogues 
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It was hoped that carrying out the above described deprotection procedure 
on the mixed anisole derivatives 85 and 86 might lead to isomers that were 
separable. Unfortunately, neither the products of the acetoxy deprotection 
with K2CO3 or reduction with LiAlH4 were separable by chromatography. As a 
primary goal for the 4-methoxyphenyl racemic analogue was to pursue 
alkylation/reduction of the amide, the mixture of diol lactams (47 and 49) 
produced by deacetylation with K2CO3, were protected as TBS groups 
(Scheme 1.23). Gratifyingly, the two TBS-protected ethers 71 and 93 were 
readily separable by flash column chromatography. 
The success of the TBS-protection was verified by 1H NMR spectroscopy. 
Specifically, the appearance of two key peaks associated with the silyl t-butyl 
groups integrating for 9 protons between 0.85 ppm and 0.91 ppm, and four 
singlets integrating for 3 protons indicative of the silyl methyls between -0.09 
and 0.18 ppm.  
Scheme 1.23: TBS protection of anisole lactams 
Given that compounds 71 and 93 are potential precursors for stereoisomers 
of (–)-codonopsinine, two routes to reduce the number of synthetic steps to 
reach them were attempted. First, direct Friedel–Crafts alkylation of the 5-
hydroxylactam 76 and 5-ethoxylactam 77 to reach 5-aryllactam 94, followed 
by dihydroxylation to give the diols 47 and 49 without the need for acetate 
protection and deprotection (Scheme 1.24). Unfortunately only 
decomposition of 94 was observed. It was theorised that a bond shift of the 
alkene of 94 from C3–C4 to C4–C5 occurs to give the unstable species 95, 
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which rapidly decomposes. Similar reactivity has been observed in previous 
research by Daïch and colleagues, and by Howard.66,95  
Scheme 1.24: Proposed decomposition pathway for aryl-substiuted 3-pyrrolin-2-
ones 
As an alternative, the crude product of the dihydroxylation of lactams 76 and 
77 was subjected to both Friedel–Crafts alkylation with anisole directly, and 
TBS protection, again with the intention of finding a way to avoid acetoxy 
protection (Scheme 1.25). Unfortunately, neither of these approaches yielded 
any improvement and mostly led to decomposition. The conclusion of these 
efforts, then, was that the most viable approach was to work through the 
longer route of dihydroxylation followed by acetoxy protection, alkylation, 
then cleavage of the acetoxy groups followed by protection of the diol as the 
silyl ethers.  
Scheme 1.25: Attempts to use crude diol in synthesis of anisole derivatives 
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Given that the best route to the TBS-protected lactams 71 and 93 had been 
established, these were taken and used to generate the corresponding final 
racemic products of the two isomers from anisole. The pyrrolidine products, 
where the TBS groups were cleaved and the amide reduced, were generated 
by treatment with excess LiAlH4, similarly to the acetoxy-protected 
intermediates, based on a literature procedure (Scheme 1.26).96 This was 
based on evidence that the presence of adjacent LiAlH4–reducible functional 
groups, in this case the amide carbonyl, facilitate the intramolecular reductive 
deprotection of silyl ethers of alcohols.97 This yielded the desired diol 
products 46 and 48. To simply cleave the silyl ether protecting groups and 
leave the amide functional group intact, lactams 71 and 93 were simply 
deprotected with TBAF, the standard approach to such transformations.98,99 
This gave the desired lactams 47 and 49 in good yields. These reactions 
completed the set of racemic desmethyl cis-diol codonopsine analogues to 
be prepared in this work.  
Scheme 1.26: Deprotection/reduction of TBS anisole substrates 
1.4.2 Towards Synthesis of Alkylated cis-diol  
Finally, the possibility of using TBS-protected diol 71 as a substrate for 
preparing methylated  (–)-codonopsinine analogues such as 63 was 
explored. Huang and colleagues’ combined alkylation/reduction procedure 
for lactams was trialled first, on TBS derivative 93 (Scheme 1.27).93 Despite 
this procedure being reported to be effective for a number of alkylmagnesium 
reagents, only decomposition of the starting material was observed, with no 
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evidence of methyl incorporation to give pyrrolidine 98. Similar results were 
observed for the model substrate N-methylpyrrolidin-2-one 99.100  
To establish whether the amide/lactam systems being used were inherently 
unsuitable to alkylation and reduction, the more technical approach of Huang 
and colleagues was shelved and simpler literature conditions trialled on the 
5-arylpyrrolidinone 101 (Scheme 1.28). Initially, alkylation followed by 
reduction was attempted, Using both MeLi and BuLi as the alkylating agent 
and LiAlH4 as the reducing agent, under mild conditions.90 Unfortunately, 
mostly decomposition was observed, with the remainder being starting 
material and trace by-products that showed no evidence of methyl or butyl 
incorporation in the 1H NMR spectrum.  
Scheme 1.27: Attempts at sequential alkylation/reduction 
The alternative approach was also attempted, carrying out the reduction first 
followed by addition of the alkylating agent.91 DIBAL-H was chosen as the 
reducing agent in this case, and a variety of conditions trialled, including 
varying the temperature, addition times and excess of reagents. Across all of 
the reactions the only identifiable products other than complete 
decomposition were starting material, and traces of the overreduction 
product 103. This indicated that it is difficult to partially reduce the amide to 
the required aminol for subsequent alkylation to occur.  
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Scheme 1.28: Other attempted reduction/alkylation conditions 
Two other approaches were attempted to try to generate alkylated racemic 
codonopsine analogues. Firstly, a Wittig procedure was trialled. While there 
have been some reports of these reactions working for γ-lactams, such 
conversions of amides to enamines are generally limited to cases where the 
conjugation of the amide bond with the lone pair of the nitrogen is weakened 
by strain in the molecule or competing resonances.101 Unfortunately, without 
such effects lactam 101 proved unreactive to the Wittig reagent. These 
conditions were also attempted on N-methylpyrrolidinone 99, with a similar 
lack of any reaction observed (Scheme 1.29).  
Scheme 1.29: Final attempts at amide alkylation 
Finally, lactam 101 was subjected to Huang and colleagues dialkylation 
conditions, minus the added complication of carrying out a reduction step at 
the same time (Scheme 1.29).92 While in this instance the 1H NMR spectrum 
of the crude compound was promising, appearing to show one major product 
with additional singlet resonances upfield at 1–2 ppm that could indicate 
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addition of two methyl groups. However, the product formed proved unstable 
to purification and could not be isolated. 
While the alkylation-reduction procedure was ultimately unsuccessful, this 
work did succeed in significantly expanding the scope of preliminary studies 
into the synthesis of racemic (–)-codonopsinine analogues. Twenty new 
desmethyl analogues were prepared using a variety of aromatic substituents, 
and variation in the functionality at the 2-position. This represents a useful 
library of compounds for carrying out future bioactivity assays.  
1.5 Strategies for Asymmetric Syntheses 
With the above syntheses of racemic (–)-codonopsinine analogues in mind, 
two pathways were envisioned for exploring the possibility of an asymmetric 
synthesis, where the absolute rather than just the relative stereochemistry of 
the products was controlled. Both of these involved the incorporation of a 
chiral amino acid derivative into the starting material, such as 106 (Scheme 
1.30).  
Scheme 1.30: Proposed routes to stereo-controlled lactams 
The first approach was to use a chiral amino alcohol as a precursor for the 
pyrrole used in the synthesis. Alcohols such as (S)-(+)-2-phenylglycinol and 
(S)-(+)-2-phenylalaninol were considered to be viable options for this. It was 
proposed that the pyrroles prepared from these could be oxidised to give a 
diastereomeric mixture of γ-lactams, but that on addition of a Lewis acid to 
generate an N-acyliminium ion at C5, the proximal pendant alcohol would 
undergo intramolecular nucleophilic attack to form a five-membered 
heterocycle 107 with stereochemistry set by the amino alcohol moiety 
(Scheme 1.30)  
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Such compounds have been reported by Meyers and colleagues. They have 
made and used bicyclic γ-lactams extensively in the synthesis of chemically 
and biologically interesting pyrrolidine natural products and other 
compounds, such as (–)-rolipram (109, Figure 1.4), mastigophorene A (110) 
and (–)-penienone (111), among others.102-106  
Figure 1.4: Examples of varied endpoints from chiral bicyclic lactams 
Meyer’s approach to synthesising such bicyclic intermediates involved 
starting with a chiral amino alcohol (S)-(+)-2-phenylglycinol, 112) and 
reacting with succinic anhydride (113) to give a succinimide (Scheme 1.31). 
The imide is then reduced with sodium borohydride before treatment with a 
Lewis acid to generate an iminium ion at the 5-position and allow for ring 
closure through attack by the alcohol functional group onto an N-acyliminium 
ion. This gave the bicyclic substrate 116 as a single enantiomer but sans the 
extra functionality of the C3-C4 double bond. Meyers and co-workers 
introduced this through a non-trivial and harsh selenylation-oxidation 
procedure, proceeding to chiral unsaturated bicyclic γ-lactam 118. The 
procedure gave the key intermediate 118 in a 55% yield over 6 steps.  
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Scheme 1.31: Meyers’ Synthesis of chiral bicyclic γ-lactam 118 
Another approach taken by Meyers and colleagues for the installation of an 
alkene in such bicyclic systems was to treat saturated intermediates such as 
119 with methyl benzene sulfinate, followed by a period of reflux in toluene 
with excess base to promote elimination of the intermediate sulfoxide 
(Scheme 1.32).107  
Scheme 1.32: Another of Meyers’ approaches to introducing an alkene at C3-C4 
Other researchers who have prepared the same scaffold by different means 
include Demir and co-workers, who utilised their established pyrrole 
photooxidation methods to do so (Scheme 1.10).75 They also used as 
starting materials pyrroles that incorporated chiral N-substituents featuring 
pendant hydroxyl groups (33). Photooxidation of the pyrrole gave the bicyclic 
lactams 34 in moderate yields.108 However, for each chiral pyrrole used a 
mixture of diastereomeric products was obtained, albeit with some 
diastereoselectivity. They supported their stereochemical findings with a 
computational study which indicated that the favoured diastereomer arose 
because of restricted rotation of the N-substituents.109 
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Building on work by Yoshifumi110 and Anaya,111 De Kimpe and colleagues 
approached bicyclic lactams from a different angle, through the silver-
mediated ring expansion of functionalised β-lactams (Scheme 1.33).112 They 
synthesised a range of highly functionalised β-lactams 123, with pendant 
alcohols as N-substituents, which when treated with AgBF4 and pyridine 
underwent ring expansion to give an iminium ion intermediate, which 
underwent cyclisation by nucleophilic attack of the pendant alcohol to give 
the bicyclic lactams 124 and 125 without stereoselectivity at the C5 position. 
Their approach, through requiring particular substituents to effect the ring 
expansion, also limited the ability to further functionalise the γ-lactam 
towards a natural product-like species.  
Scheme 1.33: de Kimpe and colleagues’ β-lactam ring expansion 
There are a number of other published examples of bicyclic γ-lactams in the 
literature. The majority utilise the cyclocondensation of a β-amino alcohol 126 
with a γ-keto acid or ester 127 (Scheme 1.34).113-120 While some of these 
take novel approaches, such as using resin-bound starting materials,121 there 
are some common problems such as a lack of stereoselectivity, and a need 
to synthesise highly functionalised starting materials to give specific 
products. In addition, many of the lactam products observed lack the 
modifiable double bond at the C3-C4 position seen in bicyclic lactam 118.  
Scheme 1.34: General scheme of cyclocondensation reactions 
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Another approach commonly taken, as is the case in both Meyers’ and de 
Kimpe’s work, is the generation of an iminium ion in a monocyclic lactam 
species and allowing ring closure through intramolecular attack of a pendant 
alcohol or other nucleophile.122-126 In these cases the iminium is usually 
generated through treatment of a partially reduced maleimide or succinimide 
with a Lewis acid. 
Scheme 1.35: Approaches to bicyclic lactams from norephedrine 
There have been some other novel approaches taken to forming these kinds 
of molecules, normally with particular built in functionality and reduced scope 
for post-formation manipulation. Belvisi and de Kimpe both developed 
approaches starting from (1R,2S)-norephedrine (129, Scheme 1.35). 
Belvisi’s approach involved the cyclisation of an iodoamide intermediate 
130.127 De Kimpe and colleagues formed bicyclic lactams both through the 
NaH deprotonation of 5-halomethyl pyrrolidinones 132 to generate an alkene 
which is attacked by the pendant alcohol, and also in a one pot condensation 
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reaction of the (1R,2S)-norephedrine with levulinic acid 134, through 
intermediate oxazoline 135.128  
Le Goff and colleagues developed a domino process with commercially 
available electron-deficient Michael acceptors and specifically prepared 
acyclic amides 137 (Scheme 1.36).129  
Scheme 1.36: Le Goff’s Domino process  
Katsumura and colleagues developed a one-pot asymmetric aza-
electrocyclisation of vinyl iodide 139 and aminoindanol 140 followed by Stille 
coupling, which yielded a complex polycyclic γ-lactam 144 in addition to a δ-
lactam 145 (Scheme 1.37).130  
Scheme 1.37: Katsumura’s one pot aza-electrocyclisation with Stille coupling 
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The planned route to chiral bicyclic γ-lactams in this work shared some 
similarities with Meyers and colleagues’ work, using a chiral amino alcohol as 
a starting point, and taking the iminium generation route to form the second 
ring in the bicycle (Scheme 1.38). However, it was instead proposed to form 
a pyrrole, 146, from the amino alcohol, rather than a succinimide, through a 
mild variation on the Clauson–Kaas pyrrole synthesis developed in the Smith  
group.131  
Scheme 1.38: Planned route to chiral bicyclic γ-lactams 
This species could then be oxidised to give the corresponding monocyclic γ-
lactam 147, using either hypervalent iodine oxidation or photochemical 
oxidation.62,80 This γ-lactam intermediate could then be treated with a Lewis 
acid such as BF3.OEt2, or a Brønsted acid such as TFA, to give a bicyclic 
lactam 107 via an N-acyliminium intermediate, with the stereochemistry set 
for the ether substituent in the 5-position by the chiral N-substituent. This 
intermediate could then be modified in much the same way as the previously 
discussed racemic compounds, through dihydroxylation and Friedel–Crafts 
alkylation to give chiral intermediates such as 148. Finally, the N-substituent 
could be cleaved through hydrogenation or other means and the nitrogen 
methylated to give (–)-codonopsine analogues 149.  
The second proposed approach to reach such analogues was one inspired 
by the use of chiral auxiliaries in asymmetric organic synthesis (Scheme 
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1.15). Probably the best known and one of the most widely used of these is 
(–)-8-phenylmenthol (150, Scheme 1.39).132 These chiral auxiliaries can 
direct the face of certain chemical transformations by placing a bulky chiral 
group in the way, as in the case of Corey’s use of (–)-8-phenylmenthol in a 
facially selective Diels–Alder reaction involving the auxiliary-substituted 
dienophile 151 and cyclopentadiene derivative 152 (Scheme 1.33).132  
 Scheme 1.39: 8-phenylmenthol/action of a chiral auxiliary 
The approach to be taken in this work was not to use 8-phenylmenthol itself, 
but to synthesise a pyrrole starting material that incorporated a bulky chiral 
N-substituent that might achieve a similar effect (Scheme 1.40). Thus, it was 
planned to use (S)-(+)-2-phenylglycine methyl ester as the basis for pyrrole 
154, which would provide a relatively bulky chiral group. It was hypothesised 
that on treatment with Dess–Martin periodinane, oxidation to yield the 2-
iodoaroyloxy moiety at C5 would favour one face over the other to give only 
one of the two possible diastereomeric products, such as 155a.  
Scheme 1.40: Plan for using chiral auxiliary to control oxidation stereochemistry 
While chiral N-benzylamines are not reported to be highly efficient chiral 
auxiliaries, they are readily removed133 and in the event of diastereomers 
forming these could be separated. This would allow for stereoselective 
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transformations to be carried out around the lactam ring without the need to 
form a chiral bicyclic lactam first. This would potentially offer a shorter 
synthetic route to the same chiral (–)-codonopsine analogues. 
1.6 Results of Bicycle Approach 
1.6.1 Bicycle Syntheses 
The first step for both the bicycle and the chiral auxiliary approaches to these 
asymmetric syntheses was the preparation of the starting pyrroles from the 
corresponding chiral amine or amino acid derivatives (Figure 1.5). For the 
bicycle approach, pyrroles 156 and 157 were prepared from the 
corresponding (S)-(+)-2-phenylglycinol and (S)-(+)-2-phenylalaninol in near 
quantitative yield, through a modified Clauson–Kaas procedure in a buffered 
biphasic mixture.131 The pyrrole derived from L-phenylglycine methyl ester 
hydrochloride, 154, was prepared similarly, to be used in the chiral auxiliary 
pathway. Finally, another less bulky pyrrole was prepared to test the limits of 
the chiral auxiliary approach, from (R)-1-phenylethylamine (158). This was 
attempted as an on-water reaction, based on work by McErlean and 
colleagues.134,135 While this made the reaction operationally simpler, the 
yields were lower than would be achieved by the method of Smith and co-
workers.  
Figure 1.5: Pyrroles prepared for this work 
The first transformation of this pyrrole was to protect the alcohol 156 with a 
Boc group to give pyrrole 159 (Scheme 1.41). While, as stated above, DMP 
has been shown to selectively target pyrroles over alcohols,62 the alcohol 
oxidation is still very facile and it was deemed prudent to prevent this 
unwanted side reaction occurring from the outset. After the reaction was 
observed to be complete by TLC, the solvent was removed and a 1H NMR 
spectrum of the crude mixture analysed to ensure that the Boc group had 
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been incorporated, through the appearance of a singlet peak integrating for 9 
protons in the 1H NMR spectrum. Protected pyrrole 159 was then subjected 
to the oxidation step without purification.  
Scheme 1.41: The synthesis of chiral bicycle 118 
Oxidation of pyrrole 159 was carried out under the previously developed 
conditions using Dess–Martin periodinane. It was found that this reaction was 
sluggish if the dichloromethane solvent was too dry. Consequently, the 
addition of one or two drops of water to the reaction mixture helped the 
oxidation to proceed smoothly to completion in 2 h, consistent with previous 
observations.66 The 1H NMR spectrum of crude 160 was observed to be 
quite complicated, indicative of the formation of a mixture of diastereomers at 
C5 of the γ-lactam. The crude mixture was subjected to the next step to 
avoid an unnecessary purification. 
The crude mixture of γ-lactams 160 was treated with trifluoroacetic acid 
(TFA, 10% v/v) overnight. The intention in this step was to carry out three 
reactions in three stages in one pot: first the acid-promoted cleavage of the 
Boc protecting group from the alcohol, secondly Brønsted acid generation of 
an iminium ion at C5 of the lactam (to give iminium 160a), and finally 
cyclisation by nucleophilic attack of the oxygen in the alcohol. Pleasingly, this 
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gave a single product, which was identified as the desired bicyclic γ-lactam 
118 as a single enantiomer. Key indicators of success in the NMR spectra 
were the alkene peaks in the 1H NMR spectrum at 6.29 pm and 7.21 ppm, 
and the now individually resolved diastereotopic proton resonances of the 
phenylethanol fragment, adjacent the newly formed ether at 4.10 ppm and 
4,75 ppm, identified by their mutual couplings and coupling with the adjacent 
methine proton. The appearance of a single carbonyl in the 13C NMR 
spectrum at 176.8 ppm supported the conclusion that the elimination of the 
iodoaroyloxy sidechain of lactam 160 had occurred.  
All characterisation data were in agreement with those reported by Meyers. 
The 1H and 13C NMR resonances’ chemical shifts were within 0.03 and 0.2 
ppm of the reported values, respectively. The observed optical rotation of 
+104o was also close to the reported value of +116o, accounting for a large 
difference in concentration between the two samples. Furthermore, x-ray 
crystal structures of derivatives of bicycle 118 supported the structural and 
absolute stereochemical assignment (vide infra). The overall yield for these 
reactions, essentially five reactions in three steps, was 55%, which is 
comparable to that reported for Meyers and co-workers’ approach, but 
obtained using much milder and less rigorous methods.102  
As all of the reactions in this sequence were carried out using 
dichloromethane as the solvent, a one-pot approach was attempted where 
each reagent was added sequentially after TLC analysis showed completion 
of the preceding step. This approach initially appeared quite successful, 
giving yields comparable to the stepwise approach, when carried out on a 
small scale. However, it was observed that the results were not reproducible 
on larger scales. Not carrying out the reductive workup procedure after the 
oxidation step hindered the progress of the TFA ring-closing step such that 
there was only partial conversion of the lactam 160 after 16 h, with little 
change even if further TFA was added. In this instance the reaction would 
need to be worked up and treated with TFA a second time to achieve full 
conversion. Thus, the best method adopted was to carry out the Boc 
protection and oxidation in one pot, followed by working up the reaction, then 
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treating the crude intermediate γ-lactams with TFA to give the key 
intermediate 118. 
Alternative oxidants were also explored to compare results. IBX was used in 
place of DMP to give similar results (Scheme 1.42). In this case, the 
reactions had to be carried out in a stepwise fashion from the outset, as it 
was necessary to oxidise the pyrrole in acetic acid rather than 
dichloromethane. An additional difficulty imposed by using this oxidant is that 
all of the acetic acid used as solvent was neutralised with a base on workup, 
which also removed the 2-iodobenzoic acid by-product. For large-scale 
reactions, this can be a slow and arduous exercise. However, the IBX 
procedure does give comparable yields of bicyclic γ-lactam 118 to the DMP 
process, albeit over a significantly longer reaction time.  
Scheme 1.42: IBX as an alternative oxidant 
It was hoped that photooxidation could also be used to reach bicyclic lactam 
118 in a more economical manner. Pyrrole 156 was subjected to 
photooxidation conditions previously developed, using a photoreactor with 
red LEDs and methylene blue as the sensitiser (Scheme 1.43).80 As with the 
hypervalent iodine route, the crude residue was treated with TFA 
immediately. Unfortunately, this gave complete decomposition of the starting 
material. The Boc-protected pyrrole 159 was subjected to the same 
photooxidation conditions. In this case, the desired bicyclic lactam 118 was 
isolated, but only in trace quantities compared with the near total 
decomposition of the starting material.  
Pyrrole 159 was also subjected to two other sets of photooxidation 
conditions, to determine whether the results could be improved. (Scheme 
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1.43) Our established conditions for using green LEDs with Rose bengal as 
the sensitiser, which worked well for a variety of pyrroles previously,80 also 
gave no sign of the desired lactam following treatment with TFA, and the 1H 
NMR of the crude reaction mixture of the oxidation prior to TFA treatment 
showed essentially complete decomposition by that stage. A white LED 
photoreactor was also used, with tetraphenylporphyrin (TPP) as the 
sensitiser, which was closest to the white light used in Demir’s work in this 
area.75 Unfortunately, this also led only to decomposition. 
It was clear from these reactions that these particular pyrroles were not 
amenable to photooxidation. It is possible that the benzylic methine hydrogen 
may be involved in causing the decomposition, although these 
photooxidation conditions were appropriate for N-benzylpyrrole itself. 
Therefore it was concluded that preparation of the desired bicyclic lactam 
was best pursued by hypervalent iodine reagent oxidation.  
Scheme 1.43: Attempted photooxidation conditions 
1.6.2 Reactivity of the Chiral Bicyclic Lactam 118 
With the chiral bicyclic lactam 118 in hand, the first transformation carried out 
towards the synthesis of chiral (–)-codonopsine analogues was a 
dihydroxylation under Upjohn conditions, which gave an 84% yield of the 
desired diol 162 (Scheme 1.44). Unlike in the racemic syntheses, this diol 
was isolable and amenable to purification. The diol did prove to be highly 
polar, however, and insoluble in common organic solvents other than DMSO 
at higher concentrations. The formation of the diol was supported by the 
appearance of two doublet peaks in the 1H NMR spectrum in DMSO-d6 at 
5.51 and 5.95 ppm representative of the hydroxyl protons coupling to the 
adjacent methines. Furthermore, these proton resonances did not display 
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HSQC correlations to carbon atoms. The fact that only a single product was 
isolated from this reaction indicated that the chiral C5 substituent was indeed 
controlling the facial selectivity of the dihydroxylation reaction, and thus most 
likely forming a diol with a trans relationship to that substituent. 
Diol 162 was then protected as a diacetate, under the same conditions as 
described for the racemic intermediates, which gave 163 in a yield of 86%. A 
significant reduction in polarity was observed, and the appearance of two 1H 
and 13C NMR resonances consistent with the introduction of two acetate 
esters supported the formation of the desired product.  
Scheme 1.44: Dihydroxylation and protection of bicycle 108 
Diacetoxylactam 163 was particularly important for establishing that the 
stereochemistry of the ether at C5 would bias transformations at other 
positions on the ring to give single stereoisomers. Initially the exact relative 
stereochemistry was uncertain, as the coupling constant observed between 
the lactam ring protons at C4 and C5 was 2.9 Hz (Figure 1.6). While this is 
considerably less than the coupling between the C3 and C4 protons of 6.8 
Hz, in a system where the C4 and C5 protons had a fixed dihedral angel of 
about 90o, the coupling constant should be close to 0 Hz, if the coupling 
followed what would be expected from the basic Karplus relationship.86 
Indeed, in the racemic work discussed in section 1.3.1 this was observed to 
be the case.  
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The observed couplings for strained five-membered rings such as 163 could 
be expected to vary greatly from the idealised unstrained open chain case of 
the original Karplus relationship, and the many substituents on the ring would 
likewise play some role in affecting the couplings observed.  
Figure 1.6: Observed coupling constants for bicyclic compound 163 
Fortunately it was possible to crystallise this species and acquire an X-ray 
crystal structure (Figure 1.7). The crystal structure of lactam 163 showed that 
the hydrogen at H5 was trans to that at C4, therefore supporting the 
conclusion that the face of addition was controlled by the C5 substituent. This 
analysis also allowed us to measure the dihedral angles between the C3, C4 
and C5 hydrogen atoms. These were 23.6o for the dihedral angle between 
the C3 and C4 protons, and 95.8o between the C4 and C5 protons, the latter 
value being very close to what was initially expected, which demonstrated 
that in this system such dihedral angles do not have the same magnitude 
effect on the coupling constants as might be expected in a less rigid and 
small ring system.  
Diol 162 was also protected as the acetal 164, which was produced in a 71% 
yield after stirring with 2,2-dimethoxypropane and catalytic amberlyst acidic 
resin (Scheme 1.44). The identity of the product was supported by the 
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appearance of two singlet peaks integrating for 3 protons at 1.42 and 1.56 
ppm in the 1H NMR spectrum indicative of the incorporation of acetone as an 
acetal. 
With the stereochemistry assigned, diacetoxy 163 was treated with a Lewis 
acid and an arene to effect a Friedel–Crafts alkylation reaction (Scheme 
1.45). However, under the previously developed conditions with BF3.OEt2 
and 1,2-dimethoxybenzene no reaction was observed after 16 h. This 
somewhat surprising result has been attributed to the high stability of the 
ether at C5, leading to a lack of N-acyliminium ion formation.   
Figure 1.7: X-ray crystal structure of bicycle 163 
Trialling different Lewis acids such as TiCl4 did not improve the outcome, 
even when added in great excess (Scheme 1.45). TMSOTf was also used, 
under the same conditions as the BF3.OEt2, in the hopes that the alcohol 
would be trapped in situ as the trimethylsilyl ether, but this also failed to 
promote any reaction.  
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Scheme 1.45: Conditions for attempted Friedel–Crafts alkylation of lactam 135 
Other attempted approaches included a Petasis borono-Mannich reaction via 
cyclic N-acyliminium ions, based on work by Batey and Pyne using vinyl or 
arylboronic acids or boronate esters with N-acyliminium ions generated by 
Lewis acids from cyclic amides with a 1,2-diol 166 (Scheme 1.46).136-138 In 
the case where the diol was not derivatised, these are theorised to proceed 
through the formation of a boron ester, such as 167, with the C3 alcohol 
adjacent to the iminium site, followed by intramolecular attack of the boron R-
group. This generally directs the stereoselectivity of the reaction to give a cis 
relationship between the alcohol and the R-group introduced, as for δ-lactam 
168. However, Pyne and colleagues observed that in the instance where the 
C3 alcohol is protected as a benzyl ether the reactions still proceed but give 
a majority trans product. They also noted that the reactions were usually only 
successful for very electron-rich boronic acids (such as methoxyphenyl 
derivatives), and that five-membered cyclic amides were usually less 
successful than their six-membered analogues.  
Scheme 1.46: Mechanism for Pyne and colleague’s Borono-Mannich reactions 
Unfortunately, when the acetoxy bicycle 163 was treated with para-
methoxyphenylboronic acid (169) and BF3.OEt2 under Batey and Pyne’s 
conditions, stirring in dichloromethane at room temperature, no reaction was 
observed. As Pyne hypothesised that the reaction can proceed through a 
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boronate ester intermediate such as 167, the reaction was repeated using 
diol 162, where such an intermediate could form (Scheme 1.47). In this case, 
the substrate was converted into a new product, which initially looked 
promising by 1H NMR analysis through the addition of resonances consistent 
with a 1,4-disubstituted aryl group and a methoxy peak at around 3.8 ppm. 
However, closer analysis by HSQC and HMBC experiments indicated that 
this aryl moiety was not incorporated into the main lactam portion of the 
molecule, and TLC analysis indicated that the compound was far less polar 
than would be expected for the desired triol product. Pyne and colleagues 
observed that in some cases with cyclic amides with 2,3-diols a boronate 
diester was the main product. Therefore, it was proposed that a similar 
process had occurred here, with the boron reacting with the diol exclusively, 
giving boronate diester 170.   
Scheme 1.47: Deduced result of attempted Petasis borono-Mannich reaction 
A variety of cuprate reaction conditions were also trialled to attempt to 
introduce a methyl group in the 5-position of bicyclic lactam 163, on the 
assumption that the aryl moiety could be introduced at a later stage through 
the amide functional group. Unfortunately at a range of temperatures, using 
CuI and CuBrMe2S as copper sources, in THF or Et2O as solvent, and even 
including TMSCl as an additive to trap the pendant alcohol, either no reaction 
or decomposition of the starting materials was observed (Scheme 1.48).  
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Scheme 1.48: Attempted cuprate conditions of diacetoxylactam 163 
To probe whether any reactivity at the C5 position was possible, diacetoxy 
lactam 163 was treated with a large excess of TiCl4 as the Lewis acid and 
triethylsilane as the nucleophile. It was hoped that a less hindered hydride 
nucleophile would have readier access to the iminium ion than a bulkier aryl. 
If this were successful, it might still be possible to reach codonopsine 
analogues through Grignard-type chemistry on the amide to introduce the 
aryl group at C2. However, even under the most forcing conditions, and long 
reaction times, results were unsatisfactory. While in a first test some of the 
desired ring-opened species was obtained (172, Scheme 1.42), these yields 
were inconsistent, and irreproducible, with reactions returning mostly starting 
material and decomposition products. This result is not without precedent, as 
Meyers’ and colleagues found in their synthesis of (–)-rolipram that reactions 
of bicyclic lactams with C3 or C4 oxygen substituents proceeded poorly 
under similar conditions, and concluded that they were not compatible with 
this methodology.103  
Scheme 1.49: Conditions for ring-opening diacetoxylactam 163 
Attempts were made to remove the N-substituent of 172, using what material 
was available from the inconsistent reactions carried out. Standard 
hydrogenation conditions using a Pd(OH)2 catalyst in EtOH gave no reaction. 
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An oxidative debenzylation approach developed by Moriyama and Togo, 
which utilised KBr with Oxone®, was also unsuccessful.139 
These studies led us to conclude that the bicyclic lactam 118, while a robust 
platform for stereoselective functionalization of C3 and C4, is too stable to 
form the N-acyliminium intermediate required to reach  (–)-codonopsine 
analogues with absolute stereochemical control. It was decided that the use 
of a chiral auxiliary that did not form a stable bicyclic system might ultimately 
prove a better solution.  
Some further transformations carried out using the bicyclic diol 162 were of 
interest. As an alternative to the acetoxy or acetal protecting groups, 
protection of the diol as a benzyl ether was also attempted (Scheme 1.50). 
The protection was carried out under standard conditions, using NaH and 
benzyl bromide. However, rather than giving the expected dibenzylated 
product, alkene 173 was isolated in a high yield. At first it was unclear what 
had happened in the reaction, as the 1H and 13C NMR spectra only indicated 
one benzyl group being present, with no evidence of another unprotected 
alcohol as might be expected. Furthermore, the 1H NMR spectrum indicated 
that there were only two protons on the pyrrolidine portion of the molecule, 
through the appearance of doublets at 5.56 ppm and 5.88 ppm. Through 
HRMS and IR analysis it was postulated that elimination of the alcohol β to 
the carbonyl had occurred. This structure was supported by acquisition of an 
X-ray crystal structure, which also provided unambiguous support for the 
stereochemical configuration of the bicycle (Figure 1.8).  
Scheme 1.50: Benzyl protection and elimination of diol 162 
Further to this, benzyl ether 173 was hydrogenated to give alcohol 174 
(Scheme 1.51). This transformation was expected to be facially selective to 
yield an alcohol with the opposite stereochemical orientation at C3 to that 
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seen in diol 162, resulting in a syn relationship between the H3 and H5 
protons. This proved successful, with the expected alcohol 174 isolated in a 
55% yield. The loss of the benzyl group was supported by disappearance of 
the benzyl CH2 signal at 5.03 ppm and a multiplet integrating for 5 protons in 
the aromatic region of 7.26–7.45 ppm of the 1H NMR spectrum, and the 
appearance of a broad OH stretch at 3335 cm-1 in the IR spectrum. The 
hydrogenation of the alkene was supported by the appearance of the two 
diastereotopic protons of H4 in the 1H NMR spectrum as a doublet of doublet 
of doublets at 2.05 ppm and a multiplet at 2.96–3.05 ppm.  
Scheme 1.51: Further transformations of the benzyl derivative 173 
Alcohol 174 was protected once again as the benzyl derivative, giving benzyl 
ether 175 in a yield of 67%. It was possible to crystallise benzyl ether 175 
and acquire an X-ray crystal structure of it (Figure 1.8), which supported our 
proposed inversion of the C3 stereochemistry through the elimination-
hydrogenation reactions. Therefore we have demonstrated that a hydroxyl 
group has been introduced at C3 in both possible orientations. 
Figure 1.8: X-ray crystal structures of benzyl-protected biycycles 173 and 175 
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1.7 Chiral Auxiliary Approach 
The chosen pyrrole substrate for testing this approach was then prepared 
from S-(+)-2-phenylglycine methyl ester hydrochloride, 154. Oxidation of this 
pyrrole under the standard Dess–Martin periodinane conditions did not, 
however, yield a single diastereomeric product. Instead two distinct products 
were obtained in a 1:1 ratio, which were believed to be the two possible 
diastereomeric products of the oxidation reaction, epimeric at the 5-position, 
lactams 155a and 155b (Scheme 1.52). The two diastereomers were 
separable by flash column chromatography, and their independent identities 
were supported by full 1H and 13C NMR analysis; through their having 
identical molecular masses as supported by HRMS analysis, and through the 
acquisition of an X-ray crystal structure of both compounds to determine the 
relative stereochemistry (Figure 1.9).  
Scheme 1.52: Synthesis of chromatographically separable chiral lactams 
This was not the ideal result, as there was no bias in facial selectivity in the 
pyrrole oxidation as a result of having the chiral moiety included in the 
pyrrole. However, it was a success in that the two diastereomers could be 
isolated. As such, it was believed that these individual diastereomers could 
be taken and subjected to the same transformations as in the racemic work, 
to give both enantiomeric series of codonopsine-like compounds starting 
from a single enantiomer of pyrrole 154. 
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Figure 1.9: X-ray structures of the diastereomers 155a (left) and 155b (right) 
Given that this oxidation did not give facial selectivity, but did give separable 
products, it was decided to take a less sterically hindered pyrrole and oxidise 
that to see whether any pyrrole with a chiral N-substituent would give 
separable diastereomers. To this end pyrrole 158 was oxidised under the 
same conditions as 154 (Scheme 1.53). This again gave what appeared to 
be two possible diastereomers. However, in this case the products were not 
separable by chromatography, and only a mixture of the two could be 
isolated, in a 47% combined yield. This indicated that the auxiliary from 
phenylglycine methyl ester was indeed necessary to give separable oxidation 
products.  
Scheme 1.53: Oxidation of the pyrrole 158 
The individual diastereomers 155a and 155b were each taken and 
separately subjected to dihydroxylation under Upjohn conditions (Scheme 
1.54). Unusually, both of these reactions led to a mixture of products rather 
than each giving a single diastereomeric dihydroxylated product – i.e. 177a 
for 155a and 177b for 155b, respectively. In fact, both led to what appeared 
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to be a 1:1 mixture of 177a and 177b, based on NMR analysis. This indicates 
under these scrambling of the C5 substituent occurred, such that it was 
unable to direct the outcome of the dihydroxylation to give a single 
diastereomer as the product. Also unfortunately, the mixture of products 
obtained were not chromatographically separable like their predecessors 
155a and 155b.  
Scheme 1.53: Scrambling through dihydroxylation 
This result seemed to eliminate the possibility of using this particular auxiliary 
inspired approach to obtain chiral codonopsine analogues. While attempts 
could have been made to carry out the transformations in a different order to 
remove the risk of epimerisation, experience with the racemic species 
indicated that the aryl intermediates with alkenes still in place at C3-C4 are 
too unstable to be subjected to dihydroxylation. And in any case, as the chiral 
N-substituent cannot control the stereochemistry at C5, carrying out further 
transformations here without functionalising the alkene first would lead to 
further mixtures of possibly inseparable diastereomers. 
1.8 Conclusions 
In conclusion, the scope of previous racemic work was successfully 
expanded to produce a range of (–)-codonopsine and (–)-codonopsinine 
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analogues. Unfortunately, it was not possible to develop a route to 2-methyl 
substituted analogues closer to the natural products. An alternative route to 
be explored in future work would involve the use of a different pyrrole starting 
material, such as N-benzylpyrrole 178 (Scheme 1.54). In Huang and 
colleagues’ work with amide alkylation and reduction they only used N-
benzylpyrrolidinones, so a lactam with this N-protecting group could be more 
amenable to that transformation.93  
Scheme 1.54: Proposed alternative racemic pyrrole route 
An advantage of the N-benzyl substituent is that it can be simply cleaved by 
hydrogenation and the free amine methylated. Also, it would be fruitful to 
consider methods for introducing a trans diol at the C3-C4 alkene of the γ-
lactams rather than a cis diol, to give analogues that more closely mimic the 
stereochemistry of the natural product. Biological testing of this full suite of 
analogues would be valuable for establishing their activity in assays 
compared with (–)-codonopsine and (–)-codonopsinine.  
A new synthesis was developed for a key chiral bicyclic lactam 118. This 
incorporated pyrrole synthesis and oxidation chemistry previously developed 
in the Smith group, and proved to be a milder and more efficient approach 
than many of those previously reported, with good overall yields and 
excellent stereochemical control. The reactivity of bicyclic lactam 118 was 
investigated with a view to carrying out asymmetric total syntheses of (–)-
codonopsine and (–)-codonopsinine, although it proved too stable to 
transformations at the ether C5 position for this to be viable. However, it 
remains a valuable intermediate, and was used successfully in the synthesis 
of fluorinated natural product analogues (See Chapter 2) 
A chiral auxiliary approach was also explored for the asymmetric synthesis of 
(–)-codonopsine and (–)-codonopsinine analogues, utilising bulky chiral N-
substituents. This led to separable mixtures of diastereomeric γ-lactams. 
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These ultimately were also not suitable to this application due to scrambling 
of the stereochemical configuration of the C5 ester in subsequent steps. 
Further studies could involve investigating transformations to these 
intermediates that do not involve ablation of stereochemistry by iminium 
formation. 
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Chapter 2: Synthesis of Fluorinated GABA Analogues 
through Pyrrole Oxidation 
2.1 Introduction to Fluorine in Natural Products and Drugs 
Organic natural products containing fluorine are rare. In fact, only five have 
been reliably reported (Figure 2.1).140 There have been few other reports141 
and in some cases the compounds have been either of suspect natural 
origin,142,143 or have been disproven through synthetic studies and proper 
interpretation of spectroscopic data.144,145  
Figure 2.1 Reported fluorine-containing natural products 
Despite this relative lack of fluorinated natural products, fluorinated 
analogues of known natural compounds have become popular and effective 
drug molecule targets.146-148 In 2007 fluorine-containing molecules made up 
an estimated 20% of all pharmaceuticals,149 and by 1990 up to 30% of all 
agrochemicals.150 Fluorine containing drugs are also among some of the best 
known and most widely used, including the antidepressant Prozac 
(fluoxetine, 186),151,152 the cholesterol-controlling drug Lipitor (atorvastatin, 
187),153 and many prospective anti-cancer agents.149  
Figure 2.2 Common fluorine-containing drugs Prozac (186) and Lipitor (187) 
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Introduction of fluorine into potential drug molecules can have significant 
effects on their activity, which is generally tied to their ability to bind to certain 
receptors effectively. Fluorine can enable this kind of increased activity 
through a number of effects it has on molecules it is added to.  
2.2 The C–F bond and How It Affects Organic Molecules’ 
Conformations and Activity 
Fluorine has a number of characteristics that affect how it bonds with carbon 
atoms in organic molecules, and what effect these bonds can have on the 
molecule’s activity, reactivity and conformation.154 Firstly, fluorine is a highly 
electronegative element, the most electronegative by the Pauling scale.155 It 
has a high nuclear charge, with 9 protons in its nucleus, and a relatively 
small number of electrons without occupancy in higher orbitals (only up to the 
2p orbital). As a result the electrons are all tightly held closer to the positive 
nucleus, which gives fluorine a relatively small atomic radius of 1.47 Å (in 
between hydrogen with 1.2 Å and oxygen with 1.52 Å).156 
This high electronegativity has an impact on the nature of C–F bonds. The 
tendency of fluorine to attract electron density means that C–F bonds have a 
highly polar character, with a significant δ- at the fluorine. The effect of this is 
to give the bonds an almost, or at least partially, ionic character, such as an 
electrostatic attraction between δ+ and δ- rather than a simple covalent 
sharing of electrons.154 This ionic character increases with the addition of 
more fluorine atoms to a single carbon centre. This makes the bond both 
shorter (1.35 Å, in between the C–H length of 1.09 Å and the C–O length of 
1.43 Å) and very strong.156 As such, it is also of itself quite unreactive. 
The atomic radius, bond length and stability of the C–F bond have made it 
something of a go-to hydrogen substitute for drug molecules in medicinal 
chemistry. However, the highly polar character of the bond compared with C–
H bonds makes it more like the C–O bonds of alcohols, and the 
electronegativity and other characteristics of fluorine can have a range of 
other effects on organic molecules to affect activity and the binding of a 
potential drug molecule to a receptor. The study of relationships between 
different functional groups’ size, conformation and packing, and 
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interchangeability within drug molecules, is called bioisosterism.157,158 It has 
been studied in great depth for fluorine containing functional groups, such as 
finding alkyl moieties that are best substituted by trifluoromethane 
groups,159,160 fluorine substituting for hydroxyl or  methyl groups,161,162 
fluorovinyl groups being used as analogues for peptide bonds,163-165, and 
difluorotoluene being used as an analogue for the DNA base thymine,166 
among others.167-169 
The electron-withdrawing character of fluorine can have a significant effect 
on the bioactivity and bioavailability of fluorine-containing drug molecules. 
Exchanging hydrogen with fluorine has generally been observed to produce 
more lipophilic molecules.170,171 This occurs through increasing the acidity of 
neighbouring functional groups and thus lowering the pKa of the molecule as 
a whole.172 This increases the logD value and hence the lipophilicity, that can 
lead to a more favourable partition of the drug between the polar aqueous 
media of the cell and the less polar receptor site.170,173,174 This is not a hard 
and fast rule of course,175 but some predictive rules have been developed to 
calculate the theoretical pKa of drug molecules based on the  introduction of 
fluorine near to heteroatom functionalities.172 This effect has been well-
studied for fluorine being introduced near amines, where increasing the 
number of fluorine atoms has been shown to decrease the basicity.172,176 
Indeed, enough adjacent fluorine atoms can leave an amine deprotonated as 
physiological pH.173 The effect has likewise been seen in increasing the 
acidity of nearby carboxylic acids, alcohols and phenols.  
The presence of a C–F bond gives rise to intermolecular and intramolecular 
interactions that can play a major role in determining the conformation of a 
molecule. This is of particular importance in drug design, where molecular 
conformation can bias a molecule towards binding or not binding to a desired 
receptor. 
One conformational effect of inclusion of fluorine is widening of the H–C–H 
bond angles of sp3 carbon atoms it is attached to, an effect that increases 
with two fluorine atoms present.154 This is possibly due to its withdrawal of 
electron density through the C–F bond into the fluorine’s p2 orbital, which 
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gives the carbon atom more of an sp2 character and widens the H–C–H bond 
angle. The change in angle is not especially large, being only on the order of 
0.8o in CH3F, but this can lead to significant conformational disorder in long-
chain molecules such as fluorinated fatty acids. 
The substantial ionic character of the C–F bond gives rise to a large dipole 
moment, which would be expected to promote electrostatic (dipole-dipole 
and charge-dipole) intermolecular and intramolecular interactions. Indeed, 
hydrogen bonding is observed with alcohols, although fluorine’s low proton 
affinity makes these interactions weaker and less favourable than traditional 
hydrogen bonds.171,177  
There are also many cases where dipole-dipole interactions between C–F 
bonds and the C=O bonds of peptide amides have been observed.146,161 
These interactions occur in an orthognonal arrangement, with the F of the C–
F bond directed towards the C of the amide carbonyl (Figure 2.3). While 
these interactions are much weaker than hydrogen bonds,178 Müller and 
colleague’s extensive analysis of various fluorinated inhibitors (mainly 
Thrombin inhibitors, with fluorophenyl substituents), show that incorporation 
of fluorine to give these interactions can have significant effects on the 
conformation of the drug molecule (twisting or changing shape to fit to 
peptide amides) and lead to great increases in potency.171,179 This effect is 
also observed for aliphatic C–F containing molecules and trifluormethyl 
groups.180  
Figure 2.3: C–F intermolecular dipole-dipole interaction 
These dipolar interactions can also occur intramolecularly, with significant 
conformational outcomes. A well-documented example of this is where a 
fluorine atom is introduced α to a carbonyl group. In this case the two dipoles 
repel each other and the molecule will twist such that they are antiparallel to 
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one another (Scheme 2.1). The effect decreases with a decreasing dipole 
moment of the carbonyl, with amides showing the most pronounced twisting, 
and aldehydes the least.181-184 1,3-Difluoroalkanes exhibit similar behaviour, 
with the dipoles of the C–F bonds forcing the fluorine atoms to avoid parallel 
alignment.185,186  
Scheme 2.1: Intramolecular dipole-dipole effects of fluorine substitution 
Substitution of fluorine onto aromatic rings greatly increases the positive 
polarisation of ortho hydrogen atoms, strengthening their interactions with N 
and O atoms and C–H---π interactions. This also affects the electronics of 
the aromatic ring, which can be seen in the case of hexafluorobenzene 
which, compared to benzene, has a large positive rather than negative 
quadrupole.187 These changes in electronics can affect the interactions of 
rings such that they π-stack in a face to face fashion, edge to face, or even 
eliminate interactions that occur in fluorine-free cases, depending on the 
number and pattern of fluorine atoms introduced.188,189 
Charge-dipole interactions, where the dipole of the C–F bond interacts 
favourably with a formally charged heteroatom, are stronger than dipole-
dipole interactions. As intramolecular interactions they can have  significant 
impacts on conformation. In cases where the fluorine and charged atom are 
vicinal, a gauche conformation will be adopted in preference (Scheme 
2.2).190-192 The effect is seen in a variety of species, such as increasing the 
puckering of azetidinium rings,192 influencing the orientation of substituents of 
six-membered heterocycles (such as 190),190 and even the orientation of 
fluorine atoms pendant to charged heterocycles (such as 191).192  
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Scheme 2.2: Effects of charge-dipole interactions on molecular conformation 
The other case where gauche conformers are preferred is in 1,2-difluoro 
compounds. While it might be expected, as is the case for 1,3-difluorinated 
species, that the two electronegative fluorine atoms would repel each other, 
another important feature of the C–F bond, called hyperconjugation, makes 
the opposite true.  
Difluoroethane (192, Scheme 2.3) provides a simple and well-studied 
example of this effect. The C–F bonds in this molecule feature a relatively 
low energy σ*C–F antibonding orbital, that is directed parallel to the bond and 
away from the fluorine. In the gauche conformation, the antibonding orbital of 
each C–F bond is aligned to have good overlap with and receive electron 
density from a vicinal C–H bond. This would normally be expected to weaken 
a bond and destabilise a molecule, but for a C–F bond the lengthening of the 
bond and reduction in its covalent character actually enhances its ionic 
character and strengthens the bond between the increasingly δ- fluorine and 
δ+ carbon.154 In the alternative trans–conformer, while dipole-dipole 
interactions are minimised, neither of the σ*C–F antibonding orbitals are 
aligned to receive electron density from a C–H bond. This makes this 
conformer only metastable, and not the equilibrium conformation.  
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Scheme 2.3: Hyperconjugation of 1,2-difluorethane 192 
This effect was first reported by Wolfe and colleagues in the 1970s,193 and 
there have been many investigations since attempting to explain it or prove 
what interactions are responsible for gauche preference. A number of 
computational studies have probed the extent to which hyperconjugation 
could play a role, through selectively analysing model difluoroethane where 
certain interactions are excluded. Brunck and colleagues found that the trans 
conformer was preferred when hyperconjugation interactions were 
excluded.194 Rablen and coworkers examined cases where a silyl group was 
in place rather than a vicinal fluorine, and found that while the trans 
conformer should have been greatly favoured in this case it was only 
marginally so due to hyperconjugation interactions.195 
Goodman and colleagues went further in probing a range of contributing 
interactions individually.196 This included relaxation effects, hyperconjugation 
with geminal substituents, and the “bent bond” alternative theory put forward 
by Wiberg and colleagues, where the electrostatic pull of F in the C–F bonds 
reduces the electron density of the C–C bond in the trans but not in the 
gauche–conformer.197,198 They found that of the possible interactions, 
relaxation effects and intramolecular hyperconjugation played the greatest 
role, while bent bond effects and others accounted for only a fraction of the 
stability of the gauche–conformer.196 
It is also worth noting that the dihedral angle of the gauche conformer in 
difluoroethane is not the ideal 60 o that might be expected to allow maximum 
overlap for hyperconjugation. Many experimental and computational 
analyses have shown that the angle is between 71–72 o, which is believed to 
be due to the effects of dipolar repulsion.196 
The σ*C–F antibonding orbital can accept electron density from neighbouring 
aligned electron-rich bonds, such as C–H bonds or π bonds, and also lone 
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pairs of electronegative heteroatoms like O and N, or nucleophiles, with more 
electronegative substituents giving a stronger effect.191,197,199-203 
2-Fluoropyran derivative 193 is a good example of hyperconjugation through 
donation from a lone pair of an oxygen atom, which favours an axial rather 
than equatorial orientation for the fluorine (Scheme 2.4).203 Benzyl fluoride 
194 demonstrates an example of fluorine favouring an orientation where the 
antibonding orbital is aligned to accept electron density from a π system.200  
Scheme 2.4: Other examples of hyperconjugation effects on conformation 
Hyperconjugation can also be used to explain the preferred conformations of 
1,3-difluorinated systems, such as for the 1,3-difluoropropane mentioned 
above.185,186 When the fluorine atoms are out of alignment with the right 
orientation (195 A, Figure 2.4), both antibonding orbitals are being fed 
electron density by a C–H orbital. In B they are not aligned, but there is only 
one interaction, reducing the stability of this conformer. In C there are no 
interactions, and in D, while there is one hyperconjugation interaction, there 
is also F–F repulsion, which makes this the least stable conformer.  
Figure 2.4: Hyperconjugation to explain 1,3-dipolar repulsion 
Combinations of the gauche effect for vicinal fluorines and the 1,3-dipolar 
repulsion effect have an influence on the conformation of extended 
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multivicinal fluorinated molecules, which have been investigated in depth by 
O’Hagan and colleagues, amongst others. In extended systems vicinal 
fluorines will arrange such that they are gauche while 1,3-fluorines will be 
effectively anti.186 
2.3 Fluorinated GABA Analogues: Activity and Synthesis 
γ-Aminobutyic acid (GABA, 196, Figure 2.5) serves as a major 
neurotransmitter molecule, and its binding to certain receptors is necessary 
for a number of actions such as the opening of ion channels and activation of 
enzymes.204 GABA binds to three main types of receptors in the body, known 
as GABAA, GABAB and GABAC receptors, each of which has its own 
subtypes.205-210 GABAA and GABAC receptors are ligand gated ion channels, 
and GABAB receptors are G-protein-coupled receptors, that rely on a 
secondary messenger system to mediate their effects.205 The signalling 
mediated by GABA receptors can differ greatly in different regions of the 
brain, different types of cells, and even cells in different locations.208 For 
example, GABAA type receptors can be involved in the symptoms of 
schizophrenia,211 and elsewhere in sensorimotor information processing.212 
This makes an understanding of how GABA binds specifically to different 
receptor types and subtypes, and what effects these can have, very 
important.  
As such, the preparation of compounds that enhance, activate or diminish 
the activity of GABA at specific receptor types/subtypes is of significant 
interest for understanding its biological role and developing therapeutic 
medications for a number of GABA receptor linked medical conditions. There 
are many and varied structures of drugs and strategies used to inhibit GABA 
receptors at present, from small molecules to proteins.207,213,214 The fact that 
GABA itself engages with all of these receptors indicates that a good 
understanding of how its conformation changes to suit receptor shape and 
functionality would be useful for more targeted drug design.  
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Figure 2.5: GABA and its proposed conformations in different receptors 
A considerable amount of research has focussed on characterising the 
GABA receptor binding pockets, initially using other related ligand-gated ion 
channel protein crystal structures and computer modelling.215-218 In 2013 a 
high resolution crystal structure was obtained of GABAB both alone and co-
crystallised with GABA and an antagonist.219 The structure of the receptor 
itself altered significantly between the three cases, suggesting agonist-
binding triggers a conformational change necessary for channel activation. 
This showed that in GABAB, GABA adopts an extended zigzag conformation 
(Figure 2.5) to establish an interaction between the carboxylic acid group and 
a tyrosine residue in the binding pocket.219 Though less definitive, testing of 
many conformationally restricted GABA analogues has given a consensus on 
the conformation of GABA in GABAA and GABAC receptors as well, 
identifying them as having a more extended geometry than in GABAB.220  
The groups of O’Hagan and Hunter have taken significant interest in 
investigating the use of fluorinated analogues of GABA as potential agonists 
and antagonists.221-223 Due to hyperconjugation effects in their vicinal 
polyfluorinated backbones, and also the charge-dipole effects of fluorine 
adjacent to the charged C–N+ bonds, these species can adopt very particular 
and well-defined conformations while having a minimal impact on the size 
and sterics of GABA, which can be used to determine the conformation of 
GABA best suited to the binding pockets of different GABA receptors.154,224  
Hunter and O’Hagan have prepared a range of mono and difluorinated GABA 
analogues, examined their lowest energy conformations and tested them for 
binding affinity with GABAA, GABAB and GABAC receptors (Figure 2.6).225 In 
H2N
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O
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the monofluorinated analogues 197 and 198, the conformation is set mainly 
by the F...N+ attraction, but in 199–202, hyperconjugation effects lead the C–
F bonds to adopt a gauche conformation.226  
Figure 2.6: GABA, and a variety of fluorinated derivatives used by Hunter and 
colleagues 
Analogues 199–202 were first tested against the GABAB receptor for 
benchmarking, as the binding mode of GABA is well established for this 
receptor (Table 2.1). Following this, the full range of fluorinated compounds 
were tested against the GABAA and GABAC receptors. Syn-difluorinated 
analogues 199 and 200 showed agonist activity against GABAB, due to their 
extended zigzag conformations most closely matching that of GABA in the 
receptor. Monofluorinated compounds 197 and 198 have an extended 
conformation, and showed agonist activity in both the GABAA and GABAC 
receptors.227 With their similar bent conformations, the anti-difluorinated 
analogues 201 and 202 showed weak agonistic activity for GABAB but weak 
antagonistic activity for the other two receptors.223,225  
These studies gave the researchers a good idea of the binding geometries of 
each of the fluorinated analogues, and helped to support the models of 
GABA binding geometries developed for the GABAA and GABAC receptors. 
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Table 2.1: Summary of activity of fluorinated GABA analogues for GABAA, GABAB 
and GABAC receptors 
 
 
 
 
 
 
 
2.4 Methods for Introducing Fluorine and Deoxyfluorination 
2.4.1 General Approach to Fluorination of Organic Molecules 
There are three main routes utilised for introducing fluorine to organic 
scaffolds: nucleophilic, electrophilic and radical fluorination (Scheme 2.5).228 
In nucleophilic fluorination, the substrate behaves as an electrophile while an 
F– source acts as a nucleophile. In these reactions, a suitable leaving group 
on the substrate is replaced with fluoride in what is generally an SN2 reaction, 
with inversion of stereochemistry at the site of substitution (Scheme 2.5). A 
particular example of these nucleophilic reactions is where an alcohol is 
substituted is called deoxyfluorination, discussed in in section 2.4.2.  
 
Compound GABAA Activity GABAB Activity GABAC Activity 
196 Agonist Agonist Agonist 
197 Weak agonist N/A Agonist 
198 Weak agonist N/A Agonist 
199 nil nil Agonist 
200 nil Agonist Antagonist 
201 Weak antagonist Weak agonist Weak antagonist 
202 Weak antagonist Weak agonist Weak antagonist 
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Scheme 2.5 General schemes for fluorination reactions  
The more traditional reagents in nucleophilic fluorination include complexes 
of HF, such as HF/pyridine, tetrabutylammonium fluoride (TBAF) and 
tetrabutylammonium difluorotriphenylsilicate (TBAT). Hypervalent iodine and 
bromine reagents have also been reported, such as IPyBF4, para-
iodotoluene difluoride and para-trifluoromethylphenylbromine difluoride (203, 
204, and 205, Figure 2.7).229-231 A number of more recently developed 
reagents aim to improve on issues associated with these, such as poor air 
stability and hygroscopicity. For example, to circumvent the issue of TBAF’s 
hygroscopicity, which can lead to unwanted side reactions of hydroxide, Sun 
and colleagues developed an approach for preparing and then using 
anhydrous TBAF in situ, through a fluoride shuttling approach starting from 
KF. They tested this successfully on a range of alkyl halides, nitro groups 
and activated alcohols.232,233 Kim and co-workers developed an alternative 
approach to circumvent TBAF’s hygroscopicity, by synthesising a non-
hygroscopic reagent, TBAF (t-BuOH)4, that also performed well in 
substituting bromides, tosylates, mesylates and silyl ethers.234 
In a similar vein, Hammond and colleagues sought to develop new versions 
of the more established hydrogen-bonded HF complexes to give stable and 
selective reagents, which gave rise to a DMPU/HF complex (206, Figure 
2.7). This proved to be useful for the selective mono or difluorination of 
alkynes.235 
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Hara and co-workers developed an alternative to the older reagent IF5, by 
mixing it with a 50:50 mix of pyridine:HF to produce IF5-pyridine-HF.236 This 
reduced issues of rearrangements and overfluorination for a number of 
fluorinations of α-(arylthio)carbonyl compounds, and 
desulfurisation/difluorination, in good to excellent yields. An obvious 
disadvantage is the use of significant amounts of HF in preparation of the 
reagent, although the reagent itself is more stable than IF5. They found 
similar results working with BrF3-KHF2.237  
Figure 2.7: Some nucleophilic fluorination reagents  
In electrophilic fluorination the roles are reversed, with the reagent designed 
to act as an equivalent for F+ (Scheme 2.5). The substrate is most often an 
electron rich system such as an alkene, alkyne or arene; although it can also 
be a carbon site with a nucleophilic labile substituent such as C–Si, C–B or 
C–Sn.238 The most common reagents deployed are those with N–F bonds, 
such as NFPy salts (207),239 NFSI (208),240 and the popular reagents 
Selectfluor®  (209) and Accufluor™  (210, Figure 2.8).241-244 Newer reagents 
again tend to build on their predecessors, such as in Yasui and colleagues 
development of NFSBI (211), a sterically demanding variant of NFSI that 
allowed for modest improvement in the enantioselectivity of fluorination 
reactions.245 Zhu and co-workers achieved better results through preparation 
of a chiral NFSI analogue.246  
Likewise, Wolstenhulme and colleagues developed a chiral F+ source based 
on Selectfluor®, with a DABCO-based dication skeleton (213), which proved 
effective in fluorocyclisation of alkenes.247  
Other researchers have looked into adding chiral metal complex catalysts to 
improve the enantioselectivity of fluorination.248 Geary and colleagues 
synthesised an interesting iodane species, a fluorinated hypervalent iodine 
reagent used for electrophilic fluorination (212).249 
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Figure 2.8: Common and newer electrophilic fluorination reagents 
Cases of radical fluorination are rarer, but do exist. The standard approach in 
these cases is to use a carbon-centred radical as the substrate, and then a 
source of molecular fluorine (Scheme 2.5).250 Early examples of the fluorine 
sources used were fluorine itself, hypofluorite sources, or XeF2.251-253 More 
recently N–F electrophilic fluorine reagents have also proven to be good 
sources,254-256 along with a couple of recent reports of using fluorinated 
solvents.257,258 
2.4.2 Reagents and Methods for Deoxyfluorination 
Deoxyfluorination is a particular case of nucleophilic fluorination, although it 
has developed its own particular subset of popular reagents. In general 
terms, deoxyfluorination proceeds via nucleophilic attack of the alcohol on to 
the electrophilic reagent, which converts the alcohol into a good leaving 
group and generates F– (Scheme 2.6). The F– then normally undergoes SN2 
substitution of the activated alcohol to give fluorination with inversion of 
stereochemistry.  
Scheme 2.6: General scheme for deoxyfluorination 
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Two of the most well-established and popular of the reagents used for 
deoxyfluorination are diethylaminosulfur trifluoride (DAST, 214, Figure 2.9) 
and Deoxo-Fluor® (bis-(2-methoxyethyl)aminosulfur trifluoride, 215).259-261 
Deoxo-Fluor® is generally superior to DAST in that it is tolerant of higher 
reaction temperatures, where DAST decomposes to explosive species. Other 
reagents have been developed based on the structure of these two, notably 
the reagents XtalFluor-E® (216) and XtalFluor-M® (217).262-264 These are 
stable crystalline solids, and showed good activity in the fluorination of 
primary alcohols and secondary alcohols, and the difluorination of ketones. 
They did however show a tendency to form elimination by-products, a 
problem in common with both DAST and Deoxo-Fluor®. More recently 
developed reagents such a PyFluor (219) claim to reduce or remove this 
complication entirely.265  
Figure 2.9: Deoxyfluorination reagents 
Alternative reagents include Fluolead™ (218). Developed by Umemoto and 
colleagues, it is an arylsulfur trifluoride reagent that is crystalline, relatively 
inert to aqueous hydrolysis, and thermally very stable.266 It can be applied to 
the deoxyfluorination of a range of alcohols, and also difluorination of 
ketones. When vicinal diols were reacted with one molar equivalent of the 
reagent, one alcohol was substituted for fluorine, while the other was 
converted to a sulfinic ester.266 The same group also developed arylsulfur 
tetrafluoride reagents, which can be converted to the arylsulfur trifluorides in 
situ and showed good reactivity in fluorination across a variety of 
substrates.267 
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Finally, Ritter and colleagues have developed the fluorination reagent 
PhenoFluor™ (220), prepared from a chloroimidazolium salt.268,269 This 
reagent showed excellent reactivity compared to the other popular reagents, 
such as DAST and Deoxo-Fluor®, for the deoxyfluorination of phenols. It was 
also proven to be very selective in deoxyfluorination of alkyl alcohols, 
including in late stage transformations of complex natural product 
analogues.270 
2.5 Proposed Approach for Synthesis of Fluorinated GABA 
Derivatives 
2.5.1 Hunter and Colleagues’ Synthesis of Fluornated GABA analogues 
Hunter and colleagues have already developed a synthesis of difluorinated 
derivatives of GABA, with two routes that both utilise cinnamyl bromide (221) 
as the starting point, and making use of methodology developed by O’Hagan 
and colleagues (Scheme 2.7).227,271-273  
Cinnamyl bromide 221 was subjected to a Sharpless asymmetric 
dihydroxylation,274 to give diol 222 in high yield and excellent enantiomeric 
excess. The protected amine 223 was then formed by reaction with 
potassium phthalimide in high yield. This gave the intermediate 223 that 
would be used for both pathways. For the first pathway, this diol was 
converted to the corresponding cyclic sulphate 224 by treatment with thionyl 
chloride, followed by oxidation with sodium periodate and ruthenium 
chloride.275 The first fluorination was then carried out by treatment with TBAF 
followed by sulphuric acid, which gave fluorination with inversion of 
stereochemistry at the C2 position and removal of the sulphate, to furnish 
fluorohydrin 225 in a good yield. 
Next, the key step of the second fluorination was carried out using Deoxo-
Fluor®.261 Unfortunately, while the difluorinated species 226 was obtained in 
a yield of 22%, the major product (in 33% yield) was branched difluorinated 
species 227, believed to arise from neighbouring group participation and 
migration of the phenyl group. A workaround was attempted where TMS 
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morpholine was added to suppress the rearrangement pathway, but this led 
to the formation of several elimination products.276 277  
Scheme 2.7: Hunter’s synthesis of syn-difluoroGABA 
Following this step, the desired difluorinated species 226 was treated with 
sodium periodate and ruthenium chloride, which oxidised the phenyl group to 
the carboxylic acid 228, giving a good yield of the syn-difluoro GABA 
analogue with the phthalimide protecting group still in place.278 This was then 
deprotected and incorporated into short peptides.  
Scheme 2.8: Oxidation of the phenyl group to reach the amino acid 
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To reach the anti difluorinated analogue, diol 223 was converted to the 
epoxide 229 with a dr of 5:1, using an approach developed by Nilewski and 
colleagues (Scheme 2.9).279 This was opened with triethylamine hydrofluride 
to give the syn fluorohydrin 230.280 This was then treated with Deoxo-Fluor® 
to give the anti-difluorinated compound 231 with a much smaller proportion of 
the side reaction/rearrangement, in a reasonable yield of 51%. This was then 
taken through the same oxidation procedure to give the carboxylic acid.  
Scheme 2.9: Variations to give the trans-difluoro GABA analogue 
With Hunter and co-workers’ synthesis in mind, an approach to the synthesis 
of fluorinated GABA derivatives was developed that would hopefully 
circumvent issues of unwanted rearrangement products in the fluorination 
process and hence allow easier access to these fluorinated GABA 
analogues.  
2.5.2 Proposed Approach to Fluorinated GABA Analogues 
The proposed starting point for this synthesis was the bicyclic heterocycle 
162, prepared originally for the synthesis of chiral (–)-codonopsinine 
analogues (Scheme 2.10). The planned route involved first fluorinating this 
diol, which could be carried out in one of two ways. Hunter’s protocol could 
be followed of first preparing a cyclic sulphate, such as 232, and then the first 
fluorination could be performed by treating this with TBAF to yield 
fluorohydrin 233. Deoxyfluorination could then be carried out on the 
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remaining alcohol using Deoxo-Fluor® or a related fluorination compound, 
such as DAST, to give the difluorinated bicyclic species 234. Alternatively, 
direct fluorination of the diol via dexoyfluorination could be explored, to 
determine whether a single difluorinated product, or a useful mixture of mono 
and difluorinated products could be obtained. This would allow fluorinated 
derivatives to be accessed while circumventing a three-step procedure.  
Scheme 2.10: Planned route/s to fluorinated GABA analogues. a. SOCl2, NaIO4, 
RuCl3 b. TBAF c. Deoxo-Fluor® 
It was hypothesised that the fluorinated derivative/s of the diol would be 
affected by hyperconjugation effects of the C–F bonds, weakening the C–O 
bond of the endocyclic ether linkage, compared to the very stable diol 
diacetate derivative 163 discussed in Chapter 1. This should allow for easier 
ring-opening with a Lewis acid, such as BF3.OEt2 or TiCl4, and trapping of the 
iminium ion thus generated with triethylsilane. This would give the 
monocyclic fluorinated lactam 235.  
From lactam 235, the following step would be cleavage of the chiral N-
phenylethanol group, either by hydrogenolysis281,282 or possibly a dissolving 
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metal reduction to give amide 236.103,283,284 Given this had proved difficult in 
the earlier work, it was not clear whether these compounds might behave 
differently due to hyperconjugtion effects from the fluorine leading to a more 
facile cleavage of the phenylethanol fragment.  
Finally, difluorinated lactam 236 could be subjected to acid-mediated ring-
opening to generate the open chain fluorinated GABA analogue 237.285 This 
should lead to fluoro-GABA analogues for which the stereochemistry of the 
substituents has been set by the bicyclic precursor. The bicyclic intermediate 
would not be prone to rearrange to form a species like 227, which ought to 
lead to a more efficient and straightforward synthetic pathway overall. It 
would also highlight an application for the chiral bicyclic intermediates. 
Furthermore, a range of different analogues could be prepared, depending 
on the chosen approach to fluorination and the prior transformations carried 
out on the bicyclic diol (Figure 2.10). For example, intermediate fluorohydrin 
233, if isolated, could provide the monofluorinated analogue 238. Also, It 
might be possible to investigate using the alcohol 174, prepared through 
elimination and hydrogenation of diol 162 (from Chapter 1), to reach 
monofluorinated analogues such as 239 or 240.  
Figure 2.10: Potential fluorinated GABA targets for this work 
2.6 Results 
2.6.1: Fluorination of the Diol 
The fluorination of diol 162 was focused on first. To begin with, applying 
Hunter’s method for fluorination of acyclic vicinal diols was explored, which 
meant that the diol 162 needed to first be converted to the cyclic sulphate 
derivative 232 (Scheme 2.11). This involved first preparing the cyclic sulphite 
241 through treatment of 134 with thionyl chloride and pyridine, which was 
immediately subjected to oxidation with ruthenium chloride and sodium 
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periodate. This provided the desired cyclic sulphate 232 in a yield of 51% 
over two steps.  
Scheme 2.11: Formation of the cyclic sulphate ester 232 
The 1H NMR spectrum for this compound supported the structure in that it 
featured resonances consistent with the bicyclic diol with no evidence of 
broad OH peaks. The compound was much less polar than the starting diol 
and soluble in chloroform, supporting the conversion. There were obviously 
no resonances in the 1H or 13C NMR spectra to confirm the presence of the 
cyclic sulphate. However, the crystalline solid compound was recrystallised 
by slow evaporation and the structure supported by X-ray crystallographic 
analysis (Figure 2.11). The result was also supported by HRMS analysis. 
Figure 2.11: X-ray crystal structure of cyclic sulphate 232 
The following step was treatment of 232 with TBAF, which theoretically 
should open the cyclic sulphate and give a single deoxyfluorination to yield a 
fluorohydrin species such as 233. In this case, the reaction led to a mixture of 
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two major products, both of which by 19F NMR contained a single fluorine 
atom (Scheme 2.12). The first, minor product was identified as the 
fluoroalkene 242, which seems to have arisen through ring-opening with 
fluoride to the desired fluorohydrin followed by elimination. The second 
product was tentatively identified as the tetrabutylammonium salt of the 
desired monofluorinated product, 243, in a 49% yield.   
Scheme 2.12: Ring-opening fluorination of cyclic sulphate 232 
Key indicators of the identity of fluoroalkene 242 were derived through 
analysing the 1H NMR spectrum of this compound, mainly though the loss of 
two aliphatic CH resonances and appearance of a single alkenyl CH signal: a 
doublet of doublets at 5.71 ppm. The coupling constants of this signal were 
of 6 Hz and 2 Hz (Figure 2.12). The 6 Hz coupling constant is consistent with 
the 2–20 Hz range expected for an alkenyl proton adjacent to an alkenyl 
fluorine atom. The smaller 2 Hz coupling is shared with another doublet of 
doublets further downfield, at 6.75 ppm. This was assigned as the methine 
proton at C5, which does not exhibit a vicinal coupling with the fluorine atom 
at C3. It is possible that this signal’s further 1 Hz coupling is shared with the 
fluorine, but that this coupling was not resolved in the 19F NMR spectrum.  
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Figure 2.12: 1H NMR spectrum of fluoroalkene 242 showing key resonances 
Figure 2.13: 13C NMR spectrum for fluoroalkene 242 
Importantly for this structural assignment, the 13C NMR spectrum showed 
splitting of three resonances associated with the lactam ring: the amide 
carbonyl signal at 169.5 ppm, the alkene signal at 89.9 ppm, the aminol 
carbon atom at 119.0 ppm, and a very large 286 Hz coupling for the 
fluoralkene carbon atom at 156.3 ppm. Also, 19F NMR spectrum of the 
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compound showed only a single peak at –134.48 ppm, a doublet with a 
resolved coupling constant of 6 Hz, which corresponds with the 6 Hz 
coupling observed in the 1H NMR spectrum. Furthermore, the mass 
spectrometry data for the compound was consistent with what would be 
expected for this fluoroalkene compound’s mass and molecular formula. 
Tetrabutylammonium salt 243 was tetnatively assigned only from its 1H NMR 
spectrum, as the product was reacted further to support its identity (Figure 
2.14). The 1H NMR spectrum featured two resonances with very diagnostic 
couplings: a doublet of doublets at 5.55 ppm, and a doublet of doublets at 
5.00 ppm. The first of these had a coupling constant of 51 Hz, indicative of a 
geminal coupling with a fluorine atom. The latter had a coupling constant of 
22 Hz, which is consistent with a vicinal H–F coupling. These indicate that a 
single deoxyfluorination did occur, most likely at the alcohol adjacent to the 
amide, as there is only one 22 Hz coupling, where two would be expected if 
deoxyfluorination had occurred at the C4 alcohol (one for the C3 and one for 
the C5 methine protons). Furthermore, a triplet at 1.00 ppm integrating for 
roughly 12 H and multiplets between 1.38 and 3.29 ppm each integrating for 
roughly 8 H indidcate that this is a tetrabutylammonium group. These 
resonances did not disappear after purification of the compound by 
chromatography and this was the major reason for assignment of this 
structure as a sulfonate salt. 
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Figure 2.14: 1H NMR spectrum of tetrabutylammonium salt 243 
To provide evidence for this characterisation, intermediate 243 was treated 
with acid, to determine whether it could be simply  converted to fluorohydrin 
233 (Scheme 2.13). When a small sample of the salt was taken and stirred in 
THF with 37 µL of conc. H2SO4 and a drop of water (20 µL), for 18 h, a single 
product was obtained, identified as the fluorohydrin 233 (vide infra). 
However, the yield of the product was quite low, at less than 8%. The 
remainder of the material appeared to be lost to decomposition.  
Scheme 2.13: Acid treatment of the tetrabutylammonium salt 243 
While this was successful in reaching the desired fluorohydrin intermediate 
233, the mixture of products and low overall yield for what became a four-
step process was far from ideal. This led us to investigate the direct 
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deoxyfluorination of the diol 162, to see whether this might be a more 
efficient approach. Thus, diol 162 was reacted with 2.2 molar equivalents of 
Deoxofluor® at reflux overnight (Scheme 2.14). This gave almost exclusively 
the fluorohydrin 233, in a yield of 57%, representing a significant 
improvement over the previous approach. There were also trace amounts of 
the fluoroalkene 242 and the difluorinated species 234 present, which were 
easily separable by flash column chromatography.  
Scheme 2.14: Deoxofluor® fluorination of diol 162 
The crude reaction mixture of 233 was heated at reflux with a greater excess 
of Deoxofluor® (10 molar equivalents) to try to form the difluorinated product. 
All of the fluorohydrin was converted into a mixture of the fluoroalkene and 
difluorinated species, in a ratio of roughly 1 : 0.7. Similar results could be 
obtained by heating the diol 162 at reflux with 5 molar equivalents of 
Deoxofluor®, giving excusively the fluoroalkene 242 and difluorinated 
product 234 in yields of 25% and 20% respectively.  These results 
demonstrated that Deoxofluor® could be used directly on the diol 162 to give 
moderate yields of three desirable fluorinated species for further 
derivatisation towards fluorinated GABA analogues. 
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The structure and stereochemistry of fluorohydrin 233 was assigned through 
analysis of the NMR spectra and other data. Firstly, the 1H NMR spectrum 
featured resonances similar to those present in that of the salt 243, with a 
doublet of doublets at 5.35 ppm integrating for a single proton, with a 52 Hz 
coupling indicative of a geminal fluorine substituent (Figure 2.15). Another 
signal at 4.49, a doublet of doublets of doublets, had a 20 Hz coupling, 
consistent with it being vicinal to the fluorine atom. As this exhibited an extra 
coupling compared with the 5.53 signal, it was most likely that this was the 
proton at C4, between the ether methine and fluoro methine protons, and the 
mutual couplings of 7.8 Hz (between the C3 and C4 protons) and 3.3 Hz  
(between the C4 and C5 protons support this.  
Figure 2.15: 1H NMR of fluorohydrin 233 
Furthermore, in the 19F NMR spectrum, a signal is observed at –198.3 ppm, 
as a doublet of doublets of doublets, with 5 2, 20.7 and 3.6 Hz couplings 
(Figure 2.16). This is consistent with a geminal coupling at C3, vicinal at C4 
and a more distant coupling at C5. The C5 1H signal at 5.14 ppm appears to 
be a triplet, likely due to the two very similar couplings observed with the CH 
proton (3.3 Hz) and the F atom (3.6 Hz). Finally, the 13C NMR spectrum 
showed splitting of resonances associated with the lactam ring carbon 
atoms, similar to fluoroalkene 242. Notable were the 24.1 Hz coupling of the 
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amide carbon at 168.8 ppm and the 196.9 Hz coupling of the fluorine-
substituted C3 carbon at 95.2 ppm. Also the 9.4 Hz coupling of the carbon at 
93.1 ppm and the 20.0 Hz coupling of the carbon at 78.7 ppm, which 
supported the presence of a single fluorine atom on the lactam ring. 
Figure 2.16: 19F NMR spectrum of fluorohydrin 233 
Given that half of the key vicinal 1H signal at 4.49 ppm was obscured by one 
of the resonances associated with the phenylethanol portion of the molecule, 
the 1H NMR spectrum of 233 was simulated using the Bruker Topspin 
software’s Simulation & Iteration of 1D spectra tool (or DAISY), to provide 
support for the assignment of chemical shifts and coupling constants. The 
resonances associated with the aryl substiuent were omitted, as they were 
not necessary for clarification. Thus, 8 atoms were added to make up the 
fragment being simulated, 7 being the protons to be simulated and another 
being the fluorine atom, and each assigned as the correct type of nucleus 
(Appendix 1). Each was given its 1H chemical shift, as gleaned from the 
empirical spectrum, or its approximate 19F chemical shift in the case of the 
fluorine. Exact fluorine chemical shifts were not strictly necessary, as only the 
1H NMR spectrum was being simulated. The couplings between each proton 
and fluorine were entered into the table of the Scalars tab. Finally, the 
Chapter 2  Results and Discussion 
 
 
84 
lineshape was optimised through the Lineshapes tab, by increasing the 
global linewidth until the peaks had a more realistic shape. This gave a 
simulated spectrum that agreed well with the experimental spectrum, 
supporting the chemical shift and coupling constant assignments (Figure 
2.17) 
Figure 2.17: Comparison of real and simulated spectra for fluorohydrin 233 
To further support this characterisation, fluorohydrin 233 was recrystallised 
and an X-ray crystal structure obtained (Figure 2.18). This validated our 
structural and stereochemical assignments, showing deoxyfluorination at the 
C3 alcohol with the expected inversion of stereochemistry, to give a trans–
relationship with the remaining alcohol. 
Figure 2.18: X-ray crystal structure of fluorohydrin 233 
Simulated 
Experimental 
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The final fluorinated product, the difluorinated bicyclic lactam 234, had its 
structure and stereochemistry assigned through a similar process. Issues 
were encountered in analysing the 1H NMR spectrum as the additional 
fluorine atom gave a complex spectrum with all of the lactam protons having 
an additional large coupling constant, such that many of the resonances 
were overlapping in the region from 5.26–5.50 ppm (Figure 2.19). Analysis of 
the 19F, 13C and 2D NMR spectra provided support for assignments in the 1H 
NMR spectrum, aided by the significant and multiple coupling constants 
observed in these spectra. 
Figure 2.19: 1H NMR spectrum of lactam 234 
The evidence that two fluorine atoms were present was borne out by analysis 
of the 19F NMR spectrum, which featured two resonances, one at –215.89 
ppm, a doublet of doublets with 47.8 and 5.6 Hz couplings; and the other at –
221.79 ppm, a doublet of doublets of doublets of doublets with couplings of 
55.7, 25.2, 14.1 and 5.6 Hz (Figure 2.20). It was presumed that the latter 
signal is that at C4, and is exhibiting coupling with both its geminal proton, 
two vicinal protons and the vicinal fluorine. The other fluorine at –215.89 ppm 
only seems to have an observable coupling with its geminal proton and 
vicinal fluorine at C4, which may be associated with the dihedral angle 
between the trans oriented hydrogen and fluorine atoms.   
NO O
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Figure 2.20: 19F NMR Spectrum of lactam 234 
Assuming a geminal fluorine atom gives a coupling constant in the 1H NMR 
spectrum of roughly 50 Hz and a vicinal fluorine atom gives a coupling 
constant of approximately 20 Hz, it is reasonable to expect that the signal for 
the C3 proton would be made up of four doublets each integrating for of 0.25 
H spread over a wide area. Similarly, the protons at C4 and C5 would have 
multiple fluorine couplings, resulting in the greatly overlapped region between 
of the 1H NMR spectrum. 
To provide evidence to support this structural assignment, specific 1H based 
NMR experiments were run of compound 234. First, a J-Resolved (or JRES) 
spectrum of the compound was obtained, which separates the chemical shift 
and scalar couplings of resonances and projects these onto two axes (Figure 
2.21). This breaks down in the 2D space the number of actual resonances 
present under a given multiplet or apparent resonance (Figure 2.21).286 The 
experiment carried out only removed the homonuclear (1H–1H) couplings, 
which left the region of 5.26-5.50 ppm still hard to resolve. The resonances at 
4.25 and 4.32 ppm, for example, which represent the phenylethanol portion 
of the molecule and thus have no fluorine coupling, have their shift and 
coupling neatly separated to give one line of resonances each in the x-
a
b
NO O
234
Fb Fa
Chapter 2  Results and Discussion 
 
 
87 
dimension and four peaks each in the y-dimension, matching up with their 
doublet of doublet 1D resonances. Under the fluorine-affected region, there 
are still at least six overlapping resonances, although it does indicate that the 
region has fewer individual resonances than might have been determined 
from the 1H NMR spectrum alone. 
Figure 2.21: JRES spectrum of dlifluorinated compound 234 
Secondly, a 19F-decoupled 1H NMR spectrum was obtained (Figure 2.22). 
This proved more effective than the JRES spectrum, simplifying the region 
into essentially three peaks, where only the 1H–1H coupling was observed. 
The resolution was not ideal, but it supported the theory that there were only 
three or four distinct resonances there, and approximately the chemical shift 
of each. 
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Figure 2.22: 19F-decoupled 1H NMR spectrum of 234 
The 1H NMR spectrum of this compound was also simulated in DAISY, and 
then compared with the experimental spectrum. Unlike in the case of the 
fluorohydrin 233, for difluorinated compound 234 it was necessary to develop 
an accurate simulation to be able to correctly assign each of the chemical 
shifts and couplings when reporting the 1H NMR spectra. The process was 
much the same as for 233, with the number of resonances set first, with best 
first estimates of their chemical shifts and coupling magnitudes based on the 
data obtained from the 1H and 19F NMR spectra (Appendix 1). These values 
were adjusted until the spectrum matched the experimentally obtained 
spectrum, and the lineshape broadened to show that the assigned coupling 
constants were reasonable for that spectrum. 
Thus, the assignments for this difluorinated compound 234 were derived 
through the simulation process. This excludes those that were unambiguous 
– the phenyl multiplets at 7.25–7.29 ppm, 7.30–7.34 ppm and 7.35–7.39 
ppm. This allowed for full assignment of the lactam protons, and the 
agreement between the simulated and experimental spectra supported the 
structural assignment for the compound. 
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Chapter 2  Results and Discussion 
 
 
89 
Figure 2.23: Simulated and Experimental spectra of 234 
To provide further support for our assignment, this fluorinated lactam was 
also recrystallised successfully and an X-ray crystal obtained. This 
unambiguously established deoxyfluorination had proceeded with inversion 
of stereochemistry at both sites to give a cis-difluornated bicyclic γ-lactam 
(Figure 2.24). This demonstrated the utility of this approach for controlling the 
stereochemistry of fluorination, as the ether substituent can be used to set 
the stereochemical configuration of the diol in 162, but does not have any 
influence on the following fluorination step. 
Figure 2.24: X-ray crystal structure of difluorinated bicyclic lactam 234 
Simulated 
Experimental 
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Given the expense in using large quantities of Deoxofluor® to prepare 
fluorinated derivatives, the reagent DAST was trialled as a potentially more 
economical alternative. Due to the explosive nature of its decomposition 
products, these reactions were not carried out above 35 oC.260 They gave 
similar overall yields to the Deoxofluor® procedure, but there were some 
noticeable drawbacks. Firstly, a proportion of the elimination product 242 was 
always present, and the reactions did not proceed to completion (Scheme 
2.15). When the reactions were carried out for periods of time longer than 18 
hours (up to two days), in the hopes of consuming all of the starting material, 
the proportion of elimination product increased, while some starting material 
still remained.  
Scheme 2.15: Results of DAST fluorination 
However, the results were sufficient that it was surmised that scaling up 
would give usable quantities of both the fluorohydrin and the fluoroalkene, 
both of interest for preparing a variety of fluorinated GABA analogues. 
Unfortunately, on increasing the scale above 100-200 mg of diol, a number of 
unidentified decomposition and by-products were observed, the proportion of 
which increased with increasing reaction scale. This limited the ability to 
prepare large quantities of the fluorinated intermediates to carrying out a 
number of smaller-scale reactions and combining the products for 
purification. This approach yielded sufficient fluorohydrin 233 for carrying out 
investigations of the subsequent steps towards synthesising fluorinated 
GABA analogues. A smaller quantity of the fluoroalkene 242 was isolated, 
which allowed for some investigation towards reaching monofluorinated 
GABA analogues (Section 2.6.2) 
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2.6.2 Routes To Monofluorinated Analogues 
Investigations of fluorination pathways were carried out, to demonstrate the 
possibility of using the diol 162 as the starting point for a wide variety of 
fluorinated GABA analogues. As the above methods led to a fluoroalkene, 
fluorohydrin and difluoro species, it was seen as desirable to have efficient 
pathways to monofluorinated analogues. 
To achieve this from the fluoroalkene 242, it was clear that simple 
hydrogenation would likely be the most efficient route to give a mono-
fluorinated species with a stereogenic centre at C3. We expected that this 
reaction should give a single product, with addition of hydrogen determined 
by the ether substituent at C5, forcing it to occur on the opposite face. As 
such, the fluoroalkene 242 was hydrogenated under a balloon of H2 
overnight, which gave the desired product 244 as a single stereoisomer in a 
reasonable 51% yield (Scheme 2.16).   
Scheme 2.16: Hydrogenation of fluoroalkene 242 
The success of this reaction was obvious in the NMR spectra for 244. 
Specifically, in the 1H NMR, the fine 19F–1H couplings observed in the 
fluoroalkene were replaced by a doublet of triplets for the C3 proton at 5.41 
ppm, with the typical geminal coupling of 52.3 Hz, and a coupling with vicinal 
protons of 8.4 Hz (Figure 2.25). The vicinal 19F–1H couplings were visible in 
the upfield resonances at 2.28 ppm, which could be rationalised as a dddd 
with a clear vicinal fluorine coupling of 26 Hz. The other vicinal signal was 
identified as a complex multiplet from 3.06–3.13 ppm, which clearly by the 
spread and shape was influenced by the fluorine and a number of adjacent 
protons, but the exact coupling constants were difficult to determine. 
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Figure 2.25: 1H NMR spectrum of hydrogenation product 244 
We theorised that the monofluorinated bicyclic lactam 245 with the opposite 
stereochemistry at the C3 C–F bond could be prepared by direct 
deoxyfluoination of the alcohol 174, synthesised earlier in Chapter 1. This 
species was treated with an excess of DAST, heated to 35 oC for 16 h 
(Scheme 2.17). After this time, the majority of the alcohol had converted 
through to the fluorinated product 245, in a yield of 53%. However, even after 
this extended reaction time a reasonable portion of the starting material 
remained (13% was recovered), highlighting how DAST can be a less 
effective deoxyfluorination reagent in these systems. Fortunately, all of the 
unreacted starting material was recovered, and while some decomposition 
took place no elimination products were observed for this mono-
deoxyfluorination.  
Scheme 2.17: DAST fluorination of alcohol 174 
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This mono-fluorinated compound (245) was also distinguishable from the 
diastereomer 244 by NMR spectroscopic analysis. The chemical shifts and 
coupling constants observed in the 1H NMR spectrum were similar to those 
observed for 244, but with distinct splitting patterns as a result of the differing 
fluorine orientation. For example the C3 proton at 5.17 ppm, appeared more 
as a doublet of doublets of doublets for 245 than the doublet of triplets 
observed in 244. The complex resonances at 2.40 ppm and 2.68 ppm were 
also quite different from those observed in 244, due to changes of 
stereochemistry of the C3 centre. The two 19F NMR spectra likewise both 
featured a single resonance at approximately the same chemical shift, but for 
compound 244 appeared as a doublet of doublets of triplets while for the 
stereoisomer 245 appeared as a doublet of doublets of doublets. These 
assignments were supported by the 13C and 2D NMR spectra, and HRMS 
analysis. 
Figure 2.26: 1H NMR spectrum of fluorinated bicyclic lactam 245 
These results are significant because they demonstrate that not only is it 
possible to form a variety of fluorinated GABA precursors using the diol 162, 
but it is possible to reach both enantiomeric forms of 2-fluoro-γ-aminobutyric 
acid via a common intermediate (Scheme 2.18). This has established 
straightforward routes to reach intermediates for two monofluorinated, one 
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fluorohydrin, and one difluorinated GABA analogue, using the oxidation of 
chiral pyrroles as a starting point. In theory, this gives access to four different 
sterodefined analogues, with the potential to reach others by exploiting 
alternative fluorination or hydroxylation techniques starting from the diol 162, 
or the bicycle 118. Given bicyclic lactam 118’s ability to control 
stereochemistry of reactions at the alkene, there are many possibilities for 
potential analogues beyond those prepared here.  
Scheme 2.18: Two enantiomers of GABA from a common intermediate 
2.6.3: Further Transformations Towards Fluorinated GABA Analogues 
Once the stereo-controlled synthesis of a range of fluorinated bicycles had 
been established, it was necessary to investigate their deprotection to yield 
fluorinated GABA analogues. The most accessible of these, fluorohydrin 233, 
was employed as the test substrate. As stated in section 2.5.2, the aim was 
to first open the ring formed by the ether linkage of the phenylethanol portion, 
followed by cleavage of the chiral N-phenylethanol substituent and 
subsequent acidic or basic ring-opening of the lactam to give the open chain 
fluorinated GABA analogue. 
The first step investigated was the ring opening at the ether group of C5 of 
the lactam. As discussed above, in the case where there was no fluorine 
present in the molecule (i.e. diacetoxy compound 163), cleaving this bond 
bond through generation of an iminium ion was very difficult. However, it was 
NO O
HO OH
162
NO O
F
245
NO O
F
244
239
H2N
OH
F
O
240
H2N
OH
F
O
Chapter 2  Results and Discussion 
 
 
95 
anticipated that the presence of fluorine at C3 of the lactam would act 
through hyperconjugation effects to weaken the C–O bond at C5 and hence 
facilitate ring opening. The influence of the fluorine atom on the C5 position 
was indicated by the 13C NMR spectrum of fluorohydrin 233, through a 9.4 
Hz C–F coupling of the resonance at 95.2 ppm. Gratifyingly, this did indeed 
prove to be the case. When fluorohydrin 233 was treated with an excess of 
BF3.OEt2 and TES, a reasonable yield of the ring-opened lactam 246 was 
formed (Scheme 2.19).  
Scheme 2.19: Ring opening of fluorohydrin 233 
The structure was supported by an increase in the number of resonances in 
the 1H NMR spectrum, specifically by the appearance of two resonances: a 
doublet of doublets of doublets at 2.94 ppm and a doublet of doublets at 3.79 
ppm, representative of the methylene protons at C5 of the lactam. HRMS 
analysis gave a result consistent with an increase equivalent of two hydrogen 
atoms from the bicyclic fluorohydrin 233. The compound was also 
recrystallised and an X-ray crystal structure obtained, supporting the 
reduction (Figure 2.27).  
Figure 2.27: X-ray crystal structure of the ring-opened fluorohydrin 246 
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The next step was to remove the N-phenylethanol substituent, prior to the 
final ring-opening. Given that this should behave similarly to an N-benzyl 
group, the first attempts were hydrogenolysis. However, use of both Pd/C 
and Pd(OH)2, provided no reaction even after extended reaction times. There 
are many examples in the literature of the cleavage of these groups from 
pyrrolidines but not for pyrrolidinones. Evidently the amide affects the 
reactivity, and the introduction of an adjacent fluorine atom had no impact on 
this. 
Based on Meyers’ work, a dissolving metal reduction was also attempted 
(Scheme 2.20).103 Ammonia was condensed into a cold solution of the 
fluorohydrin 246 containing sodium or calcium metal and allowed to warm 
slowly to room temperature. In neither case was the desired product 
obtained, with only decomposition of the starting material observed.  
Scheme 2.20: Attempts to remove N-substituent of fluorohydrin 246 
Another approach was attempted on the closed bicycle 233, treating the 
fluorohydrin with sodium naphthalenide in an attempt to cleave the benzyl 
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group and open the oxazolidine ring (Scheme 2.20).287 Unfortunately in this 
case also no reaction was observed. 
As these efforts to remove the N-substituent from the pyrrolidinone proved 
fruitless, it was decided to change tack and instead investigate opening the 
pyrrolidinone to give an acyclic species first. It was believed that this would 
remove the difficulties associated with cleaving the N-substituent from a 
cyclic amide and make hydrogenolysis a viable approach again. 
The ring-opening of fluorohydrin 246 was carried out by simply stirring in 
hydrochloric acid for several hours (Scheme 2.21). This gave the desired 
acyclic compound 249 as the hydrochloride salt in near-quantitative yield. 
The 1H and 13C NMR spectra were consistent with what would be expected 
for this transformation. A doublet at 5.01 ppm with a 47.7 Hz coupling in the 
1H NMR spectrum represented the proton geminal to the fluorine atom and 
adjacent to the carboxylic acid. Changes in the 1H and 13C NMR spectra 
were noticeable but not major, however other spectroscopic techniques 
supported the outcome. In the IR spectrum, the carbonyl stretch of the acid 
appears at 1730 cm–1, compared with the carbonyl stretch in lactam 246 at 
1690 cm–1. HRMS analysis gave an exact mass consistent with the, 
protonated amino acid.  
Scheme 2.21: Acidic ring-opening of pyrrolidinone 246 
The final step towards the synthesis of fluorinated GABA analogues was to 
identify a method to cleave the N-substituent to give the free amino acid. 
Hydrogenolysis was again tried, this time with more success. First attempts 
examined using both Pd/C and Pd(OH)2 as catalysts, under both 1 atm of 
hydrogen and at elevated pressures on a shaker-hydrogenator. Results 
ranged from no reaction to decomposition in most cases. Importantly, when 
the reaction was carried out with acetic acid present, the 1H NMR spectrum 
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of the crude reaction mixture gave clear signs of the phenylethanol fragment 
disappearing with the remaining resonances staying much the same as those 
in the precursor. Therefore the product was tentatively assigned as 238 
(Scheme 2.22). Difficulties were encountered in attempting to purify this 
compound, as it proved to be (unsurprisingly) insoluble in organic solvents 
and highly polar, and the small amount of product obtained did not prove 
amenable to recrystallization by dissolving in hot MeOH or vapour diffusion 
methods.  
Scheme 2.22: Attempts to reach a characterisable GABA analogue 
With a view to providing further evidence that these reactions could be 
successful, the presumed amino acid 238 was treated with Boc2O in the 
hopes of giving an N-protected species 250 that might be more easily 
purified and characterised. The 1H NMR spectrum of the crude reaction 
mixture appeared promising, with a singlet peak integrating for 9 protons 
appearing at 1.38 ppm. However, after 24 h another compound started to 
appear in the 1H NMR spectrum, and over the course of several days 
increased in quantity until there was nearly a 1:1 ratio of it with the desired 
product. The chemical shifts of this second compound matched those of the 
amino acid 238. This led to the conclusion that the Boc-protected product 
was deprotecting itself. As the other key functionality in the molecule is a 
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carboxylic acid with an adjacent fluorine atom, similar to TFA, it was 
theorised that the carboxylic acid of this molecule was acidic enough to 
slowly promote cleavage of the Boc group. Addition of 2 drops of 
trifluoroacetic acid to the NMR sample (in D2O) led to complete reversion 
within 12 hours, supporting this theory.  
While this result was not helpful for reaching a pure Boc-protected analogue, 
it did provide further support for the observation that the N-phenylethanol 
fragment had been successfully removed via the hydrogenation procedure. 
Additionally, it was possible through analysis of the HSQC NMR spectrum to 
assign the 1H and 13C NMR resonances of amino acid 238, which showed 
that there were four proton resonances for the carbon backbone and four 
carbon atoms in the molecule, each coupled with the fluorine atom. This was 
consistent with the expected structure. HRMS analysis of the sample also 
indicated that the desired amino acid had been formed.  
Hunter and colleagues observed that for syn-difluorinated GABA analogues 
the αH-βH, αF-βH and also the βH-γH NMR coupling constants were either 
reatively high or low, which implied a rigid zigzag conformation.223 In the anti-
difluorinated analogues the coupling constants tended to be closer to each 
other. For the fluorohydrin analogue 238, the βH-γH coupling constants were 
determined to be 2.9 and 9.2 Hz, a more pronounced difference than that 
observed even in the syn-difluorinated analogues prepared by Hunter. 
However, the key αF-βH coupling constant was determined to be 24 Hz, in 
the middle of the range observed in Hunter’s difluorinated analogues, and the 
αH-βH coupling constant of 1.7 HZ was closer to those observed in the anti-
difluorinated compounds. This indicated that for the fluorohydrin analogue 
238 NMR spectroscopic data alone is not sufficient to establish the 
conformation. As such, preparation of an analogue of 238 stable to 
crystallisation would be valuable for defining the conformation through an X-
ray crystal structure. Alternatively, computational methods could be explored 
to determine the lowest energy conformers for this compound. 
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2.7 Conclusions 
A route to a range of fluorinated bicycles starting from bicyclic diol 162 has 
been established, giving the potential for preparing a variety of fluorinated 
GABA analogues varying in substitution pattern and stereochemistry. 
Spectroscopic evidence was acquired to support that the novel fluorinated 
GABA analogue 238 had been successfully reached as a proof of concept for 
this synthesis, but due to time constraints this procedure could not be 
repeated on a larger scale and the product isolated as desired. For future 
work, this synthesis would be repeated and then applied to the other 
fluorinated bicyclic lactams prepared, to give a full suite of monofluorinated 
and difluorinated GABA analogues. NMR spectroscopic analysis, X-ray 
crystallography and computational modelling could then be used to 
determine the new analogues’ conformations and compare them with the 
known compounds. 
This would be assisted by further development of the approach to reaching 
the key fluorinated intermediates to make it more scalable, or by performing 
the reactions in parallel. Potential availability of new deoxyfluorinating 
reagents such as PyFluor, or their preparation, could also make this step in 
the synthesis proceed more selectively.265 
Finally, alternative methods for introducing fluorine to the bicycle 118 could 
be explored. Direct hydrofluorination of the alkene might be a convenient 
approach at least for reaching monofluorinated analogues without the need 
to go through intermediate diol 162 (Scheme 2.23).288,289  
Scheme 2.23: Potential direct hydrofluorination route to fluorinated analogues 
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Chapter 3: Development and Applications of Pyrroles 
and Pyrrolidines Prepared from Polygodial 
3.1 Introduction to Polygodial and Derivatives 
3.1.1 Source and isolation of polygodial 
Polygodial (251, Figure 3.1) is a bicyclic sesquiterpenoid natural product 
isolated from the leaves of Tasmannia lanceolata in Tasmania and south-
eastern Australia,290 and from varieties of Winteraceae,291 Polygonaceae292 
and Canellaceae.293 It has also been isolated from some varieties of marine 
sponges  and molluscs.294,295 It is a chiral molecule with three contiguous 
stereogenic centres, and a 1,4-dialdehyde system made up of an allylic and 
a pseudo-neopentyl aldehyde. Moreover, its carbon backbone features in the 
structure of many other natural products.  
Figure 3.1: Polygodial (251), drimendiol (252), (–)-drimenol (253) and euryfuran 
(254) 
Recent work has established a versatile and efficient method of pressurised 
hot water extraction (PHWE) of natural products from plant material using a 
household espresso machine.296 This was applied to the extraction of 
polygodial from dried leaves of T. lanceolata bred to have high polygodial 
content, such that it was possible to isolate the compound in high purity and 
gram quantities in a matter of hours.297 Further to this, polygodial was used 
as a starting point to rapidly prepare some structurally similar natural 
products: drimendiol (252), (–)-drimenol (253) and euryfuran (254).298-300 This 
methodology showed that it was viable to isolate polygodial from plants and 
employ it as a complex chiral scaffold for the synthesis of natural products 
and their derivatives, which remain of significant interest in drug design.301  
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3.1.2 Biological Activity and Mechanism 
Polygodial is reported to have a diverse range of biological activities and 
applications, including antifouling acivity,302 activity as a deterrant or anti-
feedant for insects,295,303,304 antibacterial and antiparasitic activity,305-307 anti-
fungal activity,308-310 anti-allergic and anti-inflammatory activity.311 It also has 
vanilloid and antinociceptive activity, giving similar responses to capsaicin.312-
317 
Its biological activity has been theorised to involve the 1,4-dialdehyde 
undergoing Paal–Knorr-type reactions with an amine group, such as that of 
lysine in cells, to form pyrroles.318 This hypothesis was given some support in 
early investigations where 1H NMR monitoring experiments suggested the 
formation of a pyrrole-like product when polygodial and methylamine were 
reacted under pseudo-biological conditions.319,320 However, the unsaturated 
pyrrole product of this reaction was not isolable. 
Recent work by Kornienko and colleagues aimed to build on this research 
and show that a modified Paal–Knorr reaction of polygodial with amines 
could yield pyrrole products similar to those understood to be involved in the 
biological activity.321 TLC analysis suggested polygodial reacted with 
benzylamine in the presence of an acid catalyst, but that any pyrrole 
products formed swiftly decomposed and were not isolable. This was 
consistent with previous reports.319,320 They proposed a mechanism for the 
reaction where the endocyclic double bond present in polygodial shifts as the 
aromatic ring is formed, and that this product is unstable and likely 
decomposes via some oxidative pathway (Scheme 3.1). However, they were 
able to form more stable pyrroles using electron- deficient amines such as 
aniline and 4-nitroaniline, which supported their hypothesis of the double 
bond shifting (Scheme 3.2).  
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Scheme 3.1: Mechanism for pyrrole formation and alkene shift in Kornienko’s work 
They also had success in forming pyrroles from derivatised polygodial.322 In 
these cases they carried out Wittig reactions on the allylic aldehyde with a 
range of ylides, and then the pyrrole formation by conjugate addition and 
imine formation. In these cases, the pyrrole products formed were more 
stable to isolation, although only one of the Wittig precursors was tested in 
anti-cancer studies to gauge their potential effectiveness (Scheme 3.2).   
Scheme 3.2: Examples of polygodial-derived pyrroles synthesised by Kornienko 
and colleagues 
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3.1.3 Goals and Strategy 
The goals for this project were twofold: firstly, to develop an approach to 
synthesising stable N-alkylpyrroles and pyrrolidine species from polygodial. 
Secondly, to take these molecules to form novel natural product analogues, 
thus further illustrating the potential for polygodial to be used as an advanced 
scaffold in the synthesis of valuable biologically active compounds.  
For the first goal, the intention was to optimise the pyrrole formation reaction 
conditions developed by Kornienko and colleagues to remove the double 
bond that seems to impart such instability to any N-alkylpyrroles formed. 
Previous experience in the group of synthesis and reduction of pyrroles led 
us to postulate that an approach combining pyrrole synthesis with reduction 
of any unstable intermediates could be a viable option. Prior work in the 
Smith group demonstrated that unstable α-hydroxypyrroles could be reduced 
to stable alkyl derivatives by employing sodium cyanoborohydride in acetic 
acid (Scheme 3.3).29,323 We envisioned using similar conditions for the 
pyrrole formation reaction to trap and reduce unstable intermediates/pyrroles.   
Scheme 3.3: Example of sodium cyanoborohydride reduction of an α-
hydroxypyrrole 
Assuming this was successful, we had a number of additional goals for 
applications for these polygodial-derived pyrroles. Firstly, oxidation of these 
pyrroles by our established methods would provide rapid access to highly 
functionalised chiral intermediates.62 It would be interesting to observe the 
regioselectivity and stereoselectivity (if any) that would be observed under 
such conditions, i.e. what impact the stereogenic centres in the polygodial 
backbone would have on transformations to the adjacent pyrrole. This would 
make it possible to access novel analogues of a range of natural products, 
such as (+)-crispin A (265, Scheme 3.4), an antifungal natural product.324 An 
N-dimethoxyphenethyl substituted pyrrole derivative such as pyrrole 263 was 
seen as a viable starting point for this synthesis (Scheme 3.4) 
N
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Scheme 3.4: Proposed starting material for (+)-crispin A analogue target 
Synthesis of an N-H pyrrole derivative would also be of interest as a starting 
point for accessing chiral secondary amines. Through hydrogenation of 
substituted pyrroles such as 266, chiral pyrrolidines 267 could be reached. 
These could provide interesting substrates for asymmetric organocatalysis 
(Scheme 3.5). For example, as a replacement for L-proline (268) in Hajos–
Parrish reactions,325 Aldol additions326-329 or Mannich reactions.330-334 They 
could also potentially serve as substitutes for McMillan’s catalyst (269) in 
Diels–Alder and other cycloaddition reactions.335,336  
Scheme 3.5: Potential applications for N-H pyrroles prepared from polygodial 
3.2 Results and Discussion 
3.2.1 Development of Selective Pyrrole/Pyrrolidine Syntheses 
In line with our goals outlined above, a simple strategy was devised for a test 
reaction where polygodial, benzylamine and a reducing agent (sodium 
cyanoborohydride) would all be mixed in a solution of 10:1 ethanol:acetic 
acid, under an inert atmosphere, and stirred until TLC analysis indicated 
complete consumption of the polygodial (Scheme 3.6).  
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This approach led to the formation of two different products, that were 
isolated by flash column chromatography. One featured resonances in the 1H 
NMR spectrum at 6.31 (a singlet) and 6.37 ppm (a doublet with very fine 
coupling of 2.2 Hz), and no evidence of any remaining alkene (Figure 3.2). 
This was consistent with the formation of a pyrrole, where the C5 proton was 
potentially demonstrating some weak coupling with the nearest polygodial 
backbone methylene proton. This indicated successful formation of the N-
benzylpyrrole 270, with the destabilising alkene removed through reduction, 
and was supported by subsequent HRMS analysis.  
Scheme 3.6: First test of pyrrole formation reaction 
The second product isolated featured no 1H NMR resonances indicative of a 
pyrrole, but did include similar resonances indicating incorporation of the 
benzylamine, and a singlet at 5.37 ppm characteristic of the alkene in 
polygodial still being present (Figure 3.2). With HRMS analysis supporting 
this it was identified as the N-benzylpyrrolidine 271, which is likely formed 
through a competitive reductive amination mechanism (vide infra). The 
stereochemical configuration at the pyrrolidine position C3 was assigned as 
R, based on the assumption that the stereochemistry of the pseudo-
neopentylaldehyde in polygodial would not be altered through the reductive 
amination. The ratio of pyrrole:pyrrolidine was 1:2, indicating that the 
pyrrolidine reductive amination pathway is favoured when all of the reagents 
are added to the reaction at the same time.  
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Figure 3.2: Key peaks in the pyrrole and pyrrolidine NMR spectra 
To see whether the reaction conditions could be altered to favour pyrrole 
formation over the double reductive amination, the reaction was repeated 
where the amine was added first and the sodium cyanoborohydride only 
added once TLC analysis indicated complete consumption of the polygodial, 
which occurred within 30 minutes (Scheme 3.7). In this way, all of the 
polygodial may react to form a pyrrole derivative before reduction occurs, 
and as such there would be no imine present to be reduced by the sodium 
cyanoborohydride. This precludes any formation of the pyrrolidine product 
271, with the reaction giving only the desired pyrrole 270 in a 75% yield. The 
reaction was repeated with reduced amounts of sodium cyanoborohydride, 
and it was found to proceed smoothly with just 1 molar equivalent added.  
This approach was shown to be applicable across a range of alkylamines, 
giving good to excellent yields of the desired pyrroles (Scheme 3.7). 
Difficulties were only encountered in the preparation of the GABA methyl 
ester derivative, for which GABA methyl ester hydrochloride was used as the 
amine starting material. In this case pyrrole 276 was not observed under the 
conditions described above. As the only difference was the use of an HCl 
salt, buffering the system with 2 eq. of sodium acetate was attempted. In this 
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way it was possible to reach pyrrole 276, albeit in a lower yield than those 
observed for the other alkylamines. When NaOH was used to buffer the 
system similar results were obtained.  
Scheme 3.7: Pyrrole and Pyrrolidine Syntheses. aThe reaction was performed using 
γ-aminobutyric acid methyl ester hydrochloride and NaOAc (2.4 eq.). 
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Given the success in biasing the reaction to give only pyrrole products, the 
opposite was then attempted to give only the reductive amination pyrrolidine 
products (Scheme 3.7). This was investigated by first stirring polygodial with 
an excess of sodium cyanoborohydride then slowly adding benzylamine, as a 
dilute solution in EtOH, dropwise through a dropping funnel. Tests with 
increasing excesses of sodium cyanoborohydride, and increasingly dilute 
solutions of the benzylamine, led to a ratio of about 8:1 pyrrolidine 
(271):pyrrole (270), using 5 eq. of sodium cyanoborohydride and a dilute 
solution of the amine added drop-wise over 15 minutes. This did not 
exclusively provide one product, but did ensure that the pyrrolidine was the 
major product. Given the straightforward chromatographic separation of the 
two products, it represented an efficient approach to directly access the 
pyrrolidine substrates. These conditions were also applied to two of the other 
amines, 2,4-dimethoxyphenylethylamine and 4-methoxybenzylamine. The 
overall yields were comparable, with the ratio of pyrrolidine:pyrrole between 
5:1 and 8:1.  
NOESY NMR analysis of the phenethylamine derivative 278 was used to 
provide support for the assignment of the stereocentre at C3 of the 
pyrrolidine as R-configured. First the C3 methine proton was identified as 
being the broad signal at 2.36–2.42 in the 1H NMR spectrum, and the vicinal 
methyl substituent identified as the singlet integrating for 3 protons at 0.77 
ppm. This assignment was supported by these resonances having mutual 
couplings in the HMBC NMR spectrum. While these two groups were within 
three bonds of each other, in the NOESY spectrum there was no observable 
NOE correlation (Figure 3.3), providing evidence that the methine proton at 
C3 of the pyrrolidine is oriented away from the vicinal methyl group. 
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Figure 3.3: NOESY spectrum showing absence of a C3 methine and methyl 
correlation 
3.2.2 Mechanistic Discussion for Pyrrole/Pyrrolidine Formation 
From the above empirical observations we suggest that these reactions 
proceed first through condensation of the amine and the unsaturated 
aldehyde to give the imine species A (Scheme 3.8). The pyrrolidine product 
is favoured when sodium cyanoborohydride is present at the time of amine 
addition. This implies that in this case the sodium cyanoborohydride reduces 
imine A on its formation to give an amine, which can undergo an 
intramolecular reductive amination with the remaining aldehyde to give 
pyrrolidine 271 (Scheme 3.9). However, when the reducing agent is not 
added until after polygodial and the amine have been allowed to stir together 
for 30 minutes, the pyrrole is formed exclusively. In the absence of sodium 
cyanoborohydride, then, this intermediate imine A must react further in order 
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to preclude any reduction of the imine that would lead to pyrrolidine products. 
There are a number of possible mechanistic pathways for this to occur.  
It is proposed that this may proceed through intramolecular attack of the 
pseudo-neopentyl aldehyde by the imine of A to form the cyclic iminium 
species B. This could in turn convert or interconvert with the iminium C, 
through elimination of water. In either case, pyrrole product 270 would be 
reached through elimination and reduction of the iminium by addition of 
sodium cyanoborohydride, followed by a proton shift to remove the exocyclic 
alkene and generate the aromatic system.  
An alternative pathway to give enamine D, following a mechanism more like 
Kornienko’s where the double bond shifts following formation of the first 
imine, might also be possible. In this case the enamine D would undergo a 
condensation with the aldehyde to form pyrrole 270. Under these acidic 
reaction conditions the alkene can be protonated and then reduced by the 
sodium cyanoborohydride.  
Scheme 3.8: Proposed mechanisms for pyrrole formation 
There are of course other alternative pathways to reach the pyrrole, involving 
a variety of possible cyclic intermediates, such as α-hydroxypyrroles, but 
these could all be reduced under the described reaction conditions to give 
the same pyrrole product 270. The important common feature of all, 
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however, is the transformation following the first amination to preclude 
pyrrolidine formation. Thus, whether one or more of these possible pathways 
is being followed the end result is the same.  
To provide evidence for this rapid reaction of imine A in the absence of a 
reducing agent, a 1H NMR experiment was conducted where a sample of 
polygodial and benzylamine in methanol-d4 with a drop of acetic acid was 
monitored by NMR spectroscopy (solvent-suppressed for acetic acid), before 
and after the addition of the amine. It was observed that only a few minutes 
after addition of the amine the spectrum became quite complicated, but 
notably that any trace of the aldehyde peaks associated with polygodial at 
9.46 and 9.53 ppm had completely disappeared. This implied that not only 
had the conjugated aldehyde reacted to form an imine, but that this had 
proceeded to react with the second aldehyde to form another intermediate or 
intermediates.  
Scheme 3.9: Proposed mechanism for pyrrolidine formation  
The pyrrolidine product was favoured when sodium cyanoborohydride was 
present at the time of amine addition, which implies that in this case the 
sodium cyanoborohydride reduces imine A on formation to give amine E, that 
can undergo an intramolecular reductive amination with the remaining 
aldehyde to give pyrrolidine 271 (Scheme 3.9). Clearly, through the 
experimental results, this imine reduction is a very facile reaction that 
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dominates when all three reagents are mixed at the same time. However, the 
persistence of the pyrrole formation even in the presence of an excess of 
reducing agent, and the NMR evidence of it swiftly converting the 1,4-
dialdehyde to other intermediates, shows that this too is a highly competitive 
reaction pathway.  
3.2.3 Application to (+)-Crispin A Analogues 
With the ability to form stable pyrroles and pyrrolidines from polygodial 
established, it was decided to apply these novel scaffolds for further synthetic 
manipulations. To synthesise analogues of (+)-crispin A (265), N-
dimethoxyphenethylpyrrole 263 was taken as the starting point. It was 
theorised that this could be oxidised using our Dess–Martin periodinane 
approach to give a mixture of regio- and stereoisomeric γ-lactams,62 that 
could be further manipulated to reach analogues of natural products. This 
offered potential for two regioisomers to form, lactams 279 and 280, and two 
diastereomers of each regioisomer, where the stereochemical configuration 
of the pendant iodoaryl ester is either R or S (Scheme 3.10). The ratio of 
different regio- and stereoisomers at this point would be interesting from the 
point of view of observing how much the existing stereochemistry of the 
polygodial backbone can influence the formation of a new stereogenic 
centre.  
Scheme 3.10: Possible stereochemical outcomes of oxidation of pyrrole 212 
As expected, when the pyrrole 263 was taken and submitted to Dess–Martin 
oxidation for 1 h, a complicated mixture of products was obtained. However, 
the 1H NMR spectrum did suggest that all of pyrrole 263 had been 
consumed, due to the absence of the resonances at 6.21 and 6.22 ppm. 
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Additionally, the appearance of a number of new resonances above 8 ppm 
indicated the incorporation of the iodoaroyloxy moiety.  
As the overall aim was to access (+)-crispin A analogues, rather than probe 
the crude oxidation mixture too closely, the cyclisation step was carried out 
on the complex mixture. To that end it was taken up in dry CH2Cl2 and 
treated with 1.5 molar equivalents of BF3.OEt2 for 1 h. The intention of the 
reaction was to generate an iminium ion by elimination of the iodoaroyloxy 
ester and allow intramolecular Friedel–Crafts alkylation with the pendant 3,4-
dimethoxyphenethyl group to occur (Scheme 3.11). This furnished a mixture 
of novel pentacyclic compounds, identified as γ-lactam 281, isolated as a 
single diastereomer, and its isomers 282a and 282b, an inseparable ~2:1 
mixture of diastereomers.  
Scheme 3.11: Results of BF3.OEt2 cyclisation 
The identity of these was supported by the appearance of a likely C2 methine 
signal in the 1H NMR of γ-lactam 281 at 5.28 ppm, and 13C resonances at 
172.8 ppm, representative of the amide, and eight resonances between 
112.3 and 163.2 ppm, consistent with the six dimethoxyphenethyl aryl carbon 
atoms and the two alkene carbon atoms of the lactam. The structure of 
lactam 281 was also supported by IR spectroscopy, with the presence of an 
amide stretch at 1682 cm-1, and lack of any likely ester stretch, indicating the 
iminium formation and Friedel–Crafts alkylation reaction had proceeded. 
HRMS analysis also gave an exact mass consistent with the assigned 
structure. 
The stereochemistry of γ-lactam 281 was assigned through analysis of the 
HMBC and NOESY 2D NMR spectra. The HMBC spectrum allowed for the 
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assignment of the singlet at 5.28 ppm as the C2 methine proton in the lactam 
(HA), and the singlet at 1.16 as the angular methyl substituent, through 
shared HMBC correlations for these two 1H NMR resonances (Figure 3.4).  
Figure 3.4: Expansions of pyrrolinone 281 HMBC showing shared correlations 
With these resonances established, it was possible to observe in the NOESY 
spectrum that there is a weak correlation between these two resonances, 
which indicated that they were on the same face of the molecule (Figure 3.5). 
This provides evidence that the Friedel–Crafts reaction likely proceeds with 
stereoselectivity to this product due to the steric hindrance of the proximal 
angular methyl group which directs the reaction from the α-face of the 
molecule.  
The mixed diastereomers, 282a and 282b, were identified through analysis 
of their combined 1H and 13C NMR spectra. The 1H NMR spectrum featured 
similar arrangements of 1H resonances to lactam 281, with two sets of 
backbone methyl group resonances between 0.87 and 1.06 ppm observed, 
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consistent with a mixture of diastereomers. The 2:1 ratio of products is 
proposed to arise from the β-face of the lactam opposite the angular methyl 
group being less hindered at C5, leading alkylation to occur predominantly on 
that face. The higher combined yield of these products compared with 
compound 281 could arise from it being more favourable for intermediate 
oxidised species 280 to form in the oxidation step, where the bulky 
iodoaroyloxy group is in a less sterically hindered environment.  
Figure 3.5: Expansion of NOESY spectrum for compound 281, showing weak 
correlation between C2 proton and proximal methyl protons  
Interestingly, when the reaction was repeated for 18 h rather than 1 h, a 
fourth product was obtained, identified as the 4-pyrrolin-2-one isomer 283 
(Scheme 3.12). This was hypothesised to result from the double bond in the 
two diasteromers 282a and 282b shifting from C3–C4 to C4–C5, a 
phenomenon previously observed when attempting the intermolecular 
Friedel–Crafts alkylations of racemic γ-lactams with electron-rich aryls. In this 
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case, however, the bond-shifted product was not as prone to immediate 
decomposition as those acyclic derivatives and was stable enough to purify 
and analyse to determine the structure of the molecule.  
 Scheme 3.12: Products of overnight Friedel–Crafts reactions 
The structure was supported by 1H NMR spectroscopy. In contrast to the 
other three isomers formed in the reaction there was no methine peak near 5 
ppm to indicate the presence of a C5 methine proton. There was, however, a 
resonance at 2.64 ppm, likely that of the methine proton in the C3 position at 
the junction of the lactam and polygodial backbone. Furthermore, there were 
still alkene resonances present alongside the aromatic resonances between 
109.6–148.7 ppm. Additionally, the IR and MS analysis agreed that it was a 
similar compound to lactam 281 and the diastereomers 282, with an identical 
molecular weight. 
The stereochemistry of the methine proton at C3, adjacent to the amide, was 
assigned by the analysis of the NOESY NMR spectrum of the compound 
(Figure 3.6). The 1H NMR resonance for the methine proton at C3 was 
established as the singlet at 2.64 ppm (HA), and the angular methyl group 
established as the singlet at 0.80 ppm, through the HSQC and HMBC NMR 
spectra. In the NOESY spectrum, no correlation was observed between 
these two resonances, which supported the trans relationship at these 
substituents.  
279
+
280
Lewis Acid (1.5 eq.)
CH2Cl2, 0 oC - rt 
18 h H 283
N
O
H
OCH3
OCH3
281 + 282a (α-H) + 2821b (β-H)
+
Lewis acid combined yieldfrom pyrrole 263
1  :   0.8   :    2     :   2
1  :   1.3   :   3.0   :   0.5 
1  :   1.2   :   2.4   :   1.1 
1  :     0    :    0     :   3.4 22
90%
72%
38%
64%2
281 : 282a : 282b : 283
BF3•OEt2
AlCl3
Bi(OTf)3
TMSOTf
3
Chapter 3  Results and Discussion 
 
 
118 
To investigate whether the choice of Lewis acid used could influence the 
ratio of these products, perhaps to favour formation of a single diastereomer 
of 282, or push the isomerisation to 4-pyrrolin-2-one 283, the overnight 
conditions were repeated with a selection of Lewis acids (Scheme 3.8). 
Some results remained constant: As the oxidation reaction and hence its 
regioselectivity would not be affected by a change of Lewis acid, the ratio of 
lactam 281 to the mixture of other isomers remained 1:~4 in all cases. 
Likewise the ratio of diastereomers 282a to 282b were nearly constant at 
approximately 2:1. This is understandable in that the oxidation step rather 
than the alkylation step sets the ratio of  lactam 281 to other products. Also, 
assuming both diastereomers of 282 are equally prone to the alkene shift, 
their relative abundance should not differ drastically for different reaction 
conditions. So the use of different Lewis acids did little in general to favour 
one or the other of these isomers.  
Figure 3.6: NOESY NMR spectrum of 4-pyrrolinone 283 
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However, there were significant changes in the proportion of 4-pyrrolinone 
283, such that when TMSOTf was used it was the only product isolated other 
than lactam 281. This was a pleasing result on the grounds that it greatly 
reduced the complexity of the mixtures obtained from the reaction, while still 
giving a good overall yield. It was proposed that this could result from 
adventitious water in the TMSOTf leading to formation of some triflic acid, 
that when added with the TMSOTf to the reaction promotes the 
isomerisation. This is supported by observations that an NMR sample of the 
mixed diastereomers 282a and 282b left in chloroform converted entirely to 
4-pyrrolinone 283 within 6 h, presumably due to the presence of residual 
DCl. 
Ideally, crystallisation of these compounds and assignment of their absolute 
stereochemical configurations would have been carried out. However, all four 
of the compounds 281–283 proved unstable, decomposing completely within 
a week even if stored at <0 oC under a nitrogen atmosphere.  As such, they 
were taken and reduced immediately after purification and characterisation. 
Hydrogenation was first carried out on a sample of lactam 281. This was 
found to proceed smoothly when the reaction was carried out in the presence 
of acetic acid at 35 psi, furnishing the single product pyrrolidinone 284 in a 
modest yield of 14% (Scheme 3.13).  
Scheme 3.13: Hydrogenation of 281 
Success of the hydrogenation reaction was supported by the appearance of 
new methine resonances in the 1H NMR spectrum, at 2.41 ppm, 2.68–2.72 
ppm and 4.54 ppm that were identified through 2D NMR spectral analysis as 
the three lactam methine protons. Importantly, in the 13C NMR spectrum 
there were only six resonances between 109.9 ppm and 148.2 ppm, 
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indicating that while the dimethoxyphenyl moiety was still present, there was 
no longer an alkene in the molecule. The accurate mass of the compounds 
as determined by HRMS was also consistent with an increase of two mass 
units from pyrrolinone 281 to pyrrolidinone 284.  
The stereochemistry of pyrrolidinone 284 was assigned through analysis of 
the NOESY NMR spectrum (Figure 3.7). Correlations between the methyl 
group signal at 1.27 ppm, identified through the HSQC and HMBC spectra as 
the stereogenic centre methyl, and three of the four methine proton 
resonances at 2.41 ppm, 2.71 ppm and 4.54 ppm suggested that all three of 
these are likely to be be on the same face of the molecule. This implied that 
that hydrogen was delivered on the face opposite the aromatic substiuent, 
and thus that the steric bulk of this substiuent played a deciding role in 
stereochemical outcomes of transformations to the molecule, over the 
angular methyl group.  
Figure 3.7: NOESY NMR spectrum of pyrrolidinone 284  
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Hydrogenation of the mixture of diastereomeric lactams 282a and 282b was 
more demanding, requiring a much longer reaction time to be complete, 
although unlike for lactam 281 it would proceed in the absence of AcOH. In 
the end, a single product was obtained, identified as pyrrolidinone 285 
(Scheme 3.14). Interestingly, hydrogenation of 4-pyrrolinone 283 proceeded 
much more readily even without the addition of acid to the reaction mixture, 
only taking 2 h, and gave the single product pyrrolidine 285 as well. This is 
consistent with the mixed diastereomers 282 spontaneously converting to the 
single diastereomer of 4-pyrrolinone 283 prior to hydrogenation. Given that 
there was no acid present for this hydrogenation, it seems possible that the 
two diastereomers isomerise in protic solvents as well, and that this process 
is more facile than hydrogenation of the alkene.  
Scheme 3.14: Hydrogenation of the other isomers to give the single product 285 
The identity of pyrrolidinone 285 was, much like for compound 284, 
established through the appearance of new methine resonances in the 1H 
NMR spectrum, at 2.54 ppm, 2.80 ppm and 4.68 ppm. It was also supported 
by the disappearance of the alkene resonances of pyrrolinones 282/283 in 
the 13C NMR spectrum. Likewise HRMS analysis showed an increase in 
molecular weight consistent with adding two hydrogen atoms. The 
stereochemistry of pyrrolidinone 285 was likewise established through 
analysis of the NOESY NMR spectrum. There were no correlations between 
the signal at 1.02 ppm (the angular methyl substituent) and the three 
resonances at 2.54 ppm, 4.68 ppm, and 2.80 ppm assigned to the three 
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methine protons in the lactam ring (Figure 3.8). This is consistent both with 
the conversion of 3-pyrrolinones 282a and 282b to 4-pyrrolinone 283, and 
with hydrogenation favouring the face least hindered by the angular methyl 
group. In this case the aryl substiuent would be approximately planar with the 
lactam ring prior to hydrogenation and thus play less of a role in hindering 
either face of the molecule.  
Unfortunately, these compounds were also rather unstable, possibly 
explaining the rather low yields of products obtained. However, this study has 
demonstrated that the polygodial backbone can be used to rapidly access 
novel and interesting polycyclic chemical structures. 
Figure 3.8: NOESY expansion of 285 
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3.2.3 Other Attempted Applications 
To reach N-H pyrrole/pyrrolidine species from polygodial, that could be used 
in chiral organocatalysis, a number of approaches were attempted. The first 
was to prepare the N-H pyrrole directly, using an ammonium salt as the 
nitrogen source (Scheme 3.15). However, use of ammonium acetate 
provided a complex mixture of products, even under conditions where large 
excesses of the salt were added, which were difficult to separate and where 
the majority of the starting material was lost to decomposition. It was also 
attempted to make the pyrrole using N-methoxyamine, to give a species that 
might be more readily converted to the N-H through hydrogenation (scheme 
3.14).337,338 However, similar decomposition of polygodial or any products 
was observed.  
Scheme 3.15: Attempts to reach N-H pyrroles/pyrrolidines 
Another approach was to investigate using the N-benzylpyrrole 270 as the 
starting material in the synthesis of proline analogues, and exploit the 
nucleophilic pyrrole to prepare a 2-carboxylic ester as a precursor for the 
proline analogue. Theoretically this species could then be reduced to both 
reduce the pyrrole to the pyrrolidine and cleave the benzyl protecting group. 
Thus, pyrrole 270 was taken and converted to the corresponding 2-
trichloromethyl ketone derivative 288, through stirring with an excess of 
trichloroacetyl chloride in diethyl ether for 48 h (Scheme 3.16).339 The 
success of this reaction was supported through analysis of the 1H NMR of the 
single product obtained, which showed a single pyrrolic singlet peak at 6.85 
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ppm, indicative of only one of the pyrrole positions being substituted. 
Additionally, the NOESY spectrum showed a weak correlation between this 
signal and that of the angular methyl group at 1.20 ppm, providing further 
evidence that the substitution only occurred at C2 of the pyrrole, most distant 
ot the angular methyl group which was predicted to be the least sterically 
hindered site. 
Trichloromethyl ketone 288 was then converted to the corresponding methyl 
ester by treatment with base in MeOH to give pyrrole 289 in an 82% yield 
(Scheme 3.16). This was identified primarily through the appearance of a 
singlet peak integrating for 3 protons in the 1H NMR spectrum at 3.73 ppm, 
characteristic of the –OCH3, and by mass spectrometry. It was proposed that 
this could be simply hydrogenated to remove the benzyl substituent and 
reduce the pyrrole to the corresponding pyrrolidine, thus furnishing an 
analogue of proline. However, hydrogenation at 35psi in EtOH/HCl for 3 h 
failed to show any reaction of the starting material to either reduce the 
pyrrole moiety or cleave the benzyl group (Scheme 3.16).  
Scheme 3.16: Synthesis of 2-methylester pyrrole 289 
To circumvent this issue, a range of hydrogenation conditions were trialled 
on a number of the pyrrolidine products instead, namely the benzylpyrrolidine 
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271 and the 4-methoxybenzylpyrrolidine 277 (Scheme 3.17). This was 
proposed as hydrogenation of pyrroles can be capricious and by starting with 
a pyrrolidine with an exocylic alkene this problem could potentially be 
overcome. 
Hydrogenation of pyrrolidine 271 under 1 atm of H2 with Pd/C resulted in 
decomposition, which given the aforementioned instability of related 
compounds is perhaps unsurprising. Further attempts with HCl present led to 
similar results, where any likely products appeared to still include the benzyl 
group. Pd(OH)2 was trialled as an alternative catalyst, and carrying out the 
reaction at higher pressures for shorter periods of time with both this or Pd/C. 
However these all led to decomposition or a complex mixture of products. 
Likewise for pyrrolidine 277, it seemed problematic to remove the benzyl 
group without decomposition.  
Scheme 3.17: Attempted global reduction of pyrrolidines 
None of the approaches trialled, either in formation of the N-H pyrrole or by 
reduction of pyrroles or pyrrolidines, have thus far provided a straightforward 
route to the desired pyrrolidine species, giving at best complex mixtures of 
undesired products or decomposition. For future investigations, either more 
particular reduction conditions could be trialled, or else more specialised 
substrates that can have their N-substituents cleaved under different 
conditions. For example, a new pyrrolidine 292 could be prepared from 
allylamine (Scheme 3.18). There are many possible methods for cleaving N-
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allyl groups, including de-allylation with a palladium catalyst and a barbituritic 
or thiobenzoic acid present to act as an allyl trapping reagent,340,341 heating 
the substrate in the presence of Wilkinson’s catalyst,342 and treatment with 
hydrazine and a base at elevated temperatures.343 Another more exotic 
method would require the use of particular amine starting materials, such as 
for the oxidative cleavage of a γ-hydoxy N-substiuent in pyrrolidine 294. This 
transformation has been previously demonstrated in work by Andrés and 
colleagues using (–)-8-aminomenthol derivatives and PCC.344 
Scheme 3.18: Potential alternatives for reaching proline analogues 
3.3 Conclusions 
In conclusion, it is now clear that with well-chosen reaction conditions 
polygodial can be used as a starting point for the synthesis of a range of 
pyrroles and pyrrolidines. These in turn show promise as intermediates in the 
synthesis of complex organic scaffolds and novel analogues of biologically 
active natural products. 
For future investigations, there are three main avenues to be explored: First, 
to widen the conditions and substrates to find a successful route to the 
desired proline analogues. This will involve either finding more specialised 
reduction conditions for the presently prepared starting pyrroles/pyrrolidines, 
or preparing new starting materials with N-substituents that are more 
amenable to cleavage by hydrogenation or some other chemical means. 
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One goal in this space beyond reaching the N-H pyrrolidine proline 
analogues is to look at forming pyrrolidines with beta amine N-substituents, 
to give diamine species such as 296 (figure 3.19). Diamines have wide range 
of uses in catalysis. Tertiary-primary diamines have been used extensively 
as catalysts for Aldol reactions and Michael additions (e.g. diamine 
297).345,346 Tertiary-tertiary diamines, such as 298, have been reported as 
catalysing stereoselective Knoevenagel reactions and alkyllithium 
additions.347,348 
Scheme 3.19: Development of chiral diamines for organocatalysis 
Secondly, the further derivatisation of the (+)-Crispin A analogues prepared 
in this work, to hopefully reach more stable species which might be screened 
for biological activity and compared to the natural product in their efficacy 
(Scheme 3.20, using pyrrolinone 281). This would be pursued most simply 
through reduction of the amide functionality present in pyrrolidinones 284 and 
285. However, the functional lactams intermediates 281-283 could also be 
derivatised in a variety of ways, such as hydroxylation, to give dihydroxy 
compound 300. This could even be further transformed to give fluorinated 
analogues, using some the methods discussed in Chapter 2. Epoxidation 
could also be carried out to give epoxide 302. Another type of reaction that 
could rapidly give libraries of more complex polycyclic frameworks would be 
Diels–Alder reactions, to give species such as hexacyclic compound 303. 
Studies of the stereoselectivity of such transformations would also be 
interesting to compare to the case where only hydrogen is added across the 
double bond.  
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Scheme 3.20: A range of potential transformations to lactam 281 
Thirdly, widening the scope of the pyrrole formation reaction by exploring a 
range of different nucleophiles other than reduction with NaBH3CN, such as 
thiols or cuprate reagents (Scheme 3.21). Depending on the mechanism 
involved in the pyrrole formation (See section 3.2.2), this could lead to the 
introduction of interesting substituents at the position of the alkene. This 
would be useful synthetically for providing more substituted intermediates for 
further reaction, and also from a mechanistic standpoint for understanding 
more about how polygodial may react in biological systems. 
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Scheme 3.21: Potential use of alternative nucleophiles in pyrrole synthesis
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Chapter 4: Conclusions 
The controlled oxidation of pyrroles is a powerful tool for accessing a variety 
of natural product analogues and other biologically active molecules. In this 
work two approaches to controlled pyrrole oxidation, using hypervalent iodine 
reagents and photooxidation, have been utilised to reach three key targets 
and thus establish the usefulness of these techniques (Scheme 4.1).  
Scheme 4.1: Summary of this work 
It was demonstrated that oxidation of simple N-substituted pyrroles could be 
used as a starting point to reach a library of racemic analogues of the natural 
product codonopsinine. In the pursuit of asymmetric syntheses of these 
analogues, it was shown that oxidation of pyrroles derived from chiral amino 
alcohols can be used to reach previously reported chiral bicyclic 
intermediates in a more step-efficient and mild fashion. 
These oxidation-derived bicyclic intermediates were also used to form 
fluorinated derivatives of GABA, without the undesirable rearrangement 
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products observed when preparing these analogues from acyclic starting 
materials. 
Finally, it was demonstrated that pyrrole oxidation methods could be applied 
to pyrroles formed from more complex chiral scaffolds, in this case the 
natural product polygodial. This approach was used to reach analogues of 
another biologically active natural product, (+)-crispin A. 
These three streams of research are united in their use of controlled pyrrole 
oxidation as a key step, and represent the potential of this technique to be 
used to rapidly reach desirable natural product targets and access novel 
complex molecular scaffolds. Looking toward the future, these methods could 
be applied to many objectives, both in the expansion on the individual 
research areas as described in Chapters 1–3, and elsewhere. A variety of 
other biologically active pyrroline and pyrrolidine natural products could be 
pursued, such as Pramanicin (306, Figure 4.1), an antifungal and possible 
anticancer agent;349 and Erysotrine (307), found in folk medicines.350,351 For 
both of these and many others a single of bicyclic pyrrole-derived lactam 
could provide a convenient template for total synthesis or access to libraries 
of analogues. 
Figure 4.1: Potential future natural product targets.
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Chapter 5: Experimental 
5.1 General Experimental 
Nuclear Magnetic Resonance Spectroscopy 
Proton  (1H), carbon (13C) and fluorine (19F) nuclear magnetic resonance 
spectra were obtained either on a Bruker Avance III spectrometer operating 
at 400 MHz, 100 MHz and 400 MHz respectively, or on a Bruker 
spectrometer operating at 600 MHz, 150 MHz and 600 MHz respectively. 
Where necessary, resonances were assigned using two-dimensional COSY, 
HSQC and HMBC experiments, and coupling constants from complex or 
non-first-order spectra were determined by simulation/iteration sequences 
using the Daisy module of the Bruker TopSpin software. Samples were 
dissolved in deuterated chloroform (CDCl3) unless otherwise stated. 
Chemical shifts were recorded as δ values in parts per million (ppm) and 
referenced to the solvent used.352 Coupling constants were recorded as J 
values in Hz. The following abbreviations were used to describe 1H, 13C and 
19F splitting patterns: s = singlet, bs = broad singlet, d = doublet, t = triplet, q 
= quartet, sex = sextet, ad = apparent doublet, , at = apparent triplet, dd = 
doublet of doublets, ddd = doublet of doublets of doublets. 
Infrared Spectroscopy 
Infrared spectra were obtained on a Shimadzu FTIR 8400s spectrometer, 
using NaCl plates. Liquids and solids were recorded as thin films from either 
CDCl3 or CH2Cl2, unless otherwise stated, in cm–1 
Mass Spectrometry 
Mass spectrometry and high resolution mass spectrometry were performed 
on a Kratos Concept ISQ mass instrument using electron impact mass 
spectrometry, or by electrospray ionization by direct influsion into an LTQ-
Orbitrap XL mass spectrometer using a syringe pump. Accurate mass was 
measured by “peak matching” at 10000 resolution against perfluorokerosene.  
Analyses were performed by The Central Science Laboratory at the 
University of Tasmania. The molecular ion and mass fragments are quoted, 
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with relative intensities of the peaks referenced to the most intense taken as 
100%. 
Column Chromatography 
Flash column chromatography was performed using Merck flash grade silica 
(32-63 µm) according to the general method of Still et al.353 
Automated flash chromatography was carried out using a Reveleris® X2 
Flash Chromatography System using silica gel cartridges.  
Thin Layer Chromatography (TLC) 
Merck silica gel 60 F254 aluminium backed sheets were used for analytical 
thin layer chromatography. TLC plates were visualised under a 254 nm UV 
lamp and by treatment with either a cerium molybdite dip (37.5 g 
phosphomolybdic acid, 7.5 g ceric sulfate, 37.5 mL sulfuric acid, 720 mL 
water) or a potassium permanganate dip (3 g KMnO4, 20 g K2CO3, 5 mL 5 % 
aqueous NaOH, 300 mL water), followed by heating. 
Solvents and Reagents 
All solvents and reagents were either purchased at high purity suitable for 
immediate use, or when necessary purified by standard laboratory 
procedures.354 
Optical Rotations 
Optical Rotations were recorded using a Rudolph research analytical Autopol 
III automatic polarimeter. Unless otherwise stated, all optical rotations were 
carried out using chloroform as the solvent. 
X-ray Crystallography 
Crystals suitable for X-ray diffraction were grown by recrystallization from hot 
MeOH for compounds 155a and 155b, and by slow evaporation from CH2Cl2 
or MeOH for al other compounds. Data were collected at −173 °C on crystals 
mounted on a Hampton Scientific cryoloop, at the MX1 or MX2 beamline of 
the Australian Synchrotron for compounds 163, 173, and 175; 355,356 and on a 
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Bruker D8 Quest diffractometer with copper ImS microfocus source for 
compounds 155a, 155b, 232–234 and 246. The structures were solved by 
direct methods with SHELXS-97,357 refined using full-matrix least-squares 
routines against F2 with SHELXL-97, and visualised using X-SEED or 
OLEX2. 358,359 The following standard procedure was adopted for refinement 
and modelling of disorder: All non-hydrogen atoms were refined 
anisotropically. All hydrogen atoms were placed in calculated positions and 
refined using a riding model with fixed C–H distances of 0.95 Å (sp2CH), 0.99 
Å (CH2), 0.98 Å (CH3). The thermal parameters of all hydrogen atoms were 
estimated as Uiso(H) = 1.2Ueq(C) except for CH3, where Uiso(H) = 1.5Ueq(C). 
 
Photoreactions 
Photooxidation reactions were carried out in a photoreactor constructed from 
a 100 mL measuring cylinder tightly wrapped with a strip of green LEDs up to 
the 70 mL graduation. The green LEDs emitted with a   λmax  of 515 nm, and 
an overall emission range measured to be approximately 450–600 nm. The 
strip of LEDs was 85 cm long and contained 102 individual LEDs, providing 
4.1 W (0.024 W cm-2) of radiant flux to the photoreactor.
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5.2 Chapter 1 Experimental Details 
(±)-5-(2-Iodobenzoyoxy)-1-methyl-3,4-dehydropyrrolidin-2-one (37)  
To a stirred solution of N-methylpyrrole (1.0076 g, 12.42 mmol) in CH2Cl2 (40 
mL) at 0 oC was added Dess–Martin periodinane (13.0867 g, 30.85 mmol, 
2.48 eq.). The reaction was stirred for 2 h, at which point H2O (30 mL) was 
added, and the reaction quenched by addition of solid Na2S2O5. The 
aqueous and organic layers were separated, and the aqueous layer 
extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were 
washed with saturated NaHCO3 (50 mL), dried over MgSO4, filtered, and the 
solvent removed under reduced pressure to give the product as a dark red oil 
(2.7724 g, 8.079 mmol, 65% yield). NMR spectra agreed with those reported 
by Howard et al.62 
1H NMR δ (400 MHz):  3.03 (s, 3 H), 6.32 (d, J = 6.0 Hz, 1 H), 6.67 
(apparent d, J = 1.4 Hz, 1 H), 7.10 (dd, J = 6.0 
Hz, 1.7 Hz, 1 H), 7.20 (td, J = 7.7 Hz, 1.7 Hz, 1 
H), 7.42 (td, J = 7.6 Hz, 1.1 Hz, 1 H), 7.82 (dd, J = 
7.8 Hz, 1.7 Hz, 1 H), 8.03 (dd, J = 8.0 Hz, 1.0 Hz, 
1 H)  
(±)-5-Acetoxy-1-methyl-3,4-dehydropyrrolidin-2-one (29)  
To a stirred solution of IBX (3.0229 g, 10.79 mmol, 2.5 eq.) in AcOH (10 mL) 
at room temperature was added N-methylpyrrole (0.3473 g, 4.28 mmol), and 
the reaction stirred for 20 h. H2O (25 mL) and CH2Cl2 (25 mL) were added, 
excess Na2S2O5 was added, and the solution made basic by addition of solid 
NaHCO3. The aqueous and organic layers were separated, and the aqueous 
layer extracted with CH2Cl2 (4 x 25 mL). The combined organic layers were 
N
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washed with NaHCO3 (25 mL), dried over MgSO4, filtered, and the solvent 
removed under reduced pressure to give the product as a brown oil (0.6272 
g, 4.04 mmol, 94% yield) that was used without further purification. NMR 
spectra matched those reported by Feringa et al.360 
1H NMR δ (400 MHz): 2.13 (s, 3 H), 2.91 (s, 3 H), 6.23 (d, J = 5.6 Hz, 1 
H), 6.40 (s, 1 H), 6.93 (d, J = 5.6 Hz, 1 H) 
(±)-5-Hydroxy-1-methyl-3,4-dehydropyrrolidin-2-one (76) and (±)-5-
Ethoxy-1-methyl-3,4-dehydropyrrolidin-2-one (77)  
Into the green LED photoreactor was added Rose bengal (0.0113 g), NaOAc 
(200 µL saturated aqueous solution), EtOH (70 mL), followed by the addition 
of N-methylpyrrole (0.4780 g, 5.892 mmol). The resultant solution was then 
submerged in an ice/water bath and a stream of O2 bubbled through it before 
the light was turned on. The solution was irradiated for 2 h before the light 
was turned off and the solvent evaporated. The crude mixture was passed 
through a plug of silica gel with ethyl acetate to yield a 0.5:1 mixture of the 5-
hydroxy-pyrrolin-2-one 76 and the 5-ethoxy-pyrrolin-2-one 77 as a red oil 
(0.3376 g, 2.569 mmol, 44% yield). NMR spectra agreed with those reported 
by Howard et al.80 
1H NMR δ (400 MHz):  2.90 (s, 3 H), 5.27 (s, 1 H), 6.06 (d, J = 5.9 Hz, 1 
H), 6.91 (dd, J = 5.9, 1.5 Hz, 1 H)  
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1H NMR δ (400 MHz):   1.16 (t, J = 7.0 Hz, 3 H), 2.89 (s, 3 H), 3.29 (q, J 
= 7.0 Hz, 2 H), 5.27 (s, 1 H), 6.19 (dd, J = 6.0, 0.8 
Hz, 1 H), 6.88 (dd, J = 6.0, 1.5 Hz, 1 H) 
(±)-(2R,3S,4R)-1-Methyl-5-oxopyrrolidine-2,3,4-triyl triacetate (39) 
To a stirred solution of acetoxylactam 29 (0.7136 g, 4.599 mmol) in a 5:1 
mixture of acetone and H2O (18 mL), at 0 oC, was added N-
methylmorpholine-N-oxide (3.00 mL of a 50% w/w solution in H2O, 14.47 
mmol, 3.1 eq.) and OsO4 (3.60 mL of a 0.0393 M solution in H2O, 0.1415 
mmol, 0.03 eq.). The resulting solution was stirred for 16 h, at which time 
acetonitrile was added and the solvent removed under reduced pressure. 
The crude product was then dissolved in pyridine (9 mL) and Ac2O (9 mL) at 
0 oC, and stirred for 16 h. H2O (30 mL) and CH2Cl2 (30 mL) were added, and 
the aqueous and organic layers separated. The aqueous layer was extracted 
with CH2Cl2 (3 x 30 mL). The combined organic layers were washed with 2 M 
HCl (2 x 30 mL) and saturated NaHCO3 (2 x 30 mL), dried over MgSO4, 
filtered, and the solvent removed under reduced pressure. The crude 
material was purified by elution through a plug of silica using EtOAc/hexanes 
(70:30) as eluent to give 39 as a yellow oil (0.8331 g, 3.049 mmol, 66% yield) 
1H NMR δ (400 MHz): 2.09 (s, 3 H), 2.11 (s, 3 H), 2.12 (s, 3 H), 2.94 (s, 
3 H), 5.36 (d, J = 5.2 Hz, 1 H), 5.65 (d, J = 5.2 Hz, 
1 H), 6.01 (s, 1 H) 
13C NMR δ (100 MHz): 20.4, 20.5, 20.8, 29.0, 67.5, 70.2, 85.1, 169.3, 
169.5, 169.6, 170.0  
IR Vmax:  1751 (C=O), 1734 (C=O)   
HRMS: For C11H15NO7+H, predicted 296.0741, found 
296.0749 
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(±)-(2R,3S,4R)-1-Methyl-5-oxopyrrolidine-2,3,4-triyl triacetate (39) 
and (±)- (2R,3S,4R)-2-ethoxy-1-methyl-5-oxopyrrolidine-3,4-diyl 
diacetate (78)  
To a stirred solution of a 3:1 mixture of hydroxylactam 76 and ethoxylactam 
77 (0.6257 g, 5.206 mmol) in a 5:1 mixture of acetone and H2O (12 mL), at 0 
oC, was added N-methylmorpholine-N-oxide (3.20 mL of a 50% w/w solution 
in H2O, 15.43 mmol, 2.96 eq.) and OsO4 (3.90 mL of a 0.0393 M solution in 
H2O, 0.155 mmol, 0.029 eq.). The resulting solution was stirred for 16 h, at 
which time acetonitrile was added and the solvent removed under reduced 
pressure. The crude product was then dissolved in pyridine (6 mL) and Ac2O 
(6 mL) at 0 oC, and stirred for 16 h. H2O (25 mL) and CH2Cl2 (25 mL) were 
added, and the aqueous and organic layers separated. The aqueous layer 
was extracted with CH2Cl2 (3 x 15 mL). The combined organic layers were 
washed with 2 M HCl (2 x 25 mL) and saturated NaHCO3 (2 x 25 mL), dried 
over MgSO4, filtered, and the solvent removed under reduced pressure. The 
crude mixture was purified by elution through a plug of silica using 
EtOAc/hexanes (80:20) as eluent, to give a 1:2 mixture of ethoxylactam 78 
and acetoxylactam 39 as yellow oil (0.9194 g, 3.423 mmol, 66% yield).  
1H NMR δ (400 MHz): 1.23 (t, J = 7.0 Hz, 3 H), 2.06 (s, 3 H), 2.11 (s, 3 
H), 2.93 (s, 3 H), 4.09 (q, J = 7.0 Hz, 2 H), 4.60 (s, 
1 H), 5.29 (d, J = 5.4 Hz, 1 H), 5.54 (d, J = 5.4 Hz, 
1 H) 
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General Procedure for the Introduction of Aryl Groups to Acetoxy- 
protected Diol Intermediates 
To a solution of either acetoxy 39 or a mixture of 39 and ethoxy 78, in dry 
CH2Cl2 at 0 oC under N2, was added the arene (1.2 eq) and BF3.OEt2 (1.5 eq) 
via syrine. The reaction was allowed to warm to room temperature and 
stirred for 16 h. It was then cooled on an ice bath and quenched with 
saturated NaHCO3. The aqueous and organic layers were separated and the 
aqueous layer extracted three times with CH2Cl2. The combined organic 
layers were dried over MgSO4 or Na2SO4, and the solvent was removed 
under reduced pressure. Products were purified by flash column 
chromatography with a mixture of EtOAc and hexanes as eluent, or by 
washing through a plug of silica with a mixture of EtOAc and hexanes. 
(±)-(2R,3R,4R)-2-(3,4-Dimethoxyphenyl)-1-methyl-5-oxopyrrolidine-3,4-
diyl diacetate  (79)  
Prepared from triacetoxy 39 (0.1132 g, 0.4143 mmol), with veratrole (0.065 
mL, 0.5099 mmol, 1.23 eq.) and BF3.OEt2 (77.5 µL, 0.6076 mmol, 1.46 eq.) 
in dry CH2Cl2 (5 mL). The crude material was purified by elution through a 
silica plug with EtOAc/hexanes (80:20) to give 79 as a clear oil (0.0463 g, 
0.1318 mmol, 32% yield). 
1H NMR δ (400 MHz): 2.05 (s, 3 H), 2.06 (s, 3 H), 2.82 (s, 3 H), 3.80 (s, 
3 H), 3.81 (s, 3 H), 4.46 (s, 1 H), 5.16 (d, J = 5.6 
Hz, 1 H), 5.45 (d, J = 5.6 Hz, 1 H), 6.61 (dd, J = 
8.0 Hz, 2.0 Hz, 1 H), 6.68 (d, J = 2.0 Hz, 1 H), 
6.80 (d, J = 8.0 Hz, 1 H) 
13C NMR δ (100 MHz): 20.55, 20.90, 29.28, 56.17, 56.18, 67.81, 68.32, 
73.62, 109.50, 111.79, 118.00, 127.39, 149.61, 
150.10, 168.55, 169.83, 170.28 
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IR Vmax:  2936, 1750, 1716, 1606, 1594, 1518, 1464, 1374, 
1241, 1141, 1064, 1026, 732 
HRMS: For C17H21NO7+Na, predicted 374.1210, found 
374.1221 
(±)-(2R,3R,4R)-2-(4-Methoxyphenyl)-1-methyl-5-oxopyrrolidine-3,4-diyl 
diacetate (85) and (±)-(2R,3R,4R)-2-(2-methoxyphenyl)-1-methyl-5-
oxopyrrolidine-3,4-diyl diacetate (86)  
Prepared from a mixture of 39 and 78 (1:0.3, 0.2577 g, 0.9543 mmol), with 
anisole (0.125 mL, 1.150 mmol, 1.20 eq.) and BF3.OEt2 (0.180 mL, 1.458 
mmol, 1.52 eq.) in dry CH2Cl2 (10 mL). The crude material was purified by 
elution through a silica plug with EtOAc/hexanes (80:20) to give an 
inseparable mixture of 85 and 86 (1:1.3, 0.1977g, 0.8332 mmol, 87% total 
yield).  
1H NMR δ (400 MHz):  2.04 (s, 3.3 H), 2.06 (s, 3 H), 2.07 (s, 4 H), 2.08 
(s, 3 H), 2.81 (s, 3 H), 2.82 (s, 3.6 H), 4.48 (s, 1 
H), 4.73 (s, 1.3 H), 5.17 (dd, J = 5.5, 6.7 Hz, 1 H), 
5.33 (d, J = 5.6 Hz, 1.3 H), 5.49 (d, J = 5.6 Hz, 1 
H), 5.51 (d, J = 5.5 Hz, 1.3 H), 6.85–6.93 (m, 6 
H), 7.06 (d, J = 8.6 Hz, 2 H), 7.29 (ddd, J = 8.0, 
7.0, 2.3 Hz, 1.3) 
13C NMR δ (100 MHz):  20.3 (2 C), 20.62, 20.68, 28.9, 29.0, 55.3, 55.4, 
63.7, 67.3, 68.1, 68.5, 71.7, 73.3, 111.0, 114.8, 
120.9, 122.6, 126.3, 126.7, 127.3, 130.1, 157.0, 
159.9, 168.2, 168.8, 169.61, 169.67, 169.9, 171.0 
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(±)-(2R,3R,4R)-2-(2,5-Dimethoxyphenyl)-1-methyl-5-oxopyrrolidine-3,4-
diyl diacetate (80)  
Prepared from triacetoxy 39 (0.0954 g, 0.3491 mmol), with 1,4-
dimethoxybenzene (0.0603 g, 0.4379 mmol, 1.25 eq.) and BF3.OEt2 (70.0 µL, 
0.5671 mmol, 1.62 eq.) in dry CH2Cl2 (5 mL). The crude material was purified 
by elution through a silica plug with EtOAc/hexanes (80:20) to give 80 as a 
clear oil (0.0730 g, 0.2078 mmol, 60% yield). 
1H NMR δ (400 MHz): 2.09 (s, 3H), 2.12 (s, 3 H), 2.88 (s, 3 H), 3.77 (s, 3 
H), 3.81 (s, 3 H), 4.73 (s, 1 H), 5.38 (d, J = 5.6 Hz, 
1 H), 5.56 (d, J = 5.2 Hz, 1 H), 6.51 (ad, J = 2.4 
Hz, 1 H), 6.81-6.87 (m, 2 H) 
13C NMR δ (100 MHz): 20.6, 20.9, 29.3, 56.0, 56.1, 64.0, 68.7, 72.0, 
112.1, 113.5, 113.8, 124.1, 151.3, 154.1, 169.1, 
169.8, 169.9  
IR Vmax:  2937, 1752, 1719, 1501, 1374, 1243, 1219, 1047 
HRMS: For C17H21NO7, predicted 351.13180, found 
351.13225. 
(±)-(2R,3R,4R)-2-(2,4-Dimethoxyphenyl)-1-methyl-5-oxopyrrolidine-3,4-
diyl diacetate (87) and (±)-(2R,3R,4R)-2-(2,6-dimethoxyphenyl)-1-methyl-
5-oxopyrrolidine-3,4-diyl diacetate (88)  
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Prepared from a mixture of 39 and 78 (1:0.3, 0.5080 g, 1.881 mmol), with 
1,3-dimethoxybenzene (0.300 mL, 2.291 mmol, 1.22 eq.) and BF3.OEt2 
(0.350 mL, 2.835 mmol, 1.51 eq.) in dry CH2Cl2 (10 mL). The crude material 
was purified by elution through a silica plug with EtOAc/hexanes (80:20) to 
give an inseparable 1:0.27 mixture of 87 and 88 (0.4385 g, 1.641 mmol, 87% 
total yield). 
1H NMR δ (400 MHz):  2.03 (s, 1 H), 2.04 (s, 3 H), 2.06 (s, 3 H), 2.08 (s, 
3 H), 2.60 (s, 0.8 H), 2.79 (s, 3 H), 3.75 (s, 3.2 H), 
3.76 (s, 4.4 H), 4.63 (s, 1 H), 5.14 (s, 0.27 H), 
5.30 (d, J = 5.5 Hz, 1 H), 5.39 (d, J = 6.8 Hz, 0.27 
H), 5.52 (d, J = 5.5 Hz, 1 H), 5.71 (d, J = 6.8 Hz, 
0.27 H), 6.39–6.46 (m, 2 H), 6.52 (d, J = 8.4 Hz, 
0.57 H), 6.80 (d, J = 8.3 Hz, 1 H), 7.22 (t, J = 8.4 
Hz, 0.27 H) 
13C NMR δ (100 MHz):  14.1, 20.3, 20.4, 20.5, 20.6, 20.9, 27.8, 28.8, 
55.43, 55.49, 55.8, 59.1, 60.3, 63.7, 68.6, 69.5, 
70.6, 71.7, 99.2, 104.0, 104.3, 110.9, 114.9, 
127.4, 130.4, 158.1, 158.5, 161.4, 168.7, 169.5, 
169.7 
(±)-(3R,4R,5R)-1-Methyl-2-oxo-5-(2,4,6-trimethoxyphenyl)pyrrolidine-3,4-
diyl diacetate (81)  
Prepared from a mixture of 39 and 78 (1:0.3, 0.2154 g, 0.7948 mmol), with 
1,3,5-trimethoxybenzene (0.1604 g, 0.9537 mmol, 1.20 eq.) and BF3.OEt2 
(0.150 mL, 1.215 mmol, 1.53 eq.) in dry CH2Cl2 (5 mL). The crude material 
was purified by flash column chromatography with EtOAc/hexanes (90:10) 
and EtOAc as the eluents to give 81 as a clear oil (0.1597 g, 0.5371 mmol, 
68% total yield). 
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1H NMR δ (400 MHz):  2.04 (s, 3 H), 2.09 (s, 3 H), 2.61 (s, 3 H), 3.76 (s, 
3 H), 3.77 (s, 6 H), 5.05 (s, 1 h), 5.38 (d, J = 6.7 
Hz, 1 H), 5.72 (d, J = 6.7 Hz, 1 H), 6.09 (s, 2 H) 
13C NMR δ (100 MHz):  20.4, 20.6, 27.7, 55.3, 55.8, 59.1, 69.6, 70.9, 
90.8, 103.5, 159.4, 161.8, 168.6, 169.80, 169.84 
IR Vmax:  2944, 2243, 1755 (C=O), 1695 (C=O), 1608, 
1592, 1470, 1436, 1423, 1373, 1245, 1207, 1154, 
1124 
HRMS: For C18H24NO8+H, predicted 382.1496, found 
382.1496 
(±)-(2S,3R,4R)-2-(Furan-2-yl)-1-methyl-5-oxopyrrolidine-3,4-diyl 
diacetate (82)  
Prepared from 39 (0.0410 g, 0.150 mmol), furan (0.020 mL, 0.275 mmol, 1.8 
eq.), and 0.028 mL (0.226 mmol, 1.5 eq.) of BF3.OEt2 in dry CH2Cl2 (3 mL). 
The crude material was purified by flash column chromatography using 
EtOAc/hexanes (80:20) as eluent to give 82 as a clear semi-solid (0.0227 g, 
0.0807 mmol, 54 % yield) 
1H NMR δ (400 MHz):  2.09 (s, 3 H), 2.12 (s, 3 H), 2.82 (s, 3 H), 4.53 (s, 
1 H), 5.48 (d, J = 5.5 Hz, 1 H), 5.73 (d, J = 5.5 Hz, 
1 H), 6.32–6.38 (m, 2 H), 7.41 (ad, J = 0.7 Hz, 1 
H) 
13C NMR δ (100 MHz):  20.5, 20.6, 28.7, 61.2, 68.7, 70.7, 109.6, 110.6, 
143.9, 147.9, 168.0, 169.7, 169.8 
IR Vmax:  2937, 1751 (C=O), 1716 (C=O), 1437, 1404, 
1375, 1240, 1217 
N
CH3
AcO OAc
O
O
(±) 82
Chapter 5  Experimental 
 
 
144 
HRMS:  For C13H15NO6+Na, predicted 304.0792, found 
304.0786 
(±)-(3R,4R,5R)-1-Methyl-2-oxo-5-(1-tosyl-1H-pyrrol-2-yl)pyrrolidine-3,4-
diyl diacetate (83)  
Prepared from 39 (0.0725 g, 0.265 mmol), N-tosylpyrrole (0.0734 g, 0.331 
mmol, 1.25 eq.), and BF3.OEt2 (0.050 mL, 0.405 mmol, 1.5 eq.) in dry 
CH2Cl2, with exclusion from light. The resulting solution was stirred at room 
temperature for 16 h. The crude material was purified by flash column 
chromatography using EtOAc/hexanes (80:20) as eluent to give 83 as an off 
white solid (0.0753 g, 0.1733 mmol, 65 % yield). 
1H NMR δ (400 MHz):  2.05 (s, 3 H), 2.11 (s, 3 H), 2.40 (s, 3H), 2.74 (s, 3 
H), 5.04 (s, 1 H), 5.26 (d, J = 5.2 Hz, 1 H), 5.60 
(d, J = 5.2 Hz, 1 H), 6.04 (s, 1 H), 6.27 (t, J = 3.4 
Hz, 1 H), 7.28–7.35 (m, 3 H), 7.64 (d, J = 8.3 Hz, 
2 H) 
13C NMR δ (100 MHz):  20.4, 20.5, 21.7, 29.1, 60.7, 67.7, 71.2, 112.1, 
113.5, 124.7, 126.7, 128.4, 130.4, 135.8, 145.9, 
168.3, 169.42, 169.45 
IR Vmax:  2933, 2249, 1755 (C=O), 1716 (C=O), 1595, 
1481, 1437, 1402, 1371, 1240, 1192 
HRMS:  For C20H22N2O7S+Na, predicted 457.1040, found 
457.1030 
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(±)-(2R,3R,4R)-1-methyl-2-(1-Methyl-1H-pyrrol-2-yl)-5-oxopyrrolidine-3,4-
diyl diacetate (89) and (±)-(2R,3R,4R)-1-methyl-2-(1-methyl-1H-pyrrol-3-
yl)-5-oxopyrrolidine-3,4-diyl diacetate (90)   
Prepared from a mixture of 39 and 78 (1:0.2, 0.3751 g, 1.384 mmol), with N-
methylpyrrole (0.1368 g, 1.686 mmol, 1.22 eq.) and BF3.OEt2 (0.260 mL, 
1.215 mmol, 1.52 eq.) in dry CH2Cl2 (10 mL). The crude mixture was purified 
by automated flash column chromatography, using a solvent gradient from 
CH2Cl2 to EtOAc/CH2Cl2 (60:40) to give 89 as a clear oil (0.1136g, 0.3860 
mmol, 28% yield) and 90 as a clear oil (0.0909 g, 0.3089 mmol, 22% yield).  
1H NMR δ (400 MHz):  2.12 (s, 3 H), 2.13 (s, 3H), 2.92 (s, 3 H), 3.67 (s, 3 
H), 4.58 (s, 1 H), 5.34 (d, J = 5.1 Hz, 1 H), 5.56 
(d, J = 5.1 Hz, 1 H), 5.85 (d, J = 2.76 Hz, 1 H), 
6.07 (t, J = 3.1 Hz, 1 H), 6.65 (s, 1 H) 
13C NMR δ (100 MHz):  20.4, 20.7, 29.2, 33.9, 61.0, 68.4, 71.3, 107.1, 
107.7, 124.4, 125.3, 168.0, 169.0, 170.0  
IR Vmax:  2936, 1755 (C=O), 1713 (C=O), 1494, 1436, 
1402, 1374, 1296, 1242, 1220, 1128, 1084, 1061 
HRMS:  For C14H18N2O5, predicted 294.12157, found 
294.12232. m/z (EI+): 294 (M+, 5), 234 (50), 192 
N
CH3
AcO OAc
NCH3
(±) 89
N
CH3
AcO OAc
H3CN
(±) 90
O O
N
CH3
AcO OAc
NCH3
(±) 89
O
N
CH3
AcO OAc
H3CN
(±) 90
O
Chapter 5  Experimental 
 
 
146 
(100), 175 (45), 163 (10), 134 (10), 123 (80), 106 
(10), 94 (20)  
1H NMR δ (400 MHz):  2.08 (s, 3 H), 2.11 (s, 3 H), 2.87 (s, 3 H), 3.61 (s, 
3 H), 4.46 (s, 1 H), 5.29 (d, J = 5.3 Hz, 1 H), 5.61 
(d, J = 5.3 Hz, 1 H), 5.96 (s, 1 H), 6.49 (s, 1 H), 
6.57 (s, 1 H) 
13C NMR δ (100 MHz):  20.4, 20.7, 28.8, 36.3, 62.1, 68.7, 73.5, 106.6, 
118.3, 119.5, 123.2, 167.8, 169.7, 170.0 
IR Vmax:  2936, 1750 (C=O), 1713 (C=O), 1558, 1510, 
1481, 1438, 1403, 1373, 1301, 1242, 1221, 1168, 
1128, 1081, 1060 
HRMS:  For C14H18N2O5, predicted 294.12157, found 
294.12100. m/z (EI+): 294 (M+, 1), 268 (1), 234 
(80), 192 (100), 175 (80), 163 (5), 136 (5), 123 
(100), 106 (5) 
(±)-(2R,3R,4R)-2-(1H-Indol-3-yl)-1-methyl-5-oxopyrrolidine-3,4-diyl 
diacetate (84)  
Prepared from a mixture of 39 and 78 (1:0.3, 0.0981 g, 0.3607 mmol), with 
indole (0.0524 g, 0.4473 mmol, 1.24 eq.) and BF3.OEt2 (0.070 mL, 0.5672 
mmol, 1.57 eq.) in dry CH2Cl2 (4 mL). The crude material was purified by 
flash column chromatography using EtOAc/hexanes (90:10) as eluent to give 
84 as a white solid (0.0824 g, 0.2494 mmol, 69% yield). 
1H NMR δ (400 MHz):  2.10 (s, 3 H), 2.16 (s, 3 H), 2.96 (s, 3 H), 4.93 (s, 
1 H), 5.46 (dd, J = 5.3, 1.0 Hz, 1 H), 5.66 (d, J = 
5.2 Hz, 1 H), 6.99 (d, J = 2.4 Hz, 1 H), 7.16 (td, J 
= 7.5, 0.7 Hz, 1 H), 7.24 (td, J = 7.5, 0.8 Hz, 1 H), 
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7.41 (d, J = 8.1 Hz, 1 H) 7.65 (d, J = 7.9 Hz, 1 H), 
8.81 (bs, 1 H) 
13C NMR δ (100 MHz):  20.5, 20.9, 29.3, 61.5, 69.0, 72.6, 110.1, 111.8, 
118.6, 120.5, 122.0, 123.0, 125.3, 137.0, 168.4, 
169.8, 170.2 
IR Vmax:  3311, 2931, 1751 (C=O), 1705 (C=O), 1460, 
1435, 1404, 1371, 1242, 1085, 1062 
HRMS:  For C17H18N2O5, predicted 330.12157, found 
330.12116. m/z (EI+): 330 (M+, 10), 270 (50), 228 
(100), 211 (60), 159 (70), 130 (25), 60 (10) 
MP:     184.5–185 oC 
General Procedure for Deacetoxylation of Diols With Base 
To a solution of the diacetoxylactam in MeOH (5 mL) was added K2CO3 (2-
10 eq). This was stirred at room temperature for 30 minutes, at which point 
sufficient CH2Cl2 was added to make the reaction mixture a 20% v/v solution 
of MeOH in dichloromethane. This was then filtered through a small plug of 
silica, which was washed with further MeOH/CH2Cl2 (20:80) and the solvent 
evaporated. When necessary, further purification was carried out by flash 
column chromatography.  
(±)-(3R,4R,5R)-5-(3,4-Dimethoxyphenyl)-3,4-dihydroxy-1-
methylpyrrolidin-2-one (45)  
Prepared from 79 (0.0644 g, 0.18 mmol) and K2CO3 (0.0511 g, 0.370 mmol, 
2.0 eq.). Product 45 was isolated as a clear oil (0.0322 g, 0.1204 mmol, 66 % 
yield). 
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1H NMR δ (400 MHz):  2.79 (s, 3 H), 3.84 (s, 3 H), 3.85 (s, 3 H), 4.16 (s, 
1 H), 4.46 (s, 1 H), 4.81 (s, b, 1 H), 6.61 (d, J = 
8.0 Hz, 1 H), 6.68 (s, 1 H), 6.83 (d, J = 8.4 Hz, 1 
H) 
13C NMR δ (100 MHz):  29.4, 56.2, 69.5, 70.38, 73.3, 109.5, 111.8, 118.2, 
128.6, 149.3, 150.0, 173.4 
IR Vmax:  3356 (OH), 2934, 1681 (C=O), 1518, 1464, 1419, 
1400, 1256, 1239, 1139, 1079, 1024 
HRMS:  For C13H17NO5, predicted 267.11067, found 
267.11111. m/z (EI+): 267 (M+, 100), 249 (5), 220 
(5), 192 (5), 180 (45), 164 (15), 151 (50), 133 (5) 
(±)-(3R,4R,5R)-5-(2,5-Dimethoxyphenyl)-3,4-dihydroxy-1-
methylpyrrolidin-2-one (50)  
Prepared from 80 (0.0157 g, 0.0446 mmol) in MeOH (3 mL) with K2CO3 
(0.0803 g, 0.581 mmol, 13 eq.). The solution in 20% MeOH in CH2Cl2 was 
filtered through a pad of celite, and the solvent removed. The crude material 
was purified by by flash column chromatography, with EtOAc/MeOH (90:10) 
as eluent, to give 50 as a clear oil (0.0048 g, 0.0179mmol, 40 % yield)  
1H NMR δ (400 MHz):  2.81 (s, 3 H), 3.73 (s, 3 H), 3.84 (s, 3 H), 4.06 (d, 
J = 5.1 Hz, 1 H), 4.25 (d, J = 5.1 Hz, 1 H), 4.70 (s, 
1 H), 6.42 (d, J = 2.8 Hz, 1 H), 6.88 (dd, J = 8.8, 
2.8 Hz, 1 H), 6.99 (d, J = 8.9 Hz, 1 H) 
13C NMR δ (100 MHz):  29.4, 56.1, 56.4, 67.7, 71.1, 73.5, 113.3, 113.6, 
114.2, 126.5, 152.8, 155.4, 175.9 
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IR Vmax:  3313 (OH), 2931, 1689 (C=O), 1496, 1280, 1219, 
1155, 1078, 1047, 1024 
HRMS:  For C13H17NO5, predicted 267.11067, found 
267.11020. m/z (EI+): 267 (M+, 100), 249 (5), 206 
(10), 190 (10), 180 (45), 164 (20), 151 (45), 121 
(15) 
(±)-(3R,4R,5R)-5-(2,4,6-Trimethoxyphenyl)-3,4-dihydroxy-1-
methylpyrrolidin-2-one (56)  
Prepared from 81 (0.1027g, 0.2693 mmol) and K2CO3 (0.0801g, 0.5795 
mmol, 2.15 eq.). Product 56 isolated as a clear oil (0.0628 g, 0.2112 mmol, 
78% yield). 
1H NMR δ (400 MHz):  2.57 (s, 3 H), 3.72 (s, 6 H), 3.76 (s, 3 H), 3.92 (bs, 
1 H), 4.21 (d, J = 6.5 Hz, 1 H), 4.63 (d, J = 6.5 Hz, 
1 H), 5.05 (s, 1 H), 6.07 (s, 2 H), 6.11 (bs, 1 H) 
13C NMR δ (100 MHz):  27.8, 55.3, 55.7, 62.4, 70.1, 70.3, 90.6, 104.6, 
159.5, 161.4, 174.1 
IR Vmax:  3330 (OH), 2941, 2245, 1674 (C=O), 1608, 1495, 
1467, 1418, 1335, 1226, 1205, 1153, 1124 
HRMS:  For C14H19NO6, predicted 297.12124, found 
297.12196. m/z (EI+): 297 (M+, 50), 279 (20), 220 
(15), 210 (60), 194 (20), 181 (100), 168 (15), 151 
(10), 121 (15) 
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(±)-(3R,4R,5S)-5-(Furan-2-yl)-3,4-dihydroxy-1-methylpyrrolidin-2-one (62) 
Prepared from 82 (0.0144 g, 0.0511 mmol) and K2CO3 (0.0881 g, 0.6374 
mmol, 12 eq.). The crude material was purified by by flash column 
chromatography with EtOAc/hexanes (10:90) as eluent to give the product 62 
as a clear oil (0.0034 g, 0.0172 mmol, 34 % yield) 
1H NMR δ (400 MHz):  2.76 (s, 3 H), 4.26 (dd, J = 5.2, 1.2 Hz, 1 H), 4.47 
(d, J = 5.2 hz, 1 H), 4.49 (d, J = 1.2 Hz, 1 H), 6.41 
(ad, J = 1.3 hz, 2 H), 7.51 (at, J = 1.3 hz, 1 H) 
13C NMR δ (100 MHz):  28.7, 65.0, 71.5, 72.1, 110.0, 111.5, 144.6, 151.2, 
174.9 
IR Vmax:  3259 (OH), 1689 (C=O), 1485, 1402, 1311, 1247, 
1143, 1076, 1012 
HRMS:  For C9H11NO4, predicted 197.06881, found 
197.06875. m/z (EI+): 197 (M+, 85), 180 (10), 168 
(10), 150 (5), 122 (5), 110 (100), 100 (25), 94 
(15), 81 (75), 66 (10), 60 (20), 53 (10) 
(±)-(3R,4R,5R)-3,4-Dihydroxy-1-methyl-5-(1-tosyl-1H-pyrrol-2-
yl)pyrrolidin-2-one (58)  
Prepared from 83 (0.0888g, 0.2044 mmol) and K2CO3 (0.0577g, 0.4175 
mmol, 2.0 eq.). The crude material was purified by flash column 
chromatography using EtOAc/hexanes (80:20) and EtOAc/MeOH (90:10) as 
eluents to give the product 58 as a clear oil (0.0256 g, 0.0730 mmol, 36% 
yield) 
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1H NMR δ (400 MHz, MeOD):  2.42 (s, 3 H), 2.59 (s, 3 H), 4.04 (d, J = 4.9 
Hz, 1 H), 4.28 (d, J = 4.9 Hz, 1 H), 4.90 (s, 
1 H), 5.97–5.99 (m, 1 H), 6.31 (t, J = 3.4 
Hz, 1 H), 7.41–7.48 (m, 3 H), 7.81 (d, J = 
8.4 Hz, 2 H) 
13C NMR δ (100 MHz):  21.5, 29.2, 65.0, 70.6, 72.9, 112.9, 113.9, 
125.5, 128.0, 131.0, 131.4, 137.2, 147.3, 
175.2 
IR Vmax:  3335 (OH), 2490, 1689 (C=O), 1595, 1485, 
1448, 1402, 1369, 1240, 1192, 1174, 1128, 
1080 
HRMS:  For C16H18N2O5S, predicted 350.09364, 
found 350.09459. m/z (EI+): 350 (M+, 15), 
263 (20), 195 (100), 177 (40), 155 (20), 
120 (15), 109 (40), 91 (80) 
(±)-(3R,4R,5R)-3,4-Dihydroxy-1-methyl-5-(1-methyl-1H-pyrrol-2-
yl)pyrrolidin-2-one (60)  
Prepared from 89 (0.0350 g, 0.1189 mmol) and K2CO3 (0.0296 g, 0.2141 
mmol, 1.80 eq.). Product isolated as a clear oil (0.0186 g, 0.0885 mmol, 74% 
yield). 
1H NMR δ (400 MHz):  2.88 (s, 3 H), 3.66 (s, 3 H), 4.15 (bs, 1 H), 4.20 (d, 
J = 4.9 Hz, 1 H), 4.50 (d, J = 4.7 Hz, 1 H), 4.59 (s, 
1 H), 5.32 (bs, 1 H), 5.76 (s, 1 H), 6.04 (s, 1 H), 
6.62 (s, 1 H) 
13C NMR δ (100 MHz):  29.5, 34.0, 63.6, 69.6, 71.4, 106.2, 107.5, 123.7, 
127.1, 173.7 
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IR Vmax:  3336 (OH), 1683 (C=O), 1496, 1448, 1399, 1298, 
1247, 1147, 1078 
HRMS:  For C10H14N2O3+Na, predicted 233.0897, found 
233.0905 
(±)-(3R,4R,5R)-3,4-dihydroxy-1-methyl-5-(1-methyl-1H-pyrrol-3-
yl)pyrrolidin-2-one (92)  
Prepared from 90 (0.0296 g, 0.1006 mmol) and K2CO3 (0.0346 g, 0.2503 
mmol, 2.49 eq.). Product isolated as a clear oil (0.0156 g, 0.0742 mmol, 74% 
yield). 
1H NMR δ (400 MHz):  2.82 (s, 3 H), 3.61 (s, 3 H), 4.21 (d, J = 4.4 Hz, 1 
H), 4.42 (s, 1 H), 4.57 (s, 1 H), 5.90 (s, 1 H), 6.46 
(s, 1 H), 6.55 (s, 1 H) 
13C NMR δ (100 MHz):  28.9, 36.3, 64.6, 70.0, 73.4, 106.7, 119.6, 119.7, 
123.0, 173.1 
IR Vmax:  3341 (OH), 1679 (C=O), 1555, 1509, 1401, 1299, 
1247, 1146, 1075 
HRMS:  For C10H14N2O3+Na, predicted 233.0897, found 
233.0905 
(±)-(3R,4R,5R)-3,4-dihydroxy-5-(1H-indol-3-yl)-1-methylpyrrolidin-2-one 
(64)  
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Prepared from 84 (0.0376g, 0.1138 mmol) and K2CO3 (0.0322g, 0.2329 
mmol). Product isolated as a yellow oil (0.0185 g, 0.07512 mmol, 66 % yield). 
1H NMR δ (400 MHz, CD3OD):  2.84 (s, 3 H), 4.25 (dd, J = 5.17, 1.93 Hz, 1 
H), 4.40 (d, J = 5.2 Hz, 1 H), 4.79 (d, J = 
1.6 Hz, 1 H), 7.05 (t/dd, J = 7.3 Hz, 1 H), 
7.11 (s, 1 H), 7.15 (t/dd, 7.3 Hz, 1 H), 7.39 
(d, J = 8.2 Hz, 1 H), 7.47 (d, J = 7.9 Hz, 1 
H) 
13C NMR δ (100 MHz, CD3OD):  29.0, 65.4, 71.6, 73.8, 111.6, 112.8, 118.9, 
120.5, 123.0, 123.7, 126.9, 138.7, 175.0 
IR Vmax:  3308 (OH), 2436, 1678 (C=O), 1483, 1454, 
1402, 1334, 1234, 1147, 1076 
HRMS:  For C13H14N2O3, predicted 246.10044, 
found 246.10053. m/z (EI+): 246 (M+, 
100), 230 (15), 212 (100), 178 (100), 157 
(80), 149 (60), 130 (80), 123 (60), 104 (60), 
97 (35), 91 (40), 81 (40) 
General Procedure For Reduction of Amides With LiAlH4 
To a solution of the diacetoxylactam in anhydrous THF (3 mL) under N2 was 
added LiALH4 (5 eq.). The reaction was heated at reflux for 4 hours, before 
being allowed to cool to room temperature, and quenched by addition of 
EtOAc and H2O. The mixture was filtered through celite, the organic and 
aqueous layers were separated, and the aqueous layer extracted with 
EtOAc. Combined organic extracts were dried over MgSO4 and solvent 
removed under reduced pressure to yield the target diols. When necessary, 
Purification was carried out by flash column chromatography. 
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(±)-(2R,3R,4S)-2-(3,4-Dimethoxyphenyl)-1-methylpyrrolidine-3,4-diol (43)   
Prepared from lactam 79 (0.0552 g, 0.1571 mmol,) and LiAlH4 (0.0333 g, 
0.8774 mmol, 5.58 mmol). Product isolated as a white amorphous solid 
(0.0164 g, 0.0647 mmol, 41% yield). 
1H NMR δ (400 MHz): 2.14 (s, 3 H), 2.37 (dd, J = 8.0 Hz, 4.0 Hz, 1 H), 
2.68 (bs, 2 H), 3.06 (d, J = 8.0 Hz, 1 H), 3.60 (dd, 
J = 12.0 Hz, 8.0 Hz, 1 H), 3.82-3.92 (m, 7 H), 4.27 
(q, J = 5.0 Hz, 1 H), 6.82-6.92 (m, 3 H) 
13C NMR δ (100 MHz): 40.6, 56.2, 56.3, 63.3, 68.7, 75.7, 78.7, 110.4, 
111.5, 120.6, 132.6, 149.0, 149.7 
IR Vmax: 3347, 2936, 1593, 1517 1464, 1419, 1263, 1231, 
1139, 1025 
HRMS: For C13H19NO4, predicted 253.13141, found 
253.13143. m/z (EI+): 253 (M+, 15), 217 (100), 
202 (50), 192 (60), 178 (90), 164 (30), 151 (45), 
133 (15), 108 (10), 91 (10), 83 (20), 77 (15), 65 
(10), 44 (25) 
(±)-(2R,3R,4S)-2-(2,5-Dimethoxyphenyl)-1-methylpyrrolidine-3,4-diol (44)                                                                                                                                                                                                             
Prepared from lactam 80 (0.0809 g, 0.2302 mmol,) and LiAlH4 (0.0465 g, 
1.225 mmol, 5.32 mmol). Product isolated as a white amorphous solid 
(0.0404 g, 0.1595 mmol, 69% yield). 
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1H NMR δ (400 MHz):  2.23 (s, 3 H), 2.49 (dd, J = 9.9, 5.9 Hz, 1 
H), 3.19 (bs, 2 H), 3.53 (dd, J = 9.9, 6.0 Hz, 
1 H), 3.69 (d, J = 6.3 Hz, 1 H), 3.76 (s, 3 
H), 3.80 (s, 3 H), 3.84 (t, J = 6.3 Hz, 1 H), 
4.17 (q, J = 6.0 Hz, 1 H), 6.74 (dd, J = 8.9, 
3.1 Hz, 1 H), 6.83 (d, J = 8.9 Hz, 1 H), 7.03 
(d, J = 3.1 Hz, 1 H) 
13C NMR δ (100 MHz):  41.3, 55.9, 56.5, 62.7, 69.2, 69.8, 79.1, 
112.0, 112.6, 113.1, 130.2, 151.9, 154.7 
IR Vmax:  3403, 2940, 2834, 2785, 1495, 1464, 1275, 
1217, 1177, 1159, 1045 
HRMS:  For C13H19NO4, predicted 253.13141, found 
253.13160. m/z (EI+): 253 (M+, 30), 235 
(10), 217 (15), 202 (10), 192 (100), 178 
(30), 162 (40), 150 (25), 121 (20), 83 (25), 
44 (15) 
(±)-(2R,3R,4S)-1-Methyl-2-(2,4,6-trimethoxyphenyl)pyrrolidine-3,4-diol 
(55)  
prepared from lactam 81 (0.1021 g, 0.2677 mmol,) and LiAlH4 (0.0510 g, 
1.344 mmol, 5.02 mmol). Product isolated as an amorphous white solid 
(0.0503 g, 0.1775 mmol, 66% yield). 
1H NMR δ (400 MHz, in MeOD):  2.22 (s, 3 H), 2.45 (t, J = 8.9 Hz, 1 H), 3.24 
(dd, J = 9.1, 5.9 Hz, 1 H), 3.79 (s, 6 H), 
3.80 (s, 3 H), 4.01 (d, J = 4.1 Hz, 1 H), 4.33 
(dd, J = 14.4, 6.0 Hz, 1 H), 4.42 (t, J = 5.2 
Hz, 1 H), 6.20 (s, 2 H) 
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13C NMR δ (100 MHz):  42.0, 55.7, 56.0 (broad, more than one 
methoxy signal), 61.8, 69.6, 70.8, 75.4, 
91.8, 161.2, 162.8 
IR Vmax:  3469 (OH), 1607, 1591, 1461, 1416, 1331, 
1224, 1204, 1153, 1118 
HRMS:  For C14H21NO5, predicted 283.14197, 
found 283.14212. m/z (EI+): 283 (M+, 20), 
266 95), 247 (10), 223 (30), 210 (25), 192 
(40), 179 (100), 164 (5), 136 (10), 118 
(100) 
(±)-(2S,3R,4S)-2-(Furan-2-yl)-1-methylpyrrolidine-3,4-diol (61)  
Prepared from lactam 82 (0.0631 g, 0.2243 mmol) and LiAlH4 (0.0457 g, 
1.204 mmol, 5.37 eq.). The crude material was purified by flash column 
chromatography using EtOAc as eluent to give the product 61 as a clear oil 
(0.0115g, 0.0627 mmol, 28% yield). 
1H NMR δ (400 MHz):  2.22 (s ,3 H), 2.41 (dd, J = 10.3, 4.9 Hz, 1 H), 
2.93 (bs, 2 H), 3.33 (d, J = 6.7 Hz, 1 H), 3.51 (dd, 
J = 10.2, 6.2 Hz), 1 H ), 4.21 (t, J = 6.6 Hz, 1 H), 
4.29 (dd, J = 11.6, 5.8 Hz, 1 H), 6.32 (d, J = 10.5 
Hz, 2 H), 7.40 (s, 1 H) 
13C NMR δ (100 MHz):  40.4, 62.4, 68.8, 68.9, 75.1, 109.0, 110.3, 142.8, 
152.5 
IR Vmax:  3335 (OH), 2945, 2847, 2791, 1599, 1508, 1450, 
1402, 1348, 1327, 1236, 1215, 1151, 1105, 1080, 
1043, 1010  
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HRMS:  For C9H13NO3, predicted 183.08954, found 
183.08957. m/z (EI+): 183 (M+, 30), 166 (5), 147 
(5), 123 (100), 108 (60), 94 (10), 87 (40), 82 (20), 
73 (5) 
(±)-(2R,3R,4S)-1-Methyl-2-(1-tosyl-1H-pyrrol-2-yl)pyrrolidine-3,4-diol (57)  
Prepared from lactam 83 (0.0918 g, 0.2113 mmol) and LiAlH4 (0.0402 g, 
1.059 mmol, 5.01 eq). The crude material was purified by flash column 
chromatography using EtOAc/MeOH (90:10) as the eluent, to give 57 as a 
clear oil (0.0320 g, 0.0951 mmol, 45 % yield) 
1H NMR δ (400 MHz):  1.90 (s, 3 H), 2.37-2.42 (m, 4 H), 2.91 (sb, 2 H), 
3.32 (dd, J = 9.1, 6.0 Hz, 1 H), 3.58 (d, J = 4.2 Hz, 
1 H), 3.94 (dd, J = 5.9, 4.5 Hz, 1 H), 4.16 (dd, J = 
13.3, 6.3 Hz, 1 H), 6.27 (t, J = 3.3 Hz, 1 H), 6.30-
6.33 (m, 1 H), 7.28 (d, J = 8.1Hz, 1 H) 
13C NMR δ (100 MHz):  21.7, 40.6, 60.9, 69.3, 69.8, 77.9, 112.1, 123.5, 
126.8, 130.0, 135.1, 136.4, 145.3 
IR Vmax:  3396 (OH), 2941, 1597, 1363, 1190, 1174, 1149, 
1120, 1091, 1057 
HRMS:  For C16H20N2O4S, predicted 336.11438, found 
336.11402. m/z (EI+): 336 (M+, 10), 301 (5), 276 
(30), 263 (20), 212 (30), 197 (20), 181 (80), 155 
(20), 121 (100), 108 (30), 91 (60) 
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(±)-(2R,3R,4S)-1-Methyl-2-(1-methyl-1H-pyrrol-2-yl)pyrrolidine-3,4-diol 
(59)  
Prepared from lactam 89 (0.0344g, 0.1169 mmol) and LiAlH4 (0.0221 g, 
0.5823 mmol, 4.98 eq.). The crude material was purified by flash column 
chromatography using 95:5 MeOH/NH3 in CH2Cl2 (15:85) as eluent to give 59 
as a pale yellow oil (0.0143 g, 0.0728 mmol, 62% yield). 
1H NMR δ (600 MHz):  2.20 (s, 3 H), 2.61 (dd, J = 10.7, 4.6 Hz, 1 H), 
3.37–3.51 (m, 3 H), 3.62 (s, J = 7.2 Hz, 1 H), 3.65 
(s, 3 H), 4.11 (at, J = 6.7 Hz, 1 H), 4.28 (dd, J = 
11.0, 5.88 Hz, 1 H), 6.09–6.11 (m, 1 H), 6.12–
6.15 (m, 1 H), 6.58–6.61 (m, 1 H) 
13C NMR δ (150 MHz):  34.4, 39.9, 62.0, 67.2, 68.6, 76.7, 107.4, 108.5, 
123.6, 128.9 
IR Vmax:  3319, 2938, 1733, 1574, 1489, 1450, 1409, 1301, 
1240, 1165, 1090 
HRMS:  For C10H16N2O2, predicted 196.12118, found 
196.121527. m/z (EI+): 196 (M+, 50), 160 (35), 
145 (10), 135 (75), 121 (90), 106 (30), 94 (80), 80 
(50), 72 (15) 
(±)-(2R,3R,4S)-1-Methyl-2-(1-methyl-1H-pyrrol-3-yl)pyrrolidine-3,4-diol 
(93)  
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Prepared from lactam 90 (0.0464 g, 0.158 mmol) and LiAlH4 (0.0304 g, 0.801 
mmol, 5.0 eq.). The crude material was purified by flash column 
chromatography using 95:5 MeOH/NH3 in CH2Cl2 (20:80) as eluent to give 93 
as a pale brown oil (0.0091 g, 0.0463 mmol, 29% yield). 
1H NMR δ (400 MHz):  2.22 (s, 3 H), 2.35 (dd, J = 10.5, 4.8 Hz, 1 H), 
2.77 (bs, 2 H), 3.09 (d, J = 7.8 Hz, 1 H), 3.59 (dd, 
J = 10.5, 6.5 Hz, 1 H), 3.62 (s, 3 H), 3.96 (at, J = 
7.2 Hz, 1 H), 4.23–4.30 (m, 1 H), 6.07–6.13 (m, 1 
H), 6.55–6.59 (m, 1 H), 6.59–6.63 (m, 1 H) 
13C NMR δ (100 MHz):  36.2, 40.3, 62.7, 63.2, 68.1, 69.1, 107.2, 120.9, 
121.8, 122.4 
IR Vmax:  3291, 2941, 2780, 1507, 1448, 1419, 1309, 1166, 
1103, 1096 
HRMS:  For C10H16N2O2, predicted 196.12118, found 
196.12150. m/z (EI+): 196 (M+, 45), 179 (10), 160 
(15), 136 (80), 121 (60), 106 (15), 94 (60), 87 
(50), 82 (35) 
(±)-(2R,3R,4S)-2-(1H-Indol-3-yl)-1-methylpyrrolidine-3,4-diol (63)  
Prepared from lactam 84 (0.0603 g, 0.182 mmol) and LiAlH4 (0.0346 g, 0.911 
mmol, 5.0 eq.). The crude material was purified by flash column 
chromatography using 95:5 MeOH/NH3 in CH2Cl2 (30:70) as eluent to give 63 
as a pale orange oil (0.0211 g, 0.0908 mmol, 50% yield). 
1H NMR δ (600 MHz, MeOD):  2.29 (s, 3 H), 2.50 (dd, J = 10.5, 5.3 Hz, 1 
H), 3.57 (dd, J = 10.5, 6.2 Hz, 1 H), 3.65 
(d, J = 7.7 Hz, 1 H), 4.25 (at, J = 7 Hz, 1 
H), 4.30 (dd, J = 11.9, 5.9 Hz, 1 H), 7.01 
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(at, J = 7.2 hz, 1 H), 7.10 (at, 7.2 Hz, 1 H), 
7.28 (s, 1 H), 7.36 (d, J = 8.1 Hz, 1 H) 7.68 
(d, J = 7.9 Hz, 1 H) 
13C NMR δ (150 MHz):  41.3, 63.4, 69.5, 77.3, 112.4, 119.9 (2 C), 
122.6, 124.8, 138.4 
IR Vmax:  3404 (OH), 3289, 2943, 2839, 2786, 1456, 
1338, 1228, 1195, 1162, 1096 
HRMS:  For C13H16N2O2, predicted 232.12118, 
found 232.12172. m/z (EI+): 232 (M+, 30), 
196 (15), 172 (70), 157 (35), 144 (10), 130 
(40), 117 (25), 102 (10), 87 (40) 
(±)-(3R,4R,5R)-3,4-Dihydroxy-5-(4-methoxyphenyl)-1-methylpyrrolidin-2-
one (47) and (±)-(3R,4R,5R)-3,4-dihydroxy-5-(2-methoxyphenyl)-1-
methylpyrrolidin-2-one 5 (49)  
To a solution of 85 and 86 (0.1013 g of a 2:1 mixture, 0.3152 mmol) in MeOH 
(5 mL), was added K2CO3 (0.0900 g, 0.6512 mmol, 2.07 eq). This was stirred 
at room temperature for 30 minutes, at which point CH2Cl2 (20 mL) was 
added and the solution filtered through a small plug of silica, which was 
washed with further MeOH/CH2Cl2 (20:80) and the solvent evaporated. This 
gave a mixture of 47 and 49 as clear oil (0.0453 g of a 2:1 mixture,  0.1909 
mmol, 61% yield) 
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(±)-(3R,4R,5R)-3,4-bis((tert-Butyldimethylsilyl)oxy)-5-(4-methoxyphenyl)-
1-methylpyrrolidin-2-one (71) and (±)-(3R,4R,5R)-3,4-bis((tert-
butyldimethylsilyl)oxy)-5-(2-methoxyphenyl)-1-methylpyrrolidin-2-one 
(93)  
To a stirred solution of 47 and 49 (1 : 1.5, 0.1752 g, 0.7384 mmol) in 
anhydrous DMF (10 mL), under an N2 atmosphere, was added TBDMSCl 
(0.4065 g, 2.697 mmol, 3.65 eq.) and imidazole (0.3632 g, 5.335 mmol, 7.22 
eq.) were added, and the mixture stirred at room temperature for 24 h. At this 
time water (10 mL) was added, and the solution extracted with toluene (3 x 
10 mL). The combined organic extracts were dried over MgSO4, filtered, and 
the solvent removed under reduced pressure to give the crude product. The 
crude mixture was purified by automated flash column chromatography, with 
a solvent gradient of 0–20% EtOAc/hexanes to give 93 as a clear oil (0.1062 
g, 0.2280 mmol, 31% yield) and 71 as a white semisolid (0.0585 g, 0.1256 
mmol, 17% yield)  
1H NMR δ (400 MHz):  −0.09 (s, 3 H), 0.00 (s, 3 H), 0.12 (s, 3 H), 0.18 (s, 
3 H), 0.85 (s, 9 H), 0.91 (s, 9 H), 2.72 (s, 3 H), 
3.80 (s, 3 H), 3.95 (dd, J = 3.7 Hz, 1 H), 4.23 (d, J 
= 4.6 Hz, 1 H), 4.31 (d, J = 2.7 Hz, 1 H), 6.91 (d, J 
= 8.6 Hz, 2 H), 7.04 (d, J = 8.6 Hz, 2 H) 
13C NMR δ (100 MHz):  −5.0, −4.6, −4.3, −4.2, 18.2, 18.6, 25.8, 26.0, 
28.6, 55.4, 70.0, 71.5, 114.5, 127.9, 128.9, 159.6, 
172.6 
N O
H3CO CH3
TBSO OTBS
N
CH3
TBSO OTBSCH3O
O
(±) 71 (±) 93
N O
H3CO CH3
TBSO OTBS
(±) 71
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IR Vmax:  2953, 2929, 2894, 2856, 1713 (C=O), 1612, 1514, 
1472, 1464, 1250, 1173, 1116, 1102 
HRMS:  For C24H43NO4Si2+H, predicted 466.2803, found 
466.2818 
1H NMR δ (400 MHz):  0.07 (s, 3 H), 0.10 (s, 6 H), 0.17 (s, 3 H), 0.902 (s, 
9 H), 0.909 (s, 9H), 2.82 (s, 3 H), 3.86 (s, 3 H), 
4.10 (d, J = 4.2 Hz, 1 H), 4.22 (d, J = 4.1 Hz, 1 H), 
4.62 (s, 1 H), 6.83 (d, J = 7.2 Hz, 1 H), 6.91–6.97 
(m, 2 H), 7.30 (t, J = 7.6 Hz, 1 H) 
13C NMR δ (100 MHz):  −4.9, −4.6, −4.3, −4.1, 18.2, 18.6, 25.8, 26.1, 
29.3, 55.0, 66.0, 71.8, 110.7, 120.8, 124.4, 125.5, 
129.1, 157.2, 173.2 
IR Vmax:  2957, 2929, 2894, 2885, 2856, 1721 (C=O), 1716, 
1713, 1601, 1589, 1491, 1471, 1462, 1247, 1177 
HRMS:  For C24H43NO4Si2+H, predicted 466.2803, found 
466.2818 
(±)-(3R,4R,5R)-3,4-Dihydroxy-5-(4-methoxyphenyl)-1-methylpyrrolidin-2-
one (47)  
To a stirred solution of 71 (0.0146 g, 0.0313 mmol), in dry THF (3 mL) at 0 
oC, was added TBAF (0.080 mL of a 1 M solution in THF, 0.080 mmol, 2.55 
eq.). The solution was allowed to warm to room temperature and stirred for 
2.5 h, at which time satuated NH4Cl (2 mL) was added. The aqueous and 
organic layers were separated, and the aqueous layer extracted with EtOAc 
N
CH3
TBSO OTBSCH3O
O
(±) 93
N O
H3CO CH3
HO OH
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(3 x 5 mL). The combined organic layers were dried over MgSO4, filtered, 
and the solvent removed under reduced pressure. The crude material was 
purified by flash column chromatography using EtOAc/MeOH (85:15) as 
eluent, to give product 47 as a clear oil (0.0049 g, 0.0206 mmol, 66% yield) 
1H NMR δ (600 MHz):  2.84 (s, 3 H), 3.81 (s, 3 H), 4.17 (d, J = 2.5 Hz, 1 
H), 4.49 (s, 1 H), 4.52 (bs, 1 H), 6.91 (d, J = 8.6 
Hz, 2 H), 7.06 (d, J = 8.6 Hz, 1 H) 
13C NMR δ (150 MHz):  29.2, 55.5, 69.4, 70.2, 73.2, 114.8, 127.5, 128.1, 
159.8, 173.5 
IR Vmax:  3364 (OH), 1687 (C=O), 1611, 1514, 1398, 1248, 
1177, 1150, 1078, 1030 
HRMS:  For C12H15NO4, predicted 237.10011, found 
237.09980. 
(±)-(3R,4R,5R)-3,4-Dihydroxy-5-(2-methoxyphenyl)-1-methylpyrrolidin-2-
one (49)  
To a stirred solution of 93 (0.0228 g, 0.0489 mmol), in dry THF (3 mL) at 0 
oC, was added TBAF (0.120 mL of a 1 M solution in THF, 0.120 mmol, 2.45 
eq.). The solution was allowed to warm to room temperature and stirred for 
2.5 h, at which time satuated NH4Cl (2 mL) was added. The aqueous and 
organic layers were separated, and the aqueous layer extracted with EtOAc 
(3 x 5 mL). The combined organic layers were dried over MgSO4, filtered, 
and the solvent removed under reduced pressure. The crude material was 
purified by flash column chromatography using EtOAc:MeOH (85:15) as 
eluent, to give product 49 as a clear oil (0.0103 g, 0.0434 mmol, 89% yield). 
1H NMR δ (600 MHz):  2.86 (s, 3 H), 3.89 (s, 3 H), 4.19 (d, J = 4.6 Hz, 1 
H), 4.41 (bs, 1 H), 4.83 (s, 1 H), 6.87 (d, J = 7.3 
N
CH3
HO OHCH3O
O
(±) 49
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Hz, 1 H), 6.91–6.97 (m, 2 H), 7.31 (at, J = 7.6 Hz, 
1 H) 
13C NMR δ (150 MHz):  29.4, 55.6, 65.9, 69.7, 71.9, 111.0, 120.8, 124.0, 
125.8, 129.6, 157.2, 174.1 
IR Vmax:  3389 (OH), 1687 (C=O), 1601, 1588, 1491, 1455, 
1438, 1401, 1244, 1077, 1024 
HRMS:  For C12H15NO4, predicted 237.10011, found 
237.09980. 
(±)-(2R,3R,4S)-2-(4-Methoxyphenyl)-1-methylpyrrolidine-3,4-diol (46)  
To a solution of the lactam 71 (0.0176 g, 0.0378 mmol) in anhydrous THF (3 
mL) under N2 was added LiALH4 (0.0089 g, 0.234 mmol, 6.2 eq.). The 
reaction was heated at reflux for 4 hours, before being allowed to cool to 
room temperature. The reaction was quenched by addition of H2O (0.5 mL) 
and 1 M NaOH (0.5 mL). The mixture was filtered through celite, and the 
solvent removed under reduced pressure. The crude material was purified by 
flash column chromatography using 95:5 MeOH/NH3 in CH2Cl2 (30:70) as 
eluent to give 46 as a colourless oil (0.0059 g, 0.0264 mmol, 70% yield). 
1H NMR δ (600 MHz, MeOD):  2.13 (s, 3 H), 2.35 (dd, J = 10.3, 5.4 Hz, 1 
H),  3.07 (d, J = 7.6 Hz, 1 H), 3.53 (dd, J = 
10.3, 6.4 Hz, 1 H), 3.78 (s, 3 H), 3.83 (at, J 
= 7.2 Hz, 1 H), 4.19 (dd, J = 12.1, 6.4 Hz, 1 
H), 6.90 (d, J = 8.7 Hz, 2 H), 7.26 (d, J = 
8.7 Hz, 2 H) 
13C NMR δ (150 MHz, MeOD):  40.8, 55.7, 63.8, 69.4, 76.5, 79.3, 114.9, 
130.2, 133.1, 160.8 
IR Vmax:     3291, 1576, 1419, 1346, 1247, 1022 
N
H3CO CH3
HO OH
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HRMS:  For C12H17NO3+H, predicted 224.1281, 
found 224.1289 
(±)-(2R,3R,4S)-2-(2-Methoxyphenyl)-1-methylpyrrolidine-3,4-diol (48)  
To a solution of the lactam 93 (0.00269 g, 0.0577 mmol) in anhydrous THF 
(3 mL) under N2 was added LiALH4 (0.0175 g, 0.461 mmol, 8 eq.). The 
reaction was heated at reflux for 4 hours, before being allowed to cool to 
room temperature. The reaction was quenched by addition of H2O (0.5 mL) 
and 1 M NaOH (0.5 mL). The mixture was filtered through celite, and the 
solvent removed under reduced pressure. The crude material was purified by 
flash column chromatography using 95:5 MeOH/NH3 in CH2Cl2 (20:80) as 
eluent to give 48 as a colourless oil (0.0065 g, 0.0291 mmol, 50% yield). 
1H NMR δ (600 MHz, MeOD):  2.36 (s, 3 H), 2.62–2.73 (m, 1 H), 3.56 (dd, 
J = 9.0, 5.2 Hz, 1 H), 3.86 (s, 3 H), 3.93 (d, 
J = 4.8 Hz, 1 H), 4.15–4.21 (m, 1 H), 4.23–
4.27 (m, 1 H), 6.98 (t,  
13C NMR δ (150 MHz, MeOD):  41.9, 56.0, 62.5, 70.3, 71.7, 77.6, 112.2, 
121.9, 126.8, 130.4, 130.6, 159.7 
IR Vmax:  3355 (OH), 3247, 1495, 1454, 1242, 1155, 
1108, 1047, 1022 
HRMS:  For C12H17NO3+H, predicted 224.1281, 
found 224.1288 
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(S)-2-Phenyl-2-(1H-pyrrol-1-yl)ethan-1-ol (156)  
2,5-Dimethoxytetrahydrofuran (16.0 mL, 123.5 mmol) in water (120 mL) 
under an atmosphere of N2 was heated at reflux and stirred for 2.5 h. The 
solution was allowed to cool to room temperature before dichloromethane 
(180 mL), sodium acetate (12.1845 g, 148.5 mmol, 1.20 eq.), acetic acid (8.5 
mL, 148.5 mmol, 1.20 eq.) and (S)-(+)-2-phenylglycinol (20.3714 g, 148.5, 
1.20 eq. mmol) were added. The resulting solution was stirred with exclusion 
from light for 66 h. Solid Na2CO3 was added until the solution was alkaline, 
before the aqueous and organic layers were separated and the aqueous 
layer extracted with dichloromethane (3 x 50 mL). The combined organic 
layers were dried over MgSO4, and passed through a silica plug, washed 
with EtOAc/hexanes (20:80). The solvent was removed under reduced 
pressure to yield 156 as a yellow semi-solid (22.6300 g, 120.9 mmol, 98% 
yield). NMR spectra agreed with those reported by Katritzky et al and Jefford 
et al. 282,361 
1H NMR δ (400 MHz):  1.70 (bs, 1 H), 4.16–4.28 (m, 2H), 5.27 (dd, J = 
8.1, 5.1 Hz, 1 H), 6.24 (as, 2 H), 6.82 (as, 2 H), 
7.12–7.20 (m, 2 H), 7.27–7.38 (m, 3 H) 
13C NMR δ (100 MHz):  65.1, 65.4, 109.0, 120.1, 126.8, 128.3, 129.0, 
138.6 
Methyl (S)-2-phenyl-2-(1H-pyrrol-1-yl)acetate (154)  
N
HO
156
N
O
154
O
H3C
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2,5-Dimethoxytetrahydrofuran (2.70 mL, 20.84 mmol) in water (30 mL) under 
an atmosphere of N2 was heated at reflux and stirred for 2.5 h. The solution 
was allowed to cool to room temperature before CH2Cl2 (45 mL) and sodium 
acetate (4.0759 g, 49.68 mmol, 2.38 eq), and (S)-(+)-2-phenylglycine methyl 
ester hydrochloride (4.9960 g, 24.77 mmol, 1.19 eq.) were added. The 
reaction mixture was stirred with exclusion from light for 18 h. 2 M Na2CO3 
(75 mL) was added to make the solution alkaline, before the aqueous and 
organic layers were separated and the aqueous layer extracted with 
dichloromethane (3 x 45 mL). The combined organic layers were dried over 
MgSO4, and passed through a silica plug, washed with EtOAc/hexanes 
(20:80). The solvent was removed under reduced pressure to yield 154 as a 
yellow oil (4.4019 g, 20.45 mmol, 98% yield). Data agreed with that reported 
by Demir et al.362 
1H NMR δ (400 MHz):  3.82 (s, 3 H), 5.88 (s, 1 H), 6.20–6.23 (m, 2 H), 
6.75–6.78 (m, 2 H), 7.27–7.34 (m, 2 H), 7.35–
7.44 (m, 3 H) 
13C NMR δ (100 MHz):  52.9, 65.5, 108.9, 121.0,127.8, 129.0, 129.1, 
135.4, 170.1 
IR Vmax:  2953, 1751 (C=O), 1487, 1454, 1435, 1278, 1201, 
1168, 1091, 1006 
(S)-3-Phenyl-2-(1H-pyrrol-1-yl)propan-1-ol (157)  
2,5-Dimethoxytetrahydrofuran (3.60 mL, 27.78 mmol) in water (30 mL) under 
an atmosphere of N2 was heated at reflux and stirred for 2 h. The solution 
was allowed to cool to room temperature before dichloromethane (45 mL), 
sodium acetate (2.7358 g, 33.35 mmol, 1.20 eq), acetic acid (1.90 mL, 33.19 
mmol, 1.20 eq.) and L-Phenylalaninol (5.0550 g, 33.43 mmol, 1.20 eq.)  were 
added. The reaction mixture was stirred with exclusion from light for 18 h. 
before the aqueous and organic layers were separated and the aqueous 
N
HO
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layer extracted with dichloromethane (3 x 45 mL). The combined organic 
layers were dried over MgSO4, and passed through a silica plug, washed 
with EtOAc/hexanes (20:80). The solvent was removed under reduced 
pressure to yield 157 as an off white semi-solid (5.2063 g, 25.86 mmol, 93% 
yield). Data agreed with that reported by Tokumaru et al.363 
1H NMR δ (400 MHz):  1.99 (bs, 1 H), 3.02–3.12 (m, 2 H), 3.78 (d, J = 6.0 
Hz, 2 H), 4.14–4.24 (m, 1 H), 6.19 (at, J = 2.1 Hz, 
2 H), 6.71 (at, J = 2.1 Hz, 2 H), 7.04-7.10 (m, 2 
H), 7.21–7.32 (m, 3 H) 
13C NMR δ (100 MHz):  38.7, 63.6, 65.5, 108.6, 119.3, 126.8, 128.7, 
129.0, 137.7 
IR Vmax:  3470 (OH), 2943, 1489, 1454, 1273, 1091, 1064, 
1031 
(R)-1-(1-Phenylethyl)-1H-pyrrole (158)  
2,5-Dimethoxytetrahydrofuran (0.180 mL, 1.389 mmol) in water (5 mL) under 
an atmosphere of N2 was heated at reflux and stirred for 2 h. The solution 
was allowed to cool to room temperature before R-Phenylethylamine (0.210 
mL, 1.649 mmol, 1.19 eq.)  were added. The reaction mixture was stirred 
with exclusion from light for 18 h, before the aqueous layer was extracted 
with dichloromethane (3 x 5 mL). The combined organic layers were dried 
over MgSO4, and passed through a silica plug, washed with EtOAc/hexanes 
(20:80). The solvent was removed under reduced pressure to yield 158 as an 
orange oil (0.0953 g, 0.557 mmol, 40% yield). 1H and 13C NMR spectra were 
in agreement with those reported by Gourlay et al.131 
1H NMR δ (400 MHz):  1.85 (d, J = 7.0 Hz, 3 H), 5.30 (q, J = 7.0 Hz, 1 H), 
6.20–6.23 (m, 2 H), 6.76–6.80 (m, 2 H), 7.09–
7.13 (m, 2 H), 7.23–7.36 (m, 3 H) 
N
H3C
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13C NMR δ (100 MHz):  22.2, 58.1, 108.1, 119.5, 125.9, 127.5, 128.7, 
143.6 
Procedures For the Preparation of (3S,7aR)-3-phenyl-2,3-
dihydropyrrolo[2,1-b]oxazol-5(7aH)-one (118) 
Using Dess–Martin Periodinane 
To a solution of pyrrole 156 (0.3316 g, 1.771 mmol) in dichloromethane (10 
mL) was added Boc2O (0.4661 g, 2.135 mmol, 1.2 eq.) and DMAP (0.0254 g, 
0.2079 mmol, 0.12 eq.), and the mixture stirred for 1.5 h. Water (10 mL) was 
added, and the aqueous and organic layers separated. The aqueous layer 
was extracted with dichloromethane (3 x 10 mL), the combined organic 
layers dried over MgSO4, filtered and the solvent removed under reduced 
pressure. The crude product was taken up in dichloromethane (15 mL) and 
cooled to 0 oC, before addition of Dess–Martin periodinane (1.9716 g, 4.648 
mmol, 2.62 eq.) and 2 drops of H2O, and stirring for a further 1.5 h. H2O (15 
mL0 was added, followed by solid Na2S2O5 until the solids dissolved to give a 
transparent red-brown organic layer. The organic and aqueous layers were 
separated, and the aqueous layer extracted with dichloromethane (3 x 15 
mL). The combined organic layers were then washed with saturated NaHCO3 
(2 x 15 mL), dried over MgSO4, filtered, and the solvent removed under 
reduced pressure. This crude product was likewise taken up in 
dichloromethane (15 mL) and cooled to 0 oC. TFA (1.5 mL) was added, and 
the solution was stirred for 16 h. The reaction was quenched by addition of 
saturated NaHCO3 (20 ML). The aqueous and organic layers were 
separated, and the aqueous layer extracted with dichloromethane (3 x 15 
mL). The combined organic extracts were dried over MgSO4, filtered, and the 
solvent removed under reduced pressure. The crude material was purified 
first by elution through a short plug of silica with EtOAc/hexanes (50:50), then 
on by automated flash column chromatography with a solvent gradient of 10–
NO O
118
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50% EtOAc/hexanes, to give 118 as a crystalline pale orange solid (0.1948 
g, 0.9681 mmol, 55% yield). Experimental data agreed with those reported in 
the literature.102 
1H NMR δ (400 MHz):  4.10 (dd, J = 8.7, 7.3 Hz, 1 H), 4.75 (at, J = 8.7, 1 
H), 4.98 (at, J = 7.3 Hz, 1 H), 5.67 (s, 1 H), 6.24 
(d, J = 5.9 Hz, 1 H), 7.21 (dd, J = 5.9, 1.4 Hz, 1 
H), 7.27–7.40 (m, 5 H) 
13C NMR δ (100 MHz):  58.1, 78.4, 94.1, 126.2, 127.9, 129.0, 131.6, 
139.5, 145.8, 176.8 
IR Vmax:    2872, 1712 (C=O), 1383, 1240, 1165, 1082 
HRMS  For C12H11NO2, predicted 201.07898, found 
201.07938. m/z (EI+): 201 (M+, 20), 171 (100), 
143 (60), 115 (15), 104 (10), 87 (20), 82 (10) 
[α]D20     +104 o (c = 0.0361 in acetone) 
MP:    72.5–73.0 oC 
Using IBX 
To a solution of pyrrole 156 (1.1057 g, 5.905 mmol) in dichloromethane (25 
mL) was added Boc2O (1.5652 g, 7.171 mmol, 1.2 eq.) and DMAP (0.0721 g, 
0.590 mmol, 0.10 eq.), and the solution stirred for 2.5 h. Water (25 mL) was 
added, and the aqueous and organic layers separated. The aqueous layer 
was extracted with dichloromethane (3 x 25 mL), the combined organic 
layers dried over MgSO4, filtered and the solvent removed under reduced 
pressure. The crude product was taken up in AcOH (15 mL). IBX (4.1463 g, 
14.80 mmol, 2.5 eq.) was added, and the reaction stirred at room 
temperature for 16 h. Water (50 mL) and CH2Cl2 (50 mL) were added, 
NO O
118
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excess solid Na2S2O5 was added, and the solution made basic by addition of 
solid NaHCO3. The aqueous and organic layers were separated, and the 
aqueous layer extracted with CH2Cl2 (4 x 25 mL). The combined organic 
layers were dried over MgSO4, and the solvent removed under reduced 
pressure to give a brown oil. This crude product was likewise taken up in 
dichloromethane (25 mL) and cooled to 0 oC. FA (2.5 mL) was added, and 
the solution was stirred for 16 h. The reaction was quenched by addition of 
saturated NaHCO3 (25 mL). The aqueous and organic layers were 
separated, and the aqueous layer extracted with dichloromethane (3 x 25 
mL). The combined organic extracts were dried over MgSO4, filtered, and the 
solvent removed under reduced pressure. The crude product was purified 
first by elution through a short plug of silica with EtOAc/hexanes (50:50), then 
by automated flash column chromatography with a solvent gradient of 10–
50% EtOAc/hexanes, to give 118 as a crystalline pale orange solid (0.5302 
g, 2.634 mmol, 45% yield). 
(3S,6R,7S,7aR)-6,7-Dihydroxy-3-phenyltetrahydropyrrolo[2,1-b]oxazol-
5(6H)-one (162)  
To a stirred solution of  lactam 118 (0.5906 g, 2.935 mmol) in a 5:1 mixture of 
acetone and H2O (12 mL), at 0 oC, was added N-methylmorpholine-N-oxide 
(1.85 mL of a 50% w/w solution in H2O, 8.922 mmol, 3.04 eq.) and OsO4 (2.3 
mL of a 0.0393 M solution in H2O, 0.09039 mmol, 0.030 eq.). The resulting 
solution was stirred for 16 h, at which time acetonitrile was added and the 
solvent removed under reduced pressure. The crude product was adsorbed 
on silica and purified by washing through a silica plug with EtOAc/MeOH 
(90:10) as eluent to give 162 as a white solid (0.5789 g, 2.463 mmol, 84 % 
yield) 
NO O
162
HO OH
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1H NMR δ (400 MHz, DMSO):  3.77 (dd, J = 8.7, 6.7 Hz, 1 H), 3.92–3.96 
(m, 1 H), 4.07 (t, J = 5.9 Hz, 1 H), 4.52 (dd, 
J = 8.6, 7.2 Hz, 1 H), 4.91 (t, J = 6.8 Hz, 1 
H), 5.19 (d, J = 3.6 Hz, 1 H), 5.51 (d, J = 
7.0 Hz, 1 OH), 5.95 (d, J = 5.7 Hz, 1 OH), 
7.27–7.32 (m, 3 H), 7.35–7.39 (m, 2 H) 
13C NMR δ (100 MHz, DMSO):  56.4, 72.2, 74.6, 74.9, 97.2, 126.0, 127.4, 
128.5, 139.5, 174.8 
IR Vmax: 3345 (OH), 3149, 1694 (C=O), 1314, 1267, 
1126, 1079 
HRMS:  For C12H13N1O4+Na, predicted 258.0737, 
found 258.0729 
[α]D20 (DMSO)   +153.3 o (c = 0.3) 
(3S,6R,7S,7aR)-5-Oxo-3-phenylhexahydropyrrolo[2,1-b]oxazole-6,7-diyl 
diacetate (163)  
To diol 162 (0.0998 g, 0.4242 mmol) was added in Ac2O (2 mL) and pyridine 
(2 mL), at 0 oC, and the resulting solution allowed to warm to room 
temperature and stirred for 16 h. H2O (10 mL) and CH2Cl2 (10 mL) were 
added, and the aqueous and organic layers separated. The aqueous layer 
was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers were 
dried over MgSO4, filtered, and the solvent removed under reduced pressure. 
The crude material was purified by flash column chromatography with 
EtOAc/hexanes (50:50) as eluent to give the title compound 163 as a 
crystalline pale yellow solid (0.1165 g, 0.3650 mmol, 86% yield) 
NO O
163
O O
CH3H3C
O O
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1H NMR δ (400 MHz):  2.09 (s, 3 H), 2.14 (s, 3 H), 3.96 (dd, J = 8.9, 6.5 
Hz, 1 H), 4.57 (dd, J = 8.9, 7.4 Hz, 1 H), 5.13 (at, 
J = 6.9 Hz, 1 H), 5.28 (dd, J = 6.8, 2.9 Hz, 1 H), 
5.33 (d, J = 2.9 Hz, 1 H), 5.56 (d, J = 6.8 Hz, 1 H), 
7.25–7.40 (m, 5 H) 
13C NMR δ (100 MHz):  20.30, 20.34, 57.7, 69.9, 72.7, 75.4, 94.6, 125.8, 
128.1, 129.0, 138.1, 169.1, 170.4 
IR Vmax:  2922, 1755 (C=O), 1733 (C=O), 1418, 1371, 
1240, 1212, 1068 
HRMS: For C16H17NO6, predicted 319.10559, found 
315.10622. m/z (EI+): 319 (M+, 2), 317 (10), 302 
(40), 289 (10), 260 (80), 217 (20), 190 (50), 160 
(30), 148 (100), 132 (15), 120 (70), 104 (50), 87 
(60) 
[α]D20    +146.67 o (c = 0.60) 
MP:    109.5–110.5 oC 
(3R,4R)-1-((S)-2-Hydroxy-1-phenylethyl)-2-oxopyrrolidine-3,4-diyl 
diacetate (172)  
Note: this was the best observed and an irreproducible result, with yields 
ranging from 0% up to 40% 
To a stirred solution of 163 (0.1061 g, 0.3322 mmol) in dry dichloromethane 
(6 mL), under an atmosphere of N2, cooled on a dry ice/acetone bath to -78 
oC, was added triethylsilane (0.325 mL, 2.035 mmol, 6.1 eq.) and TiCl4 
(0.190 mL, 1.733 mmol, 5.2 eq.). The reaction was allowed to warm to room 
N
HO
172
O O
CH3
O
H3C
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temperature and stirred for 20 h, before being quenched by addition of 
saturated NH4Cl (10 mL). H2O (20 mL) and CH2Cl2 (10 mL) were added, and 
the aqueous and organic layers separated. The aqueous layer was extracted 
with CH2Cl2 (3 x 10 mL), the organic fractions were combined, dried over 
MgSO4, filtered, and the solvent removed under reduced pressure. The crude 
material was purified by flash column chromatography using EtOAc as eluent 
to give 172 as a pale yellow solid (0.0421 g, 0.1310 mmol, 39% yield) 
1H NMR δ (400 MHz):  1.99 (s, 3 H), 2.14 (s, 3 H), 3.17 (d, J = 11.8 Hz, 1 
H), 3.33 (bs, 1 H), 3.69 (dd, J = 11.8, 4.0 Hz, 1 H), 
4.01 (dd, J = 11.8, 9.2 Hz, 1 H), 4.10 (dd, J = 
12.0, 4.4 Hz, 1 H), 5.21 (dd, J = 9.0, 4.4 Hz, 1 H), 
5.50 (t, J = 4.5 Hz, 1 H), 5.66 (d, J = 5.4 Hz, 1 H), 
7.21–7.37 (m, 5 H) 
13C NMR δ (100 MHz):  20.5, 20.7, 47.4, 58.4, 61.9, 67.8, 70.3, 127.3, 
128.3, 129.0, 135.8, 169.5, 169.9, 170.1 
IR Vmax:  3379 (OH), 2956, 1747 (C=O), 1688 (C=O), 1373, 
1246 
HRMS:  For C16H19NO6+H, predicted 322.1285, found 
322.1276 
[α]D20    +45.58 o (c = 0.68) 
MP:    120.2–121 oC 
(3aS,3bR,6S,8aR)-2,2-Dimethyl-6-phenyltetrahydro-
[1,3]dioxolo[4',5':3,4]pyrrolo[2,1-b]oxazol-8(3bH)-one (164)  
NO O
164
OO
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To a stirred solution of diol 162 (0.1347 g, 0.5726 mmol) in acetone (10 mL) 
under an atmosphere of N2 was added 2,2-dimethoxypropane (0.360 mL, 
2.93 mmol, 5 eq.) via syringe and catalytic amberlyst resin, and the reaction 
stirred at room temperature for 16 h. The reaction mixture was then filtered 
on cotton wool and the solvent removed under reduced pressure. The crude 
material was purified by flash column chromatography with EtOAc/hexanes 
(50:50) as the eluent, giving acetal 164 as a white semi-solid (0.1126 g, 
0.4090 mmol, 71 % yield) 
1H NMR δ (600 MHz):  1.42 (s, 3 H), 1.56 (s, 3 H), 3.85 (s, 3 H), 3.85 (dd, 
J = 8.7, 7.0 Hz, 1 H), 4.55 (at, J = 8.2 Hz, 1 H), 
4.74 (d, J = 6.8 Hz, 1 H), 4.78 (d, J = 6.8 Hz, 1 H), 
5.11 (s, 1 H), 5.12 (at, J = 7.1 Hz, 1 H), 7.22–7.25 
(m, 2 H), 7.28–7.32 (m, 1 H), 7.34–7.38 (m, 2 H) 
13C NMR δ (150 MHz):  25.5, 26.7, 58.3, 74.5, 77.6, 79.8, 96.4, 114.6, 
125.9, 128.0, 129.1, 139.0, 175.3 
IR Vmax:  1727 (C=O), 1399, 1383, 1376, 1210, 1087, 1055, 
1035 
HRMS:  For C15H17NO4+Na, predicted 298.1050, found 
298.1062. 
[α]D20    +84.68 o (c = 0.55) 
(3S,7aR)-6-(Benzyloxy)-3-phenyl-2,3-dihydropyrrolo[2,1-b]oxazol-
5(7aH)-one (173)  
To a solution of diol 162 (0.1375 g, 0.5845 mmol), in dry DMF (6 mL) was 
added NaH (0.0762 g of 60% in mineral oil, 1.905 mmol, 3.25 eq.) and 
benzyl bromide (0.140 mL, 1.177 mmol, 2.01 eq.), and the solution stirred for 
NO O
173
OBn
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3 h. The reaction was quenched with H2O (10 mL), and extracted with 
toluene (3 x 10 mL). The combined organic layers were dried over MgSO4, 
filtered, and the solvent removed under reduced pressure. The crude 
material was purified by flash column chromatography with EtOAc/hexanes 
(40:60) as the eluent to give 173 as a crystalline white solid (0.1474 g, 
0.4799 mmol, 82% yield). 
1H NMR δ (400 MHz):  4.02 (dd, J = 9.0, 7.7 Hz, 1 H), 4.78 (dd, J = 9.0, 
7.5 Hz, 1 H), 4.96 (t, J = 7.5 Hz, 1 H), 5.03 (dd, J 
= 16.7, 12 Hz, 2 H), 5.56 (d, J = 2.2 Hz, 1 H), 5.88 
(d, J = 2.2 Hz, 1 H), 7.26–7.45 (m, 10 H) 
13C NMR δ (100 MHz):  57.9, 72.7, 77.8, 90.2, 108.2, 126.1, 127.80, 
127.82,128.6, 128.7, 128.9, 134.9, 139.2, 153.8, 
170.8 
IR Vmax:  2873, 1728 (C=O), 1637, 1455, 1396, 1309, 1231, 
1217, 1203 
HRMS:  For C19H17NO3, predicted 307.12084, found 
307.12170. m/z (EI+): 307 (M+, 10), 277 (85), 216 
(18), 186 (50), 158 (80), 146 (30), 128 (40), 104 
(50), 91 (100), 77 (30), 65 (20) 
[α]D20     +146.1 o (c = 0.95) 
MP:    108.4–109.5 oC 
(3S,6S,7aR)-6-Hydroxy-3-phenyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-
one (174)  
NO O
174
OH
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To a solution of 173 (0.1608 g, 0.5231 mmol) in EtOH (10 mL) was added 
Pd/C (~0.1 g of a 10% w/w mixture), and the reaction stirred under a balloon 
of H2 (1 atm) for 20 h. The reaction mixture was filtered through a plug of 
celite, and the solvent removed under reduced pressure. The crude product 
was purified by flash column chromatography to give 174 as a white semi-
solid (0.0633 g, 0.2887 mmol, 55% yield). 
1H NMR δ (400 MHz):  2.05 (ddd, J = 13.2, 9.5, 4.7 Hz, 1 H), 2.96–3.05 
(m, 1 H), 3.88 (dd, J = 8.8, 7.7 Hz, 1 H), 4.62 (dd, 
J = 8.8, 7.7 Hz, 1 H), 4.73 (t, J = 9.0 Hz, 1 H), 
5.11 (t, J = 7.4 Hz, 1 H), 5.24 (t, J = 5.2 Hz, 1 H), 
7.21–7.39 (m, 5 H) 
13C NMR δ (100 MHz):  37.1, 57.3, 71.7, 75.0, 88.8, 126.1, 128.1, 129.1, 
138.8, 177.4 
IR Vmax:  3335 (OH), 1695 (C=O), 1633, 1456, 1298, 1091, 
997 
HRMS: For C12H13NO3+Na, predicted 242.0788, found 
242.0795 
[α]D20     +140.6 o (c = 0.34) 
MP:     136–137 oC 
(3S,6S,7aR)-6-(Benzyloxy)-3-phenyltetrahydropyrrolo[2,1-b]oxazol-
5(6H)-one (175)  
To a solution of 174 (0.0269 g, 0.1228 mmol) in dry DMF (4 mL) was added 
NaH (0.0080 g of a 60% dispersion in mineral oil, 0.2000 mmol, 1.63 eq.) 
and benzyl bromide (0.015 mL, 0.1261 mmol, 1.03 eq.), and the solution 
NO O
175
OBn
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stirred for 3 h. The reaction was quenched with H2O (5 mL), and extracted 
with toluene (3 x 10 mL). The combined organic layers were dried over 
Na2SO4, filtered, and the solvent removed under reduced pressure. The 
crude material was purified by flash column chromatography with 
EtOAc/hexanes (30:70) as the eluent to give 175 as a clear crystalline solid 
(0.0255 g, 0.08247 mmol, 67% yield). 
1H NMR δ (600 MHz):  2.08 (ddd, J = 13.5, 9.2, 4.5 Hz, 1 H), 2.86 (ddd, J 
= 13.5, 8.2, 5.6 Hz, 1 H), 3.86 (dd, J = 8.7, 7.4 Hz, 
1 H), 4.49 (at, J = 8.9 Hz, 1 H), 4.58 (dd, J = 8.6, 
7.7 Hz, 1 H), 4.76 (d, J = 11.9 Hz, 1 H), 5.01 (d, J 
= 11.9 Hz, 1 H), 5.12–5.17 (m, 2 H), 7.20–7.41 
(m, 10 H) 
13C NMR δ (150 MHz): 35.4, 57.2, 72.5, 74.7, 76.8, 88.4, 126.1, 127.9, 
128.0, 128.2, 128.6, 129.0, 137.6, 139.1, 175.5 
IR Vmax: 1695 (C=O), 1495, 1455, 1412, 1328, 1289, 1169, 
1127, 1072, 1024 
HRMS: For C19H19NO3+Na, predicted 332.1257, found 
332.1255 
[α]D20    +41.4 o (c = 0.27) 
MP:    91.0–91.5 oC 
(S)-1-((S)-2-Methoxy-2-oxo-1-phenylethyl)-5-oxo-2,5-dihydro-1H-pyrrol-
2-yl 2-iodobenzoate (155a) and (R)-1-((S)-2-methoxy-2-oxo-1-
phenylethyl)-5-oxo-2,5-dihydro-1H-pyrrol-2-yl 2-iodobenzoate (155b)  
N
O
O
OO
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H3C
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To a solution of pyrrole 154 (1.1720 g, 5.444 mmol) in dichloromethane (35 
mL) at 0 oC was added Dess–Martin periodinane (5.8989 g, 13.908 mmol, 
2.55 eq.), and the reaction stirred for 6 h. Water (35 mL) was added, and the 
reaction quenched by addition of Na2S2O5. The aqueous and organic layers 
were separated, and the aqueous layer extracted with dichloromethane (3 x 
20 mL). The combined organic layers were dried over MgSO4, filtered, and 
the solvent removed under reduced pressure. The crude mixture was purified 
by automated flash column chromatography with a solvent gradient from 15–
40% EtOAc/hexanes, to give 155a as a clear crystalline solid (0.7057 g, 
1.479 mmol, 27%) and 155b as an orange crystalline solid (0.6356 g, 1.332 
mmol, 24%). 
1H NMR δ (400 MHz):  3.76 (s, 3 H), 5.94 (s, 1 H), 6.35 (d, J = 6.0 Hz, 1 
H), 6.83 (dd, J = 7.7, 1.6 Hz, 1 H), 7.02–7.23 (m, 
7 H), 7.27–7.33 (m, 2 H), 7.89 (d, J = 7.8 Hz, 1 H) 
13C NMR δ (100 MHz):  52.8, 57.9, 83.7, 94.6, 127.4, 128.7 (2 C), 129.0, 
129.1, 131.5, 132.0, 133.2, 133.3, 141.6, 144.3, 
164.1, 170.6, 171.1 
IR Vmax:  1716 (C=O), 1579, 1390, 1249, 1219, 1197, 1101, 
1004 
HRMS: For C20H16INO5+Na, predicted 499.9965, found 
499.9984. 
[α]D20     +217.9 o (c = 6.3) 
MP:     82–84 oC 
N
O
O
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1H NMR δ (400 MHz):  3.73 (s, 3 H), 5.81 (s, 1 H), 6.31 (d, J = 6.0 Hz, 1 
H), 6.43 (ad, J = 1.3 Hz, 1 H), 7.10 (dd, J = 6.0, 
1.6 Hz, 1 H), 7.18 (td, J = 7.7, 1.3 Hz, 1 H), 7.27–
7.34 (m, 5 H), 7.38–7.43 (m, 1 H), 7.83 (dd, J = 
7.8, 1.2 Hz, 1 H), 8.02 (d, J = 8 Hz, 1 H) 
13C NMR δ (100 MHz):  52.8, 58.9, 83.5, 94.8, 128.2, 129.0, 129.10, 
129.13, 129.16, 131.7, 132.7, 133.5, 133.6, 
141.9, 143.3, 164.8, 169.7, 170.2 
IR Vmax:  1716 (C=O), 1579, 1390, 1249, 1219, 1197, 1101, 
1004 
HRMS: For C20H16INO5+Na, predicted 499.9965, found 
499.9984. 
[α]D20     −30.9 o (c = 6.3) 
MP:     92–94 oC 
(S)-5-Oxo-1-((R)-1-phenylethyl)-2,5-dihydro-1H-pyrrol-2-yl 2-
iodobenzoate (176a) and (R)-5-oxo-1-((R)-1-phenylethyl)-2,5-dihydro-1H-
pyrrol-2-yl 2-iodobenzoate (176b)  
To a solution of pyrrole 158 (0.0953 g, 0.556 mmol) in dichloromethane (10 
mL) at 0 oC was added Dess–Martin periodinane (0.6368 g, 1.501 mmol, 
N
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2.70 eq.), and the reaction stirred for 45 min. H2O (10 mL) was added, and 
the reaction quenched by addition of Na2S2O5. The aqueous and organic 
layers were separated, and the aqueous layer extracted with 
dichloromethane (3 x 5 mL). The combined organic layers were washed with 
saturated Na2SO4 (10 mL), dried over MgSO4, filtered, and the solvent 
removed under reduced pressure. The crude mixture was purified by flash 
column chromatography with EtOAc/hexanes (40:60) as the eluent, to give 
an inseparable mixture of 176a and 176b as an orange oil (0.1133 g, 0.2615 
mmol, 47% yield) 
1H NMR δ (600 MHz):  1.66 (d, J = 7.3 Hz, 2.6 H), 1.69 (d, J = 7.3 Hz, 3 
H), 5.44 (p, J = 6.9 Hz, 1.8 H), 6.26 (d, J = 5.9 Hz, 
0.8 H), 6.31 (d, J = 5.9 Hz, 1 H), 6.42 (d, J = 1.5 
Hz, 0.8 H), 6.81 (dd, J = 7.7, 1.7 Hz, 1 H), 6.90 (d, 
J = 1.5 Hz, 1 H), 7.01–7.08 (m, 3.8 H), 7.09–7.13 
(m, 1 H), 7.15–7.19 (m, 2.8 H), 7.24–7.36 (m, 7 
H), 7.40 (at, J = 7.6 Hz, 1 h), 7.73 (dd, J = 7.8, 1.5 
hz, 0.8 H), 7.90 (dd, J = 7.7, 0.8 Hz, 1 H), 8.01 
(dd, J = 7.9, 0.4 Hz, 0.8 H) 
13C NMR δ (150 MHz):  17.0, 18.4, 49.1, 50.6, 82.1, 84.0, 94.5, 94.6, 
127.10, 127.16, 127.2, 127.6, 128.0, 128.1, 
128.4, 128.9, 129.6, 129.7, 131.0, 131.6, 132.1, 
133.2, 133.3, 133.4, 139.8, 140.9, 141.5, 141.8, 
142.2, 142.4, 164.5, 165.0, 170.12, 170.14 
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5.3 Chapter 2 Experimental Details 
(3aS,3bR,6S,8aR)-6-Phenyltetrahydro-
[1,3,2]dioxathiolo[4',5':3,4]pyrrolo[2,1-b]oxazol-8(3bH)-one 2,2-dioxide 
(232)  
To a stirred solution of diol 162 (0.2631 g, 1.118 mmol) in dry CH2Cl2 (10 
mL), under N2 at 0 oC, was added pyridine (0.280 mL, 3.462 mmol, 3.1 eq.) 
and SOCl2 (0.170 mL, 2.329 mmol, 2.1 eq.) via syringe. After stirring for 30 
minutes, the reaction was quenched by addition of a saturated solution of 
CuSO4 (10 mL). The aqueous and organic layers were separated, and the 
aqueous layer extracted with CH2Cl2 (3 x 10 mL). The combined organic 
layers were dried over MgSO4, filtered, and the solvent removed under 
reduced pressure. The crude residue was dissolved in a 50:50 solution of 
CH2Cl2 and CH3CN (15 mL) under an N2 atmosphere, cooled to 0 oC and 
stirred. NaIO4 (0.4961 g, 2.319 mmol, 2.0 eq.) and RuCl3.xH2O (0.007 g) 
were added and the reaction stirred for 5 minutes, at which point Et2O (20 
mL) and H2O (15 mL) were added. The aqueous and organic layers were 
separated, and the organic layer washed with saturated NaHCO3 (2 x 10 
mL), dried over MgSO4, filtered, and the solvent removed under reduced 
pressure. The crude material was purified by flash column chromatography 
using EtOAc/hexanes (45:55) as the eluent to give the product 232 as a 
white crystalline solid (0.1681 g, 0.565 mol, 51% yield) 
1H NMR δ (600 MHz):  3.97 (dd, J = 8.8, 6.8 Hz, 1 H), 4.63 (dd, J 
= 8.8, 7.8 Hz, 1 H), 5.19–5.23 (m, 1 H), 
5.29 (d, J = 7.5 Hz, 1 H), 5.38 (d, J = 7.5 
Hz, 1 H), 5.47 (s, 1 H), 7.22–7.26 (m, 2 H), 
7.32–7.36 (m, 1 H), 7.38–7.42 (m, 2 H) 
NO O
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13C NMR δ (150 MHz):  58.4, 75.1, 77.1, 80.1, 94.2, 125.6, 128.6, 
129.4, 137.3, 167.4 
IR Vmax:  1732, 1408, 1209, 1021, 839 
HRMS:  For C12H11NO6S, predicted 297.02939, 
found 297.02939. 
[α]D20  +155.8 o (c = 0.33 CH2Cl2) 
MP 142.5–143.0 oC 
(3S,6S,7R,7aR)-6-Fluoro-7-hydroxy-3-phenyltetrahydropyrrolo[2,1-
b]oxazol-5(6H)-one (233), (3S,7aR)-6-fluoro-3-phenyl-2,3-
dihydropyrrolo[2,1-b]oxazol-5(7aH)-one (242), and (3S,6R,7S,7aR)-6,7-
difluoro-3-phenyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (234) 
Fluorination With Deoxofluor® 
To a stirred solution of diol 162 (0.5047 g, 2.1469 mmol) in dry CH2Cl2 (20 
mL) under an atmosphere of N2, at 0 oC, was added Deoxofluor® (2.00 mL of 
a 50 wt% solution in THF, 4.7007 mmol, 2.19 eq.) via syringe. The reaction 
was allowed to warm to room temperature and stirred for 18 h, at which time 
it was cooled on an ice bath quenched by slow addition of saturated NaHCO3 
(20 mL). The aqueous and organic layers were separated, and the aqueous 
layer extracted with CH2Cl2 (2 x 20 mL). The combined organic extracts were 
dried over Na2SO4, and the solvent removed under reduced pressure. The 
crude mixture was purified by automated flash column chromatography using 
a solvent gradient from 0–50% EtOAc/hexanes, to give the fluoroalkene 242 
(0.0095 g, 0.0433 mmol, 2% yield) as a pale yellow oil, difluoro compound 
234(0.0340 g, 0.1421 mmol, 7% yield) as a white crystalline solid, and 
NO O
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fluorohydrin 233 (0.2774 g, 1.169 mmol, 54% yield) as a white crystalline 
solid.  
1H NMR δ (400 MHz):  3.92 (dd, J = 8.8, 6.9 Hz, 1 H), 4.49 (ddd, J 
= 20.8, 7.3, 3.3 Hz, 1 H), 4.51–4.56 (m, 1 
H), 5.14 (at, J = 3.3 Hz, 1 H),5.19 (at, J = 
6.9 Hz, 1 H), 5.35 (dd, J = 52.2, 7.3 Hz, 
7.20–7.41 (m, 5 H) 
13C NMR δ (100 MHz):  57.3, 74.3, 78.7 (d, JC-F = 20.0 Hz), 93.1 (d, 
JC-F = 9.4 Hz), 95.2 (d, JC-F = 196.9 Hz), 
125.9, 128.2, 129.0, 137.8, 168.8 (d, JC-F = 
24.1 Hz) 
19F NMR δ (375 MHz, MeOD):  −198.3 (ddd, J = 52.1, 20.7, 3.6, 1 F) 
IR Vmax:  3407 (OH), 1733 (C=O), 1668, 1404, 1362, 
1264, 1213, 1096, 1028 
HRMS:  For C12H12FNO3, predicted 237.08012, 
found 237.07943. m/z (EI+): 237 (M+, 1), 
219 (10), 189 (50), 171 (20), 161 (30), 147 
(20), 130 (25), 117 (75), 104 (100), 90 (40), 
77 (25) 
[α]D20  +140.95 o (c = 0.42)  
MP:      138-139 oC 
NO O
233
HO F
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1H NMR δ (600 MHz, MeOD):  3.99 (dd, J = 8.3, 7.2 Hz, 1 H), 4.83–4.89 
(m, 2 H), 5.71 (dd, J = 6.0, 2.0 Hz, 1 H), 
6.75 (dd, J = 2.0, 1.0 Hz, 1 H), 7.30 (sx, J = 
4.2 Hz, 1 H), 7.37 (d, J = 4.3 Hz, 4 H) 
13C NMR δ (150 MHz, MeOD):  59.6, 79.2, 89.9 (d, JC-F = 10.6 Hz), 119.0 
(d, JC-F = 6.0 Hz), 127.2, 128.8, 129.8, 
156.3 (d, JC-F = 286 Hz), 169.5 (d, JC-F = 
30.9 Hz) 
19F NMR δ (600 MHz, MeOD):  −134.48 (d, J = 6.0 Hz, 1 F) 
IR Vmax:  1736 (C=O), 1733, 1665, 1495, 1451, 
1397, 1307, 1218, 1156, 1084 
HRMS:  For C12H10FNO2, predicted 219.06956, 
found 219.06956. m/z (EI+): 219 (M+, 20), 
189 (100), 161 (50), 133 (25), 103 (25), 91 
(10), 77 (20), 51 (10) 
[α]D20      +126.67 o (c = 0.72)  
1H NMR δ (400 MHz): 4.25 (ddd, J = 8.4, 3.0, 1.2 Hz, 1 H), 4.32 (dd, J = 
8.4, 6.0 Hz, 1 H), 5.34 (ddd, J = 47.8, 25.2, 3.0 
Hz, 1 H), 5.37 (dd, J = 14.1, 2.7 Hz, 1 H), 5.38 
(dd, J = 6.0, 3.0 Hz, 1 H), 5.43 (ddd, J = 55.7, 3.0, 
NO O
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2.7 Hz, 1 H), 7.25–7.29 (m, 2 H), 7.30–7.34 (m, 1 
H), 7.35–7.39 (m, 2 H)  
13C NMR δ (100 MHz): 57.5, 74.6, 87.1 (dd, JC-F = 17.1, 4.8 Hz), 87.6 (dd, 
JC-F = 209.5, 16.9 Hz), 89.2 (dd, JC-F = 197.9, 13.5 
Hz), 126.1, 128.4, 129.1, 138.0, 168.6 (d, JC-F = 
24.3 Hz) 
19F NMR δ (600 MHz):  −215.89 (dd, J = 47.8, 5.6 Hz, 1 F), −221.79 
(dddd, J = 55.7, 25.2, 14.1, 5.6 Hz, 1 F) 
IR Vmax: 1738 (C=O), 1709, 1457, 1423, 1346, 1297, 1155, 
1111 
HRMS:  For C12H11F2NO2, predicted 239.07579, found 
239.07573. m/z (EI+): 239 (M+, 7), 219 (15), 209 
(45), 189 (100), 161 (55), 133 (25), 117 (40), 104 
(10), 91 (20), 77 (10) 
[α]D20     +125.8 o (c = 0.345) 
MP:    139–140 oC 
Fluorination With DAST 
To a stirred solution of diol 162 (0.1105 g, 0.4697 mmol) in dry CH2Cl2 (7 mL) 
under N2 was added DAST (0.100 mL, 0.7568 mmol, 1.61 eq.). The mxture 
was heated to 35 oC and stirred at that temperature for 18 h. The reaction 
was quenched by addition of saturated NaHCO3 (5 mL), and the aqueous 
and organic layers separated. The aqueous layer was extracted with CH2Cl2 
(3 x 5 mL), the combined organic layers dried over MgSO4, and the solvent 
removed under reduced pressure. The crude mixture was adsorbed on silica 
NO O
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and purified by flash column chromatrography using EtOAc (30:70), 
EtOAc/hexanes (60:40), and EtOAc/MeoH (90:10) as the eluents to give 
fluorohydrin 233 (0.0468 g, 0.1972 mmol, 42% yield), fluoroalkene 241 
(0.0027 g, 0.0123 mmol, 3% yield), traces of difluoro compound 234, and 
unreacted diol 162 (0.0094 g, 0,0399 mmol, 8%). 
Fluorination With Greater Excess of Deoxofluor® 
To a stirred solution of diol 162 (0.0934 g, 0.3970 mmol), in dry CH2Cl2 (10 
mL), under an atmosphere of N2, was added deoxofluor (0.8501 mL of a 50 
wt% solution in THF, 1.9978 mmol, 5.03 eq.) via syringe. The reaction was 
heated at reflux and stirred for 18 h, at which time an additional portion of 
Deoxofluor (0.450 mL, 1.057 mmol, 2.66 eq) was added and the reaction 
stirred at reflux for 6 h. It was then cooled on an ice bath quenched by slow 
addition of saturated NaHCO3 (15 mL). The aqueous and organic layers were 
separated, and the aqueous layer extracted with CH2Cl2 (2 x 10 mL). The 
combined organic extracts were dried over MgSO4, and the solvent removed 
under reduced pressure. The crude mixture was purified by flash column 
chromatography using EtOAc/hexanes (30:70) as eluent, to give the 
fluoroalkene 242 (0.0196 g, 0.0894 mmol, 22% yield) as a pale yellow oil, 
difluoro compound 234 (0.0211 g, 0.0882 mmol, 22% yield) as a white 
crystalline solid, and trace amounts of fluorohydrin 233. 
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(3S,6S,7aR)-6-Fluoro-3-phenyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one 
(244)  
To a stirred solution of fluoroalkene 242 (0.0232 g, 0.1058 mmol) in EtOH (3 
mL) was added Pd/C (~0.1 g of a 10% w/w mixture) and the mixture stirred 
under a balloon of H2 for 16 h, before being filtered through a small plug of 
celite and the solvent removed under reduced pressure. The crude material 
was adsorbed onto silica and purified by flash column chromatography, using 
EtOAc/hexanes (40:60) as the eluent to give the compound 244 as a clear oil 
(0.0120 g, 0.0542 mmol, 51 % yield) 
1H NMR δ (600 MHz):  2.28 (dddd, J = 26.6, 13.9,8.2, 4.0 Hz, 1 H), 3.06-
3.13 (m, 1 H), 3.90 (dd, J = 8.8, 7.5 Hz, 1 H), 4.63 
(dd, J = 8.8, 7.7 Hz, 1 H), 5.17–5.21 (m, 2 H), 
5.41 (dt, J = 52.3, 8.4 Hz, 1 H), 7.22–7.32 (m, 3 
H), 7.33–7.37 (m, 2 H) 
13C NMR δ (150 MHz): 35.0 (d, JC-F = 19.7 Hz, 1 C), 57.5, 74.8, 87.9 (d, 
JC-F = 5.4 Hz, 1 C), 89.2 (d, JC-F = 190.9 Hz, 1 C), 
126.0, 128.1, 129.1, 138.5, 171.9 (d, JC-F = 22.9 
Hz, 1 C) 
19F NMR δ (600 MHz): −187.97 (ddt, J =  52, 26, 5 Hz) 
IR Vmax: 1727, 1495, 1447, 1414, 1332, 1293, 1167, 1089, 
1044, 1018, 996 
HRMS:  For C12H12FNO2, predicted 221.08521, found 
221.08559. m/z (EI+): 221 (M+, 10), 191 (75), 163 
(60), 146 (25), 128 (55), 117 (100), 104 (30), 87 
(70), 70 (10) 
NO O
244
F
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[α]D20 +100.9 o (c = 0.61) 
(3S,6R,7aR)-6-Fluoro-3-phenyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one 
(245)  
To a solution of alcohol 174 (0.0211 g, 0.0962 mmol), in dry CH2Cl2 (5 mL), 
under an atmosphere of N2, was added DAST (0.020 mL, 0.1513 mmol, 1.57 
eq.) via syringe. The mixture was heated to 35 oC, and stirred for 16 h. The 
reaction was quenched with saturated NaHCO3 (3 mL), and the organic and 
aqueous layers separated .The aqueous layer was extracted with CH2Cl2 (2 x 
5 mL) and EtOAc (1 x 5 mL), and the combined organic extracts dried over 
MgSO4 and the solvent removed under reduced pressure. The crude mixture 
was purified by flash column chromatography using EtOAc/hexanes (50:50) 
and EtOAc as the eluents, to give the compound 245 as a white solid (0.0113 
g, 0.0511 mmol, 53 % yield) and unreacted starting material 174 (0.0028 g, 
0.0127 mmol, 13%). 
1H NMR δ (600 MHz): 2.40 (dddd, J = 31.0, 15.6, 7.0, 3.1 Hz, 1 H), 2.68 
(dddd, J = 25.3, 15.6, 5.7, 1.6 Hz, 1 H), 3.92 (dd, 
J = 8.8, 7.6 Hz, 1 H), 4.65 (at, J = 8.3 Hz, 1 H), 
5.06 (at, J = 7.3 Hz, 1 H), 5.17 (ddd, J = 51.6, 7.0, 
1.4 Hz, 1 H), 5.46 (dd, J = 5.6, 3.1 Hz, 1 H), 7.24–
7.28 (m, 2 H), 7.28–7.32 (m, 1 H), 7.34–7.39 (m, 
2 H) 
13C NMR δ (150 MHz): 34.4 (d, JC-F = 23.4 Hz, 1 C), 57.6 , 76.0, 91.2 (d, 
JC-F = 0.7 Hz, 1 C), 92.0 (d, JC-F = 184.6 Hz, 1 C), 
125.9, 128.1, 129.1, 138.4, 172.0 (d, JC-F = 16.6 
Hz, 1 C) 
19F NMR δ (600 MHz): −181.81 (ddd, J =  51.6, 31, 25 Hz) 
NO O
245
F
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IR Vmax:   1717, 1429, 1412, 1295, 1167, 1091, 1083 
HRMS:  For C12H12FNO2+Na, predicted 244.0744, found 
244.0755 
[α]D20     +170.26 o (c = 0.56) 
(3S,4R)-3-fluoro-4-hydroxy-1-((S)-2-hydroxy-1-phenylethyl)pyrrolidin-2-
one (246)  
To a stirred solution of fluorohydrin 233 (0.1909 g, 0.8047 mmol) in dry 
CH2Cl2 (8 mL) at 0 oC, was added triethylsilane (0.525 mL, 3.286 mmol, 4.1 
eq.) and BF3.OEt2 (0.400 mL, 3.241 mmol, 4.0 eq.) via syringe. The reaction 
was stirred for 18 h, before being quenched with saturated NaHCO3 (8 mL). 
The aqueous and organic layers were separated, and the aqueous layer 
extracted with EtOAc (3 x 5 mL). The combined organic extracts were dried 
over MgSO4, filtered, and the solvent removed under reduced pressure. The 
crude material was purified by flash column chromatography using 
EtOAc/hexanes (50:50) and EtOAc as the eluents, to give the compound 246 
as a crystalline white solid (0.1291 g, 0.5396 mmol, 67 % yield). 
1H NMR δ (400 MHz, MeOD):  2.94 (ddd, J = 9.7, 6.8, 1.1 Hz, 1 H), 3.79 
(dd, J = 9.8, 7.9 Hz, 1 H), 3.94 (dd, J = 
11.8, 5.2 Hz, 1 H), 4.08 (dd, J = 11.8, 9.3 
Hz, 1 H), 4.48 (m (likely dddd), 1 H), 4.94 
(dd, J = 52.6, 6.5 Hz, 1 H), 5.21 (dd,  = 9.3, 
5.2 Hz, 1 H), 7.28–7.39 (m, 5 H) 
13C NMR δ (100 MHz, MeOD):  47.9 (d, JC-F = 8.5 Hz), 58.7, 61.1, 71.4 (d, 
JC-F = 21.3 Hz), 95.9 (d, JC-F = 189.5 Hz), 
128.7, 129.2, 129.8, 137.5, 170.5 (d, JC-F = 
21.6 Hz) 
N O
246
HO F
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19F NMR δ (400 MHz, MeOD):  −200.63 (dd, J = 52.5, 21.1 Hz, 1 F) 
IR Vmax: 3340 (OH), 1690 (C=O), 1488, 1452, 1355, 
1260, 1176, 1127, 1079, 1046 
HRMS:  For C12H14FNO3+Na, predicted 262.0850, 
found 262.0857 
[α]D20 (acetone)   +30.18 o (c = 0.34) 
MP:     130.6–131 oC 
(2S,3R)-2-fluoro-3-hydroxy-4-((2-hydroxy-1-phenylethyl)amino)butanoic 
acid hydrochloride (249)  
Ring-opened fluorohydrin 246 (0.0805 g, 0.3364 mmol) was dissolved in 6 M 
HCl (5mL) and the solution heated at reflux and stirred for 16 h. The solvent 
was removed under reduced pressure to yield the hydrochloride salt 249 
(0.0966 g, 0.3288 mmol, 98% yield) as a white amorphous solid. 
1H NMR δ (600MHz, D2O):  3.08 (dd, J = 12.8, 10.8 Hz, 1 H), 3.31 (dd, 
J = 13.0, 2.5 Hz, 1 H), 4.01 (dd, J = 12.3, 
`5.2 Hz, 1 H), 4.06 (dd, J = 12.3, 7.8 Hz, 1 
H), 4.46–4.55 (m, 2 H), 5.01 (d, J = 47.7 
Hz, 1 H), 7.47–7.57 (m, 5 H) 
13C NMR δ (150 MHz, D2O):  47.3 (d, JC-F = 5.3 HZ, 1 C), 61.4, 63.6, 
66.7 (d, JC-F = 19.9 Hz, 1 C), 90.5 (d, JC-F = 
188.0 Hz, 1 C), 128.2, 129.5, 130.1, 131.1, 
173.3 (d, JC-F = 21.8 Hz, 1 C) 
19F NMR δ (600 MHz, D2O):  −206.45 (dd, JH-F = 47.3, 26.1 Hz, 1 F) 
IR Vmax: 3322, 2942, 1738, 1592, 1455, 1423, 1225, 
1133, 1071 
N
H
OH
O
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HRMS:  For C12H17FNO4, predicted 258.1136, 
found 258.1133 
[α]D20 (MeOH)   +26.22 o (c = 2.55) 
(2S,3R)-4-amino-2-fluoro-3-hydroxybutanoic acid (238)  
A mixture of hydrochloride salt 249 (0.0184 g, 0.0626 mmol) and Pd/C 
(~0.030 g of 10% w/w mixture) in a solution of 95:5 EtOH/AcOH (10 mL), was 
reacted under a balloon of H2 for 18 h. The reaction mixture was then filtered 
on celite, and the solvent removed under reduced pressure to give the crude 
product 238 (0.0187 g). 
1H NMR δ (600MHz, D2O):  3.24 (dd, J = 13.2, 9.6 Hz, 1 H), 3.36 (dd, J 
= 13.2, 2.9 Hz, 1 H), 4.37–4.45 (m, 1 H), 
5.04 (dd, J = 48.5, 1.7 Hz, 1 H) 
13C NMR δ (150 MHz, D2O):  41.3 (d, JC-F = 5.4 Hz, 1 C), 67.4 (d, JC-F = 
19.6 Hz, 1 C), 90.5 (d, JC-F = 188.0 Hz, 1 
C), 172.6 (d, J C-F = 22.2 Hz, 1 C) 
19F NMR δ (600 MHz, D2O):  −199.39 (dd, JH-F = 47.6, 24.1 Hz, 1 F)  
HRMS:  For C4H9FNO3, predicted 138.0516, found 
138.0559 
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5.4 Chapter 3 Experimental Details 
General Method For the Synthesis of Pyrroles From Polygodial 
Polygodial (1 eq.) was dissolved in 5 mL of EtOH and 0.5 mL AcOH, under 
an atmosphere of N2. Light was excluded, the primary amine (1.2 eq.) was 
added, and the solution allowed to stir for 0.5 h. NaBH3CN (1.0 eq) was then 
added, and the reaction allowed to stir for a further 0.5 h. H2O (5 mL) and 
CH2CL2 (5 mL) were added, and the solution made alkaline by addition of 
solid Na2CO3. The aqueous and organic layers were separated and the 
aqueous layer extracted with CH2Cl2 (3 x 5 mL). The combined organic layers 
were dried over MgSO4, filtered, and the solvent removed under reduced 
pressure. Compounds were purified by adsorption on silica and elution 
through a silica plug, with EtOAc/hexanes (20:80) as the eluent. 
(5aS,9aS)-2-Benzyl-6,6,9a-trimethyl-4,5,5a,6,7,8,9,9a-octahydro-2H-
benzo[e]isoindole (270)  
Prepared from polygodial (0.0513 g, 0.220 mmol), benzylamine (0.030 mL, 
0.27 mmol, 1.2 eq.) and NaBH3CN (0.0142g, 0.220 mmol, 1.0 eq.). Product 
isolated as a clear oil (0.0506 g, 0.164 mmol, 75 % yield).  
1H NMR δ (400 MHz):  0.98 (S, 3 H), 1.01 (s, 3 H), 1.29 (s, 3 H), 1.34 
(dd, J = 13.8, 4.2 Hz, 1 H), 1.43 (dd, J = 12, 1.8 
Hz, 1 H), 1.47–1.62 (m, 3 H), 1.67–1.84 (m, 2 H), 
1.84–1.91 (m, 1 H), 1.97–2.05 (m, 1 H), 2.56–
2.68 (m, 1 H), 2.82 (d, J = 15.6, 6.2 Hz, 1 H), 5.00 
(s, 2 H), 6.31–6.35 (m, 1 H), 6.37 (d, J = 2.2 Hz, 1 
H), 7.16-7.21 (m, 2 H), 7.29-7.41 (m, 3 H) 
H
N
270
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13C NMR δ (100 MHz):  19.4, 19.9, 21.6, 23.0, 25.8, 33.2, 33.7, 34.7, 
40.0, 42.3, 52.2, 53.4, 113.6, 115.9, 118.0, 127.3, 
127.5, 128.6, 136.3, 138.7 
IR Vmax:  2922, 1521, 1494, 1454, 1440, 1394, 1373,1352, 
1317, 1215, 1139 
HRMS:  For C22H29N, predicted 307.23000, found 
307.22913. m/z (EI+): 307 (M+, 10), 292 (45), 236 
(5), 118 (55), 87 (100), 70 (10) 
[α]D20     +19.8 o (c = 0.0456) 
(5aS,9aS)-2-(4-Methoxybenzyl)-6,6,9a-trimethyl-4,5,5a,6,7,8,9,9a-
octahydro-2H-benzo[e]isoindole (272)  
Prepared from polygodial (0.0527 g, 0.2249 mmol), 4-methoxybenzylamine 
(0.0375 mL, 0.2869 mmol, 1.27 eq.) and NaBH3CN (0.0148 g, 0.2355 mmol, 
1.05 eq.). Product isolated as a clear oil (0.0743 g, 0.2201 mmol, 98% yield). 
1H NMR δ (400 MHz):  0.95 (s, 3 H), 0.98 (s, 3 H), 1.26 (s, 3 H), 1.28-
1.34 (m, 1 H), 1.40 (dd, J = 11.9, 1.5 Hz, 1 H), 
1.44–1.59 (m, 3 H), 1.63–1.78 (m, 2 H), 1.81–
1.89 (m, 1 H), 1.94–2.02 (m, 1 H), 2.54–2.66 (m, 
1 H), 2.79 (dd, J = 15.7, 6.2 Hz, 1 H), 3.83 (s, 3 
H), 4.91 (s, 2 H), 6.30 (s, 1 H) 6.33 (d, J = 2.1 Hz, 
1 H), 6.89 (d, J = 8.6 Hz, 2 H), 7.13 (d, J = 8.6 Hz, 
2 H) 
13C NMR δ (100 MHz):  19.4, 19.8, 21.6, 23.0, 25.8, 33.2, 33.6, 34.7, 
39.9, 42.2, 52.2, 52.8, 55.3, 113.3, 114.0, 115.7, 
117.8, 128.7, 130.5, 136.2, 159.0 
H
N
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IR Vmax:  2922, 1612, 1586, 1513, 1458, 1440, 1387, 1302, 
1290, 1174, 1139, 1035 
HRMS:  For C23H31NO+H, predicted 338.2478, found 
338.2475 
[α]D20 :    +31.87 o (c = 3.10)  
(5aS,9aS)-2-(3,5-Dimethoxybenzyl)-6,6,9a-trimethyl-4,5,5a,6,7,8,9,9a-
octahydro-2H-benzo[e]isoindole (273)  
Prepared from Polygodial (0.0552 g, 0.2356 mmol), 3,5-
dimethoxybenzylamine (0.0581 g, 0.3474 mmol, 1.47 eq.) and NaBH3CN 
(0.0185 g, 0.2943 mmol, 1.25 eq.). Product isolated as a clear oil (0.0713 g, 
0.1940 mmol, 82 % yield). 
1H NMR δ (400 MHz):  0.94 (s, 3 H), 0.97 (s, 3 H), 1.24 (s, 3 H), 1.26–
1.33 (m, 1 H), 1.38 (dd, J = 11.9, 1.6 Hz, 1 H), 
1.43–1.57 (m, 3 H), 1.63–1.76 (m, 2 H), 1.80–
1.86 (m, 1 H), 1.94–2.01 (m, 1 H), 2.52–2.63 (m, 
1 H), 2.77 (dd, J = 15.6, 6.1 Hz, 1 H), 3.77 (s, 6 
H), 4.90 (s, 2 H), 6.27–6.30 (m, 3 H), 6.32–6.34 
(m, 1 H), 6.37–6.40 (m, 1 H) 
13C NMR δ (100 MHz):  19.4, 19.9, 21.6, 23.0, 25.8, 33.2, 33.7, 34.7, 
40.0, 42.3, 52.2, 53.4, 55.3, 99.3, 105.2, 113.7, 
116.1, 118.0, 136.4, 141.2, 161.1 
IR Vmax:  2937, 1610, 1597, 1471, 1460, 1429, 1388, 1346, 
1317, 1205, 1157, 1138, 1068 
H
N
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HRMS:  For C24H33NO2+H, predicted 368.2584, found 
368.2582 
[α]D20 :    +34.35 o (c = 2.12)   
(5aS,9aS)-2-(3,4-Dimethoxyphenethyl)-6,6,9a-trimethyl-4,5,5a,6,7,8,9,9a-
octahydro-2H-benzo[e]isoindole (263)  
 Prepared from polygodial (0.2002 g, 0.8543 mmol), 3,4-
dimethoxyphenethylamine (0.200 mL, 1.203 mmol, 1.40 eq.) and NaBH3CN 
(0.0574 g, 0.9134 mmol, 1.07 eq.). Product isolated as a clear oil (0.2854 g, 
0.7480 mmol, 87 % yield). 
1H NMR δ (400 MHz):  0.90 (s, 3 H), 0.93 (s, 3 H), 1.19 (s, 3 H), 1.23–
1.35 (m, 2 H), 1.37–1.56 (m, 3 H), 1.58–1.84 (m, 
3 H), 1.88–1.97 (m, 1 H), 2.47–2.60 (m, 1 H), 2.73 
(dd, J = 15.6, 6.1 Hz, 1 H), 2.94 (t, J = 7.4 Hz, 2 
H), 3.80 (s, 3 H), 3.86 (s, 3 H), 3.94 (t, J = 7.3, 2 
H), 6.21 (s, 1 H), 6.22 (s, 1 H), 6.44 (s, 1 H), 6.66 
(d, J = 6.9 Hz, 1 H), 6.78 (d, J = 8.12 Hz, 1 H) 
13C NMR δ (100 MHz):  19.4, 19.9, 21.6, 23.0, 25.8, 33.2, 33.7, 34.7, 
38.0, 40.0, 42.3, 51.5, 52.4, 55.8, 56.0, 111.3, 
112.1, 112.8, 115.5, 117.4, 120.6, 131.6, 136.0, 
147.7, 148.9 
IR Vmax:    2935, 1516, 1452, 1263, 1236, 1135, 1031 
HRMS:  For C25H35NO2+Na, predicted 404.2560, found 
404.2558   
H
N
263
OCH3
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[α]D20 :    +27.4 o (c = 3.15) 
 
(5aS,9aS)-6,6,9a-Trimethyl-2-octyl-4,5,5a,6,7,8,9,9a-octahydro-2H-
benzo[e]isoindole (274)  
Prepared from polygodial (0.0489 g, 0.2086 mmol), octylamine (0.0425 mL, 
0.2572 mmol, 1.23 eq.) and NaBH3CN (0.0150 g, 0.2387 mmol, 1.14 eq.). 
Product isolated as a clear oil (0.0532 g, 0.1614 mmol, 77 % yield). 
1H NMR δ (400 MHz):  0.88–0.92 (m. 3 H), 0.93 (s, 3 H), 0.95 (s, 3 H), 
1.23 (s, 3 H), 1.26–1.35 (m, 8 H), 1.36–1.41 (m, 1 
H), 1.42–1.57 (m, 4 H), 1.61-1.86 (m, 5 H), 1.94–
2.02 (m, 1 H), 2.52–2.64 (m, 1 H), 2.77 (dd, J = 
15.6, 6.0 Hz, 1 H), 3.75 (t, J = 7.3 Hz, 2 H), 6.26 
(s, 1 H), 6.28 (s, 1 H) 
13C NMR δ (100 MHz):  14.2, 19.5, 19.9, 21.6, 22.7, 23.1, 25.8, 27.0, 
29.30, 29.33, 31.7, 31.9, 33.2, 33.7, 34.7, 40.0, 
42.3, 49.7, 52.3, 112.9, 115.2, 117.2, 135.6 
IR Vmax:  2924, 2853, 1526, 1457, 1441, 1387, 1372, 1354, 
1213, 1149, 1140 
HRMS:  For C23H39N, predicted 329.30825, found 
329.30752. m/z (EI+): 329 (M+,20), 314 (100), 
286 (5), 244 (10), 231 (5), 190 (5), 148 (10), 118 
(35) 
[α]D20 :     +22.93 o (c = 4.1) 
H
N
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(S)-2-Phenyl-2-((5aS,9aS)-6,6,9a-trimethyl-4,5,5a,6,7,8,9,9a-octahydro-
2H-benzo[e]isoindol-2-yl)ethan-1-ol (275)  
Prepared from polygodial (0.0426 g, 0.1818 mmol), S-(+)-2-phenylglycinol 
(0.0319 g, 0.2325 mmol, 1.28 eq.) and NaBH3CN (0.0123g, 0.1957 mmol, 
1.08 eq.). Product isolated as a clear oil (0.0354 g, 0.1049 mmol, 58 % yield). 
1H NMR δ (400 MHz):  0.91 (s, 3 H), 0.95 (s, 3 H), 1.20 (s, 3 H), 1.24–
1.31 (m, 1 H), 1.33–1.38 (m, 1 H), 1.40–1.55 (m, 
3 H), 1.60–1.85 (m, 3 H), 1.92–2.00 (m, 1 H), 
2.49–2.61 (m, 1 H), 2.76 (dd, J = 15.8, 6.0 Hz, 1 
H), 4.06–4.20 (m, 2 H), 5.12 (dd, J = 8.2, 5.2 Hz, 
1 H), 6.39 (s, 1 H), 6.43 (d, J = 1.7 Hz, 1 H), 7.14 
(d, J = 7.2 Hz, 2 H), 7.26-7.37 (m, 3 H) 
13C NMR δ (100 MHz):  19.4, 19.8, 21.6, 23.1, 25.8, 33.2, 33.7, 34.8, 
40.0, 42.2, 52.1, 65.0, 65.4, 112.4, 114.5, 118.3, 
126.8, 127.9, 128.8, 136.6, 139.1 
IR Vmax:  3362 (OH), 2924, 1662, 1452, 1386, 1373, 1211, 
1139, 1066, 1037 
HRMS:  For C23H31NO+Na, predicted 360.2298, found 
360.2292 
[α]D20 :    +29.4 o (c = 1.43) 
 
 
H
N
275
OH
Chapter 5  Experimental 
 
 
199 
Methyl 4-((5aS,9aS)-6,6,9a-trimethyl-4,5,5a,6,7,8,9,9a-octahydro-2H-
benzo[e]isoindol-2-yl)butanoate (276)  
NaOAc (0.0360 g, 0.4388 mmol, 1.55 eq.) and γ-aminobutyric acid methyl 
ester hydrochloride (0.0324 g, 0.2109 mmol, 1.20 eq.) were added to a 
magnetically stirred solution of polygodial (0.0412 g, 0.1758 mmol) in 
EtOH/AcOH (6 mL of 10:1 solution) maintained under N2 (the reaction flask 
was covered in foil to exclude light). After 0.5 h, NaBH3CN (0.0171 g, 0.2721 
mmol, 1.55 eq.) was added. After 0.5 h, H2O (5 mL) and CH2Cl2 (5 mL) were 
added followed by solid Na2CO3 until the solution was made alkaline. The 
aqueous and organic layers were then separated and the aqueous layer 
extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were dried 
over MgSO4, filtered, and concentrated under reduced pressure. The crude 
material was purified by flash column chromatography using EtOAc/hexanes 
(12: 88) as the eluent to give pyrrole 276 as a clear, colourless oil (0.0166 g, 
0.0523 mmol, 30% yield) 
1H NMR δ (400 MHz):  0.89 (s, 3 H), 0.92 (s, 3 H), 1.19 (s, 3 H), 1.22–
1.29 (m, 1 H), 1.30–1.36 (m, 1 H), 1.38–1.54 (m, 
3 H), 1.58–1.73 (m, 2 H), 1.74–1.83 (m, 1 H), 
1.90–1.97 (m, 1 H), 1.98–2.09 (m, 2 H), 2.28 (t, J 
= 7.2 Hz, 2 H), 2.47–2.59 (m, 1 H), 2.73 (dd, J = 
15.7, 6.2 Hz, 1 H), 3.67 (s, 3 H), 3.80 (t, J = 6.9 
Hz, 2 H), 6.22 (s, 1 H), 6.24 (s, 1 H) 
13C NMR δ (150 MHz):  19.4, 19.9, 21.6, 23.0, 25.8, 26.8, 31.1, 33.2, 
33.7, 34.7, 40.0, 42.3, 48.6, 51.7, 52.2, 113.0, 
115.4, 117.7, 136.1, 173.5 
H
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IR Vmax:  2922, 1739, 1653, 1459, 1437, 1363, 1208, 1149, 
1141 
HRMS:  For C20H31NO2, predicted 317.23548, found 
317.23591. m/z (EI+): 317 (M+,20), 302 (100), 
274 (5), 246 (10), 171 (20), 143 (15), 101 (10) 
[α]D20 :     +15.62 o (c = 0.32) 
General Method For the Synthesis of Pyrrolidines From Polygodial 
Polygodial (1 eq.) was dissolved in EtOH (7 mL) and AcOH (0.7 mL), under 
an atmosphere of N2. NaBH3CN (5 eq.) was added, and the flask covered to 
exclude light. A solution of the amine (1.2 eq.) in EtOH (5 mL) was then 
added slowly via pressure equalising dropping funnel, and the reaction 
allowed to stir for 1 h. H2O (10 mL) and CH2Cl2 (10 mL) were added and the 
solution made alkaline by addition of solid Na2CO3, before the organic and 
aqueous layers were separated and the aqueous layer extracted with CH2Cl2 
(3 x 5 mL). The combined organic layers were dried over MgSO4, filtered, 
and the solvent removed under reduced pressure. The crude mixture was 
purified by flash column chromatography using EtOAc/hexanes as eluent. 
(5aS,9aS)-2-Benzyl-6,6,9a-trimethyl-4,5,5a,6,7,8,9,9a-octahydro-2H-
benzo[e]isoindole (270) and (5aS,9aS,9bR)-2-benzyl-6,6,9a-trimethyl-
2,3,5,5a,6,7,8,9,9a,9b-decahydro-1H-benzo[e]isoindole (271)  
Using polygodial (0.0989 g, 0.4220 mmol), benzylamine (0.055 mL, 0.5035 
mmol, 1.19 eq.) and NaBH3CN (0.1350 g, 2.148 mmol, 5.09 eq.). The crude 
mixture was purified by flash column chromatography using EtOAc/hexanes 
(20:80) as eluent to give 271 as a clear oil (0.0656 g, 0.2119 mmol, 50% 
yield) and 270 as a clear oil (0.0089 g, 0.0289 mmol, 7% yield).  
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1H NMR δ (400 MHz):  0.77 (s, 3 H), 0.85 (s, 3 H), 0.89 (s, 3 H), 1.04-
1.25 (m, 2 H), 1.27 (dd, J = 11.8, 5.3 Hz, 1 H), 
1.34–1.47 (m, 2 H), 1.48-1.61 (m, 2 H), 1.80-1.93 
(m, 1 H), 2.06–2.15 (m, 1 H), 2.18 (t, J = 9.1 Hz, 1 
H), 2.34-2.44 (m, 1 H), 2.79 (t, J = 8.1 Hz, 1 H), 
2.82–2.89 (m, 1 H), 3.40–3.48 (m, 1 H), 3.55 (d, J 
= 12.8 Hz, 1 H), 3.71 (d, J = 12.8 Hz, 1 H), 5.39 
(s, 1 H), 7.20-7.36 (m, 5 H)  
13C NMR δ (100 MHz):  13.8, 18.8, 21.6, 24.2, 33.0, 33.4, 34.1, 40.4, 
42.6, 50.2, 54.1, 55.2, 58.1, 61.0, 115.9, 127.0, 
128.1, 128.3, 128.9, 138.6 
IR Vmax:  2921, 1494, 1471, 1453, 1441, 1387, 1365, 1350, 
1142, 1072, 1028 
HRMS:  For C22H31N, predicted 309.24565, found 
309.24533. m/z (EI+): 309 (M+,50), 308 (55), 290 
(20), 266 (10), 236 (10), 222 (25), 200 (30), 184 
(20), 170 (30), 157 (10), 131 (10), 105 (50), 91 
(100) 
[α]D20 :    +15.88 o (c = 2.595) 
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(5aS,9aS)-2-(4-Methoxybenzyl)-6,6,9a-trimethyl-4,5,5a,6,7,8,9,9a-
octahydro-2H-benzo[e]isoindole (272) and (5aS,9aS,9bR)-2-(4-
methoxybenzyl)-6,6,9a-trimethyl-2,3,5,5a,6,7,8,9,9a,9b-decahydro-1H-
benzo[e]isoindole (277)  
Using polygodial (0.1005 g, 0.4288 mmol), 4-methoxybenzylamine (0.070 
mL, 0.5357 mmol, 1.25 eq.) and NaBH3CN (0.1350 g, 2.148 mmol, 5.01 eq.). 
The crude mixture was purified by flash column chromatography using 
EtOAc/hexanes (20:80) as eluent to give 277 as a clear oil (0.0615 g, 0.1811 
mmol, 42% yield) and 272 as a clear oil (0.0100 g, 0.0296 mmol, 7% yield).  
1H NMR δ (400 MHz):  0.77 (s, 3 H), 0.86 (s, 3 H), 0.90 (s, 3 H), 1.06–
1.23 (m, 2 H), 1.24–1.31 (m, 1 H), 1.35-1.46 (m, 2 
H), 1.49–1.59 (m, 2 H), 1.80–1.92 (m, 1 H), 2.16-
2.18 (m, 2 H), 2.33-2.42 (m, 1 H), 2.76 (t, J = 8.0 
Hz, 1 H), 2.79–2.86 (m, 1 H), 3.37–3.44 (m, 1 H), 
3.48 (d, J = 12.6 Hz, 1 H), 3.63 (d, J = 12.6 Hz, 1 
H), 3.79 (s, 3 H), 5.38 (s, 1 H), 6.84 (d, J = 8.5 Hz, 
2 H), 7.24 (d, J = 8.5 Hz, 2 H) 
13C NMR δ (100 MHz):  13.8, 18.8, 21.6, 24.2, 33.0, 33.3, 34.1, 40.4, 
42.6, 50.2, 54.0, 55.2, 55.3, 58.0, 60.4, 113.7, 
115.7, 129.9, 131.4, 138.7, 158.7 
IR Vmax:  2921, 1612, 1585, 1512, 1464, 1441, 1387, 1365, 
1349, 1301, 1247, 1171, 1038 
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HRMS:  For C23H33NO, predicted 339.25621, found 
339.25602. m/z (EI+): 339 (M+,45), 322 (10), 296 
(5), 218 (25), 202 (10), 148 (10), 121 (100), 109 
(25), 77 (15) 
[α]D20     25.51 o (c = 1.21) 
(5aS,9aS)-2-(3,4-Dimethoxyphenethyl)-6,6,9a-trimethyl-4,5,5a,6,7,8,9,9a-
octahydro-2H-benzo[e]isoindole (263) and (5aS,9aS,9bR)-2-(3,4-
dimethoxyphenethyl)-6,6,9a-trimethyl-2,3,5,5a,6,7,8,9,9a,9b-decahydro-
1H-benzo[e]isoindole  (278)  
Using polygodial (0.1063 g, 0.4536 mmol), 3,4-dimethoxyphenethylamine 
(0.0925 mL, 0.5568 mmol, 1.22 eq.) and NaBH3CN (0.1590 g, 2.530 mmol, 
5.58 eq.). The crude mixture was purified by flash column chromatography 
using EtOAc/hexanes (50:50),  and EtOAc  as eluents to give 278 as a white 
amorphous solid (0.0903 g, 0.2354 mmol, 52% yield) and 263 as a clear oil 
(0.0231 g, 0.0605 mmol, 13% yield).  
1H NMR δ (600 MHz):  0.77 (s, 3 H), 0.86 (s, 3 H), 0.90 (s, 3 H), 1.11-
1.24 (m, 2 H), 1.28 (dd, J = 11.8, 5.3 Hz, 1 H), 
1.38–1.45 (m, 2 H), 1.52–1.61 (m, 2 H), 1.83-1.91 
H
N
263
H
N
278
OCH3
OCH3
OCH3
OCH3
H
N
278
OCH3
OCH3
Chapter 5  Experimental 
 
 
204 
(m, 1 H), 2.08–2.15 (m, 1 H), 2.22 (t, J = 9.1 Hz, 1 
H), 2.36–2.42 (m, 1 H), 2.55–2.63 (m, 1 H), 2.72–
2.79 (m, 3 H), 2.83–2.89 (m, 2 H), 3.54 (d, J = 
13.1 Hz, 1 H), 3.84 (s, 3 H), 3.85 (s, 3 H), 5.42 (s, 
1 H), 6.71–6.75 (m, 2 H), 6.76–6.79 (m, 1 H) 
13C NMR δ (150 MHz):  13.8, 18.8, 21.6, 24.2, 33.0, 33.3, 34.1, 35.2, 
40.4, 42.6, 50.1, 54.3, 55.1, 55.9, 56.0, 58.2, 
59.1, 111.3, 112.1, 115.9, 120.5, 133.2, 138.3, 
147.4, 148.9 
IR Vmax:  2927, 2332, 2171, 1592, 1517, 1464, 1441, 1261, 
1238,  1158, 1141, 1119, 1028 
HRMS:  For C25H37NO2+H, predicted 384.2897, found 
384.2895 
[α]D20 :    +18.22 o (c = 2.52)  
Synthesis of Crispin A Analogues 
(10aS,14aS,14cS)-2,3-Dimethoxy-11,11,14a-trimethyl-
5,9,10,10a,11,12,13,14,14a,14c-decahydrobenzo[6,7]isoindolo[1,2-
a]isoquinolin-8(6H)-one (281), (8bS,12aS,14bR)-2,3-dimethoxy-8b,12,12-
trimethyl-5,8b,9,10,11,12,12a,13,14,14b-
decahydrobenzo[4,5]isoindolo[1,2-a]isoquinolin-8(6H)-one (282a) and 
(8bS,12aS,14bS)-2,3-dimethoxy-8b,12,12-trimethyl-
5,8b,9,10,11,12,12a,13,14,14b-decahydrobenzo[4,5]isoindolo[1,2-
a]isoquinolin-8(6H)-one (282b)  
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To a stirred solution of pyrrole 263 (0.2854 g, 0.7480 mmol) in CH2Cl2 (15 
mL) at 0 oC was added Dess–Martin periodinane (0.8267 g, 1.949 mmol, 
2.60 eq.) in a single portion, and the reaction mixture stirred for 50 minutes, 
until TLC analysis indicated complete consumption of starting material. The 
reaction was quenched by addition of H2O (15 mL) and Na2S2O5. The 
aqueous and organic layers were separated, and the aqueous layer 
extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were 
washed with saturated NaHCO3 (2 x 15 mL), dried over MgSO4, and the 
solvent removed under reduced pressure. The crude residue was dissolved 
in dry CH2Cl2 (10 mL), under N2, and stirred at 0 oC. BF3.OEt2 (0.140 mL, 
1.134 mmol, 1.52 eq.) was added via syringe, and the reaction stirred and 
allowed to warm slowly to room temperature for 1 h. The reaction was 
quenched with saturated NaHCO3 (10 mL), the aqueous and organuc layers 
separated, and the aqueous layer extracted with CH2Cl2 (3 x 10 mL). The 
combined organic layers were dried over MgSO4, and the solvent removed 
under reduced pressure. The crude mixture was purified by flash column 
chromatography, using EtOAc/hexanes (50:50) and EtOAc/hexanes (70:30) 
as the eluent, to give 282a and 282b as a pale yellow oil (0.1852 g, 0.4682 
mmol, 63 % yield; inseparable mixture of diastereomers) and compound 281 
as a pale yellow oil (0.0666 g, 0.1683 mmol, 22% yield).  
1H NMR δ (600 MHz, acetone-d6):  0.87 (s, 1.8 H), 0.89 (s, 6 H), 0.94 
(s, 1.8 H), 0.99–1.05 (m, 1 H), 1.06 
(s, 1.8 H), 1.11–1.25 (m, 8 H), 1.39–
1.51 (m, 4.3 H), 1.53–1.61 (m, 1 H), 
1.63–1.73 (m, 1.6 H), 1.88–1.94 (m, 
1.6 H), 2.50–2.67 (m, 4 H), 2.73–
2.81 (m, 3 H), 2.89–2.95 (m, 0.6 H), 
2.98 (ddd, J = 12.7, 12.0, 3.8 Hz, 1 
H), 3.77 (s, 3 H), 3.78 (s, 1.8 H), 
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3.81 (s, 3 H), 3.83 (s, 1.8 H), 4.26–
4.32 (m, 1.6 H), 4.99 (s, 1.6 H), 
6.750 (s, 1 H), 6.759 (s, 0.6 H), 6.92 
(s, 0.6 H), 6.94 (s, 1 H) 
13C NMR δ (150 MHz, acetone-d6):  19.23, 19.27, 19.3, 19.5, 20.2, 20.5, 
21.7, 21.8, 26.3, 27.7, 30.0, 30.1, 
33.72, 33.74, 33.77, 35.6, 36.00, 
36.08, 36.6, 38.5, 38.9, 42.5, 42.7, 
52.8, 53.1, 56.0, 56.1, 56.33, 56.36, 
61.9, 62.0, 110.8, 111.62, 113.62, 
113.61, 126.0, 126.5, 127.4, 128.0, 
141.3, 141.5, 148.9, 149.0, 149.2, 
149.3, 153.0, 153.2, 171.2, 171.8 
1H NMR δ (600 MHz):  0.89 (s, 3 H), 0.93 (s, 3 H), 1.12 (dd, J = 12.2, 1.1 
Hz, 1 H), 1.16 (s, 3 H), 1.23–1.30 (m, 1 H), 1.42-
1.52 (m, 2 H), 1.59 (td, J = 13.0, 3.4 Hz, 1 H), 
1.64–1.70 (m, 1 H), 1.79–1.88 (m, 2 H), 2.16–
2.25 (m, 1 H), 2.36–2.45 (m, 2 H), 2.48–2.53 (m, 
1 H), 2.84–2.92 (m, 1 H), 2.95 (td, J = 12.1, 3.0 
Hz, 1 H), 3.84 (s, 3 H), 3.87 (s, 3 H), 4.42 (ddd, J 
= 12.6, 5.0, 1.8 Hz, 1 H), 5.28 (s, 1 H), 6.60 (s, 1 
H), 7.15 (s, 1 H) 
13C NMR δ (150 MHz):  17.8, 18.9, 20.1, 21.8, 22.7, 30.6, 33.6, 33.7, 
37.7, 39.0, 39.1, 41.7, 54.3, 55.9, 56.2, 61.8, 
112.3, 112.7, 126.0, 128.8, 132.0, 146.8, 147.8, 
163.2, 172.8 
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IR Vmax:    2932, 1682 (C=O), 1516, 1464, 1283, 1271, 1224 
HRMS:  For C25H33NO3, predicted 395.24604, found 
395.24552. m/z (EI+): 395 (M+,30), 393 (40), 378 
(95), 308 (10), 257 (100), 164 (80), 149 (10), 118 
(60) 
[α]D20     −55.38 o (c = 0.910) 
(10aS,14aS,14cS)-2,3-Dimethoxy-11,11,14a-trimethyl-
5,9,10,10a,11,12,13,14,14a,14c-decahydrobenzo[6,7]isoindolo[1,2-
a]isoquinolin-8(6H)-one (281) and (8bS,12aS)-2,3-dimethoxy-8b,12,12-
trimethyl-5,8a,8b,9,10,11,12,12a,13,14-
decahydrobenzo[4,5]isoindolo[1,2-a]isoquinolin-8(6H)-one (283)  
To a stirred solution of pyrrole 263 (0.0400 g, 0.1040 mmol) in CH2Cl2 (5 mL) 
at 0 oC was added Dess–Martin periodinane (0.1110 g, 0.2617 mmol, 2.51 
eq.) in a single portion, and the reaction mixture stirred for 1 hour, until TLC 
analysis indicated complete consumption of starting material. The reaction 
was quenched by addition of H2O (5 mL) and Na2S2O5. The aqueous and 
organic layers were separated, and the aqueous layer extracted with CH2Cl2 
(3 x 5 mL). The combined organic extracts were washed with saturated 
NaHCO3 (2 x 5 mL), dried over MgSO4, and the solvent removed under 
reduced pressure. The crude residue was dissolved in dry CH2Cl2 (5 mL), 
under N2, and stirred at 0 oC. TMSOTf (0.030 mL, 0.165 mmol, 1.58 eq.) was 
added via syringe, and the reaction allowed to warm to room temperature 
and stirred for 18 h. The reaction was quenched with saturated NaHCO3 (5 
mL), the aqueous and organic layers separated, and the aqueous layer 
extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were dried 
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over MgSO4, and the solvent removed under reduced pressure. The crude 
mixture was purified by flash column chromatography, using EtOAc/hexanes 
(70:30) as the eluent, to give 281 as a pale yellow oil (0.0060 g, 0.015 mmol, 
15% yield) and 283 as a pale yellow oil (0.0200 g, 0.051 mmol, 49 % yield).  
1H NMR δ (600 MHz):  0.80 (s, 3 H), 0.82 (s, 3 H), 0.93 (s, 3 H), 1.19 (dd, 
J = 12.5, 2.3 Hz, 1 H), 1.28 (dd, J = 12.6, 5.0 Hz, 
1 H), 1.31–1.41 (m, 2 H), 1.42–1.47 (m, 1 H), 
1.48–1.53 (m, 2 H), 1.75–1.80 (m, 1 H), 2.31–
2.38 (m, 1 H), 2.53–2.58 (m, 1 H), 2.64 (ad, J = 
0.5 Hz, 1 H), 2.77–2.82 (m, 2 H), 3.12–3.17 (m, 1 
H), 3.17–3.23 (m, 1 H), 3.895 (s, 3 H), 3.898 (s, 3 
H), 4.02 (dt, J = 12.4, 4.4 Hz, 1 H), 6.72 (s, 1 H), 
7.10 (s, 1 H) 
13C NMR δ (150 MHz):  14.4, 18.6, 21.9, 22.9, 25.8, 29.9, 33.6, 33.9, 
37.1, 39.2, 40.2, 42.3, 53.4, 56.1, 56.2, 62.1, 
109.6, 111.5, 113.5, 120.8, 128.5, 129.1, 147.9, 
148.7, 175.6 
IR Vmax:  2945, 1687 (C=O), 1511, 1464, 1390, 1367, 1285, 
1269, 1243, 1224, 1211, 1169, 1116 
HRMS:  For C25H33NO3, predicted 395.24604, found 
395.24519. m/z (EI+): 395 (M+,25), 380 (10), 308 
(10), 258 (50), 207 (95), 178 (40), 164 (100), 150 
(50), 135 (40), 121 (25), 95 (15) 
[α]D20     +21.54 o (c = 0.13) 
H
N
283
O
OCH3
OCH3
Chapter 5  Experimental 
 
 
209 
(8aR,10aS,14aS,14bR,14cR)-2,3-Dimethoxy-11,11,14a-trimethyl-
5,8a,9,10,10a,11,12,13,14,14a,14b,14c-
dodecahydrobenzo[6,7]isoindolo[1,2-a]isoquinolin-8(6H)-one (284)   
A mixture of 281 (0.0378 g, 0.0956 mmol) and Pd/C (~0.1 g of a 10% w/w 
mixture) in a solution of 95/5 EtOH/AcOH (15.75 mL), was reacted under H2 
in a Parr shaker hydrogenator (35 psi) for 2 h. The reaction mixture was then 
filtered on celite, and the solvent removed under reduced pressure. The 
crude material was purified by flash column chromatography using EtOAc as 
eluent, to give the product 284 as a pale yellow oil (0.0054 g, 0.014 mmol, 
14% yield) 
1H NMR δ (600 MHz):  0.90 (s, 3 H), 0.92 (s, 3 H) 1.08–1.14 (m, 1 H), 
1.14–1.19 (m, 1 H), 1.23–1.33 (m, 1 H), 1.27 (s, 3 
H), 1.36–1.51 (m, 4 H), 1.55–1.70 (m, 3 H), 2.30–
2.36 (m, 1 H), 2.41 (t, J = 8.2 Hz, 1 H), 2.68–2.74 
(m, 1 H), 2.83–2.88 (m, 1 H), 2.90–2.98 (m, 1 H), 
3.19 (td, J = 11.9, 5.0 Hz, 1 H), 3.53–3.59 (m, 1 
H), 3.87 (s, 3 H), 3.88 (s, 3 H), 4.54 (d, J = 8.0 Hz, 
1 H), 6.75 (s, 1 H), 6.92 (s, 1 H) 
13C NMR δ (150 MHz):  18.7, 19.9, 22.2, 24.0, 28.4, 29.7, 33.51, 33.53, 
35.9, 39.5, 40.5, 41.4, 41.6, 47.8, 50.5, 56.0, 
56.2, 56.5, 109.9, 111.1, 130.4, 131.7, 147.1, 
148.2, 176.8 
IR Vmax:  2935, 1678 (C=O), 1513, 1463, 1453, 1438, 1329, 
1286, 1246, 1212, 1102 
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HRMS:  For C25H35NO3, predicted 397.26169, found 
397.26191. m/z (EI+): 397 (M+, 70), 382 (20), 258 
(20), 191 (100), 176 (20), 123 (10), 81 (10) 
[α]D20     +17.04 o (c = 0.270) 
(8aS,8bS,12aS,14aS,14bR)-2,3-Dimethoxy-8b,12,12-trimethyl-
5,8a,8b,9,10,11,12,12a,13,14,14a,14b-
dodecahydrobenzo[4,5]isoindolo[1,2-a]isoquinolin-8(6H)-one (285)  
A mixture of 282a and 282b (0.1768 g, 0.4469 mmol) and Pd/C (~0.1 g of a 
10% w/w mixture) in EtOH (15 mL), was reacted under H2 on a Parr shaker 
hydrogenator (35 psi) for 12 h. The reaction mixture was then filtered on 
celite, and the solvent removed under reduced pressure. The crude material 
was purified by flash column chromatography using EtOAc/hexanes (70:30) 
as eluent, to give the product 285 as a pale yellow oil (0.0734 g, 0.1846 
mmol, 41% yield) 
1H NMR δ (600 MHz):  0.85 (s, 3 H), 0.89 (s, 3 H), 0.89 (s, 3 H), 0.89–
0.95 (m, 1 H), 1.02 (s, 3 H), 1.14–1.21 (m, 3 H), 
1.31 (ddd, J = 13.7, 9.3, 4.4 Hz, 1 H), 1.35–1.46 
(m, 3 H), 1.50–1.64 (2 H), 2.38–2.44 (m, 1 H), 
2.54 (d, J = 8.5 Hz, 1 H), 2.60–2.64 (m, 1 H), 
2.73–2.87 (m, 3 H), 3.85 (s, 3 H), 3.86 (s, 3 H), 
4.33–4.38 (m, 1 H), 4.68 (d, J = 7.0 Hz, 1 H), 6.48 
(s, 1 H), 6.59 (s, 1 H) 
13C NMR δ (150 MHz):  17.8, 18.8, 18.9, 19.1, 22.0, 29.1, 33.2, 33.6, 
35.3, 35.8, 37.0, 42.6, 44.8, 47.1, 55.9, 56.3, 
57.98, 57.99, 109.4, 111.9, 125.9, 127.3, 147.8, 
147.9, 173.3 
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IR Vmax:  2926, 1680, 1518, 1464, 1430, 1358, 1316, 1255, 
1231, 1121 
HRMS:  For C25H35NO3+Na, predicted 420.2509, found 
420.2511 
[α]D20     +62.42 o (c = 0.165) 
(8aS,8bS,12aS,14aS,14bR)-2,3-Dimethoxy-8b,12,12-trimethyl-
5,8a,8b,9,10,11,12,12a,13,14,14a,14b-
dodecahydrobenzo[4,5]isoindolo[1,2-a]isoquinolin-8(6H)-one (285)  
A mixture of 283 (0.1768 g, 0.4469 mmol) and Pd/C (~0.1 g of a 10% w/w 
mixture) in EtOH (15 mL), with a spatula full of 10% Pd/C was reacted under 
H2 on a Parr shaker hydrogenator (35 psi) for 2 h. The reaction mixture was 
then filtered on celite, and the solvent removed under reduced pressure. The 
crude material was purified by flash column chromatography using 
EtOAc/hexanes (70:30) as eluent, to give the product 285 as a pale yellow oil 
(0.040 g, 0.1006 mmol, 21% yield) 
1-((5aS,9aS)-2-Benzyl-6,6,9a-trimethyl-4,5,5a,6,7,8,9,9a-octahydro-2H-
benzo[e]isoindol-3-yl)-2,2,2-trichloroethan-1-one (288)  
To a stirred solution of benzylpyrrole 270 (0.1460 g, 0.4748 mmol) in Et2O (8 
mL) was added trichloroacetyl chloride (0.320 mL, 2.867 mmol, 6 eq.), and 
the mixture stirred for 24 h. At this time a further 0.320 mL of trichloroacetyl 
chloride was added and the reaction stirred for a further 24 h. H2O (8 mL) 
H
N
285
O
OCH3
OCH3
H H
H
H
N
288
CCl3
O
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was added, and solid K2CO3 until the solution was alkaline. The aqueous and 
organic layers were separated, and the aqueous layer extracted with 
dichloromethane (3 x 8 mL). The combined organic extracts were dried over 
MgSO4, filtered, and the solvent removed under reduced pressure. The crude 
material was purified by elution through a plug of silica with EtOAc/hexanes 
(10:90) as eluent, to give the title compound as a yellow oil (0.1435 g, 0.3169 
mmol, 67% yield). 
1H NMR δ (400 MHz):  0.91 (s, 3 H), 0.95 (s, 3 H), 1.20 (s, 3 H), 1.23–
1.33 (m, 2 H), 1.37–1.59 (m, 3 H), 1.59–1.79 (m, 
2 H), 1.85–1.93 (m, 1 H), 1.93–2.00 (m, 1 H), 2.84 
(ddd, J = 17.6, 11.3, 7.0 Hz, 1 H), 3.29 (ddd, J = 
17.6, 5.9, 1.1 Hz, 1 H), 6.85 (s, 1 H), 7.01 (d, J = 
6.9 Hz, 2 H), 7.20–7.31 (m, 3 H) 
13C NMR δ (100 MHz):  19.2, 19.6, 21.5, 27.6, 33.0, 33.4, 34.6, 39.6, 
41.9, 51.0, 53.8, 96.5, 121.3, 126.8, 127.5, 128.3, 
128.6, 129.6, 136.8, 138.1, 175.4 
IR Vmax:    2926, 1654, 1651, 1456, 1383, 1330, 1209, 1157 
HRMS:  For C24H28Cl3NO, predicted 451.12365, found 
451.12305. m/z (EI+): 451 (M+, 20), 438 (40), 403 
(65), 388 (70), 366 (60), 334 (100), 298 (50), 228 
(70), 172 (50), 131 (60), 91 (85), 69 (85), 55 (60) 
[α]D20     −0.116 o (c = 1.17) 
Methyl (5aS,9aS)-2-benzyl-6,6,9a-trimethyl-4,5,5a,6,7,8,9,9a-octahydro-
2H-benzo[e]isoindole-3-carboxylate (289)  
H
N
289
OCH3
O
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To a stirred solution of chloromethylketone 288 (0.0407 g, 0.0899 mmol) in 
MeOH (5 mL), was added solid K2CO3 (0.0361 g, 0.2612 mmol, 2.9 eq.), and 
stirred for 30 minutes, until TLC analysis indicated consumption of the 
starting material. The solvent was removed under reduced pressure ,and the 
crude residue purified by elution through a plug of silica with EtOAc/hexanes 
(10:90) as eluent to give the title compound as an orange oil (0.0268 g, 
0.0733 mmol, 82% yield) 
1H NMR δ (400 MHz):  0.91 (s, 3 H), 0.95 (s, 3 H), 1.19 (s, 3 H), 1.21–
1.33 (m, 2 H), 1.34–1.44 (m, 1 H), 1.45–1.56 (m, 
2 H), 1.59–1.77 (m, 2 H), 1.83–1.91 (m, 1 H), 
1.92–1.99 (m, 1 H), 2.70 (ddd, J = 18.0, 11.8, 7.4 
Hz, 1 H), 3.06 (dd, J = 18.0, 5.8 Hz, 1 H), 3.73 (s, 
3 H), 5.48 (s, 2 H), 6.59 (s, 1 H), 7.05–7.10 (m, 2 
H), 7.20–7.32 (m, 3 H) 
13C NMR δ (100 MHz):  19.2, 19.4, 21.5, 25.3, 25.6, 33.1, 33.5, 34.3, 
39.7, 42.2, 50.6, 51.5, 52.4, 116.9, 122.7, 126.8, 
127.2, 128.6, 129.0, 136.1, 139.1, 162.3 
IR Vmax:  2943, 1693, 1456, 1438, 1396, 1388, 1282, 1205, 
1163, 1120, 1095, 1072 
HRMS:  For C24H31NO2, predicted 365.23548, found 
365.23580. m/z (EI+): 365 (M+, 60), 350 (100), 
322 (10), 292 (30), 228 (10), 118 (40), 87 (100), 
69 (15) 
[α]D20    +16.39 o (c=0.80) 
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Appendices 
Appendix 1: 1H NMR Spectral Simulation Parameters 
(3S,6S,7R,7aR)-6-Fluoro-7-hydroxy-3-phenyltetrahydropyrrolo[2,1-
b]oxazol-5(6H)-one (233) 
 
NO O
233
HO F
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(3S,6R,7S,7aR)-6,7-difluoro-3-phenyltetrahydropyrrolo[2,1-b]oxazol-
5(6H)-one (234)  
 
 
 
NO O
234
FF
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Appendix 2: X-ray Crystallograpy Data 
(3S,6R,7S,7aR)-5-Oxo-3-phenylhexahydropyrrolo[2,1-b]oxazole-6,7-diyl 
diacetate (163)  
Bond precision: C–C = 0.0022 Å  Wavelength=0.71090  
Cell:   a=6.6080(5)   b=9.1090(4)   c=12.9440(5) 
   α=90   β=104.234(3) γ=90 
Temperature: 100 K   
Calculated  Reported 
Volume  755.21(7)  755.21(7) 
Space group  P 21   P 21 
Hall group  P 2yb   P 2yb 
Moiety formula C16 H17 N O6 ? 
Sum formula  C16 H17 NO6 C16 H17 NO6 
Mr   319.31 
Dx, gcm−3  1.404   1.404 
Z   2   2 
µ (mm−1)  0.107   0.108 
F000   336.0   336.0 
F000’   336.2 
h,k,lmax  8,11,17  8,11,17 
Nref   3591[1908]  3458 
Tmin,Tmax  0.984,0.984 
Tmin’   0.984 
 
Correction method = not given 
 
Data completeness = 1.81/0.96  Theta(max) = 27.887 
 
R (reflections) = 0.0293 (3440)  wR2(reflections) = 0.0757 (3458) 
 
S = 1.121    Npar = 210 
NO O
163
O O
CH3H3C
O O
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(3S,7aR)-6-(Benzyloxy)-3-phenyl-2,3-dihydropyrrolo[2,1-b]oxazol-
5(7aH)-one (173)  
Bond precision: C–C = 0.0025 Å  Wavelength=0.71080  
Cell:   a=17.784(4)   b=6.291(1)   c=13.938(3) 
   α=90   β=92.090(4)  γ=90 
Temperature: 100 K 
 
   Calculated  Reported 
Volume  1558.3(5)  1558.3(5) 
Space group  C 2   C 2 
Hall group  C 2y   C 2y 
Moiety formula C19 H17 N O3 ? 
Sum formula  C19 H17 N O3 C19 H17 N O3 
Mr   307.34 
Dx, gcm−3  1.310   1.310 
Z   4   4 
µ (mm−1)  0.088   0.089 
F000   648.0   648.0 
F000’   648.30 
h,k,lmax  23,8,18  23,8,18 
Nref   3753[2045]  3564 
Tmin,Tmax  0.995,0.996 
Tmin’   0.915 
 
Correction method = not given 
 
Data completeness = 1.74/0.95  Theta(max) = 27.914 
 
R (reflections) = 0.0322 (3523)  wR2(reflections) = 0.0832 (3564) 
 
S = 1.101    Npar = 208 
 
NO O
173
OBn
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(3S,6S,7aR)-6-(Benzyloxy)-3-phenyltetrahydropyrrolo[2,1-b]oxazol-
5(6H)-one (175)  
Bond precision: C–C = 0.0024 Å  Wavelength=0.71080  
Cell:   a=6.6790(17)  b=9.0560(13)  c=13.292(3) 
   α=90   β=104.16(3)  γ=90 
Temperature: 100 K 
 
   Calculated  Reported 
Volume  779.5(3)  779.6(3) 
Space group  P 21   P 21 
Hall group  P 2yb   P 2yb 
Moiety formula C19 H19 N O3 ? 
Sum formula  C19 H19 N O3 C19 H19 N O3 
Mr   309.35 
Dx, gcm−3  1.318   1.318 
Z   2   2 
µ (mm−1)  0.088   0.089 
F000   328.0   328.0 
F000’   328.15 
h,k,lmax  9,12,18  9,12,18 
Nref   4577[2422]  4018 
Tmin,Tmax  0.999,0.999 
Tmin’   0.998 
 
Correction method = not given 
 
Data completeness = 1.66/0.88  Theta(max) = 30.028 
 
R (reflections) = 0.0418 (3932)  wR2(reflections) = 0.1096 (4018) 
 
S = 1.051    Npar = 208 
 
NO O
175
OBn
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(S)-1-((S)-2-Methoxy-2-oxo-1-phenylethyl)-5-oxo-2,5-dihydro-1H-pyrrol-
2-yl 2-iodobenzoate (155a)  
Bond precision: C–C = 0.0058 Å  Wavelength=1.54178 
Cell:   a=9.2928(12)  b=12.7228(11)  c=16.320(4) 
   α=90   β=90   γ=90 
Temperature: 125 K 
 
   Calculated  Reported 
Volume  1929.5(6)  1929.5(6) 
Space group  P 21 21 21  P 21 21 21  
Hall group  P 2ac 2ab  P 2ac 2ab 
Moiety formula C20 H16 I N O5 C20 H16 I N O5 
Sum formula  C20 H16 I N O5 C20 H16 I N O5 
Mr   477.24  477.26 
Dx, gcm−3  1.643   1.643 
Z   4   4 
µ (mm−1)  13.309  13.312 
F000   944.0   946.3 
F000’   945.59 
h,k,lmax  11,15,19  10,17,19 
Nref   3413[1961]  3251 
Tmin,Tmax  0.078,0.394  0.340,0.753 
Tmin’   0.010 
 
Correction method = # Reported T Limits: Tmin=0.340 Tmax=0.753 
AbsCorr = MULTI–SCAN 
 
Data completeness = 1.66/0.95  Theta(max) = 66.700 
 
R (reflections) = 0.0296 (3205)  wR2(reflections) = 0.0750 (3251) 
 
S = 1.042    Npar = 245 
 
N
O
O
OO
OI
H3C
155a
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(R)-1-((S)-2-methoxy-2-oxo-1-phenylethyl)-5-oxo-2,5-dihydro-1H-pyrrol-
2-yl 2-iodobenzoate (155b) 
Bond precision: C–C = 0.0043 Å  Wavelength=1.54178 
Cell:   a=8.2367(2)   b=8.2369(2)   c=27.4363(7) 
   α=90   β=90   γ=90 
Temperature: 125 K 
 
   Calculated  Reported 
Volume  1861.41(8)  1861.41(8) 
Space group  P 21 21 21  P 21 21 21  
Hall group  P 2ac 2ab  P 2ac 2ab 
Moiety formula C20 H16 I N O5 C20 H16 I N O5 
Sum formula  C20 H16 I N O5 C20 H16 I N O5 
Mr   477.24  477.26 
Dx, gcm−3  1.703   1.703 
Z   4   4 
µ (mm−1)  13.796  13.799 
F000   944.0   946.3 
F000’   945.59 
h,k,lmax  9,9,32   9,9,32 
Nref   3273[1909]  3266 
Tmin,Tmax  0.158,0.063  0.109,0.7287 
Tmin’   0.025 
 
Correction method = # Reported T Limits: Tmin=0.109 Tmax=0.287 
AbsCorr = ANALYTICAL 
 
Data completeness = 1.71/1.00  Theta(max) = 66.650 
 
R (reflections) = 0.0205 (3222)  wR2(reflections) = 0.0517 (3266) 
 
S = 1.043    Npar = 245 
N
O
O
OO
OI
H3C
155b
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(3aS,3bR,6S,8aR)-6-Phenyltetrahydro-
[1,3,2]dioxathiolo[4',5':3,4]pyrrolo[2,1-b]oxazol-8(3bH)-one 2,2-dioxide 
(232)  
Bond precision: C–C = 0.0031 Å  Wavelength=1.54178 
Cell:   a=6.4543(2)   b=10.6214(3)  c=17.9169(5) 
   α=90   β=90   γ=90 
Temperature: 100 K 
 
   Calculated  Reported 
Volume  1228.27(6)  1228.27(6) 
Space group  P 21 21 21  P 21 21 21 
Hall group  P 2ac 2ab  P 2ac 2ab 
Moiety formula C12 H11 N O6 S C12 H11 N O6 S 
Sum formula  C12 H11 N O6 S C12 H11 N O6 S 
Mr   297.28 
Dx, gcm−3  1.608   1.607 
Z   4   4 
µ (mm−1)  2.623   2.623 
F000   616.0   619.6 
F000’   619.44 
h,k,lmax  7,12,21  7,12,21 
Nref   2167[1281]  2162 
Tmin,Tmax  0.766,0.854  0.675,0.753 
Tmin’   0.660 
 
Correction method = # Reported T Limits: Tmin=0.675 Tmax=0.753 
AbsCorr = MULTI–SCAN 
 
Data completeness = 1.69/1.00  Theta(max) = 66.440 
R (reflections) = 0.0253 (2054)  wR2(reflections) = 0.0625 (2162) 
S = 1.053    Npar = 181 
NO O
232
O
S
O
OO
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(3S,6S,7R,7aR)-6-Fluoro-7-hydroxy-3-phenyltetrahydropyrrolo[2,1-
b]oxazol-5(6H)-one (233)  
Bond precision: C–C = 0.0022 Å  Wavelength=1.54178 
Cell:   a=6.5579(2)   b=21.3008(6)  c=7.6892(2) 
   α=90   β=90.2866(9) γ=90 
Temperature: 100 K 
 
   Calculated  Reported 
Volume  1074.37(5)  1074.37(5) 
Space group  P 21   P 21  
Hall group  P 2yb   P 2yb 
Moiety formula C12 H12 F N O3 C12 H12 F N O3 
Sum formula  C12 H12 F N O3 C12 H12 F N O3 
Mr   237.23 
Dx, gcm−3  1.467   1.467 
Z   4   4 
µ (mm−1)  0.994   0.994 
F000   496.0   497.9 
F000’   497.80 
h,k,lmax  7,25,9   7,25,9 
Nref   3788[1950]  3726 
Tmin,Tmax  0.788,0.820  0.687,0.753 
Tmin’   0.672 
 
Correction method = # Reported T Limits: Tmin=0.687 Tmax=0.753 
AbsCorr = MULTI–SCAN 
 
Data completeness = 1.91/0.98  Theta(max) = 66.680 
 
R (reflections) = 0.0296 (3668)  wR2(reflections) = 0.0767 (3726) 
 
S = 1.055    Npar = 309 
NO O
233
HO F
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(3S,6R,7S,7aR)-6,7-Difluoro-3-phenyltetrahydropyrrolo[2,1-b]oxazol-
5(6H)-one (234)  
Bond precision: C–C = 0.0030 Å  Wavelength=1.54178 
Cell:   a=8.7855(3)   b=6.1749(2)   c=10.2618(4) 
   α=90   β=105.699(2) γ=90 
Temperature: 100 K 
 
   Calculated  Reported 
Volume  535.93(3)  535.93(3) 
Space group  P 21   P 1 21 1  
Hall group  P 2yb   P 2yb 
Moiety formula C12 H11 F2 N O2 C12 H11 F2 N O2 
Sum formula  C12 H11 F2 N O2 C12 H11 F2 N O2 
Mr   239.22 
Dx, gcm−3  1.482   1.482 
Z   2   2 
µ (mm−1)  1.068   1.068 
F000   248.0   249.0 
F000’   248.95 
h,k,lmax  10,7,12  10,7,12 
Nref   1902[1048]  1856 
Tmin,Tmax  0.825,0.852  0.541,0.753 
Tmin’   0.344 
 
Correction method = # Reported T Limits: Tmin=0.541 Tmax=0.753 
AbsCorr = MULTI–SCAN 
 
Data completeness = 1.77/0.98  Theta(max) = 66.670 
 
R (reflections) = 0.0321 (1739)  wR2(reflections) = 0.0770 (1856) 
 
S = 1.071    Npar = 154 
NO O
234
FF
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(3S,4R)-3-fluoro-4-hydroxy-1-((S)-2-hydroxy-1-phenylethyl)pyrrolidin-2-
one (246)  
Bond precision: C–C = 0.0019 Å  Wavelength=1.54178 
Cell:   a=9.2406(2)   b=14.4797(4)  c=16.1907(4) 
   α=90   β=90   γ=90 
Temperature: 100 K 
 
   Calculated  Reported 
Volume  2166.33(9)  2166.33(9) 
Space group  P 21 21 21  P 21 21 21  
Hall group  P 2ac 2ab  P 2ac 2ab 
Moiety formula C12 H14 F N O3 C12 H14 F N O3 
Sum formula  C12 H14 F N O3 C12 H14 F N O3 
Mr   239.24 
Dx, gcm−3  1.467   1.467 
Z   8   8 
µ (mm−1)  0.986   0.986 
F000   1008.0  1011.8 
F000’   1011.61 
h,k,lmax  11,17,19  10,17,19 
Nref   3815[2183]  3795 
Tmin,Tmax  0.782,0.821  0.690,0.753 
Tmin’   0.782 
 
Correction method = # Reported T Limits: Tmin=0.690 Tmax=0.753 
AbsCorr = MULTI–SCAN 
 
Data completeness = 1.74/0.99  Theta(max) = 66.620 
 
R (reflections) = 0.0255 (3730)  wR2(reflections) = 0.0655 (3795) 
 
S = 1.079    Npar = 311 
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